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Abstract 
 
Peptide-based fluorescent reporters of enzyme activity in living cells have been proposed to 
complement, or provide alternatives to, genetically-encoded probes, such as those based on the 
Green Fluorescent Protein and its colourful variants. The use of well-established chemical 
methodologies – especially solid phase synthesis – and the vast array of fluorescent dyes 
available allow the preparation and the evaluation of compounds with different specificities, 
making a wide range of investigations possible. However, cell uptake of these compounds is 
generally poor, and normally requires invasive methods such as microinjection or electroporation. 
In these conditions, the usefulness of these probes can be severely limited. 
 
The discovery of the so-called cell-penetrating peptides (CPPs), more than ten years ago, 
has actually revealed that some of these compounds can cross efficiently the cell membranes and 
are able to deliver hydrophilic cargoes, such as DNA, proteins or even nanoparticles inside the 
cell. Unfortunately, much of the initial enthusiasm dissipated when it was found that endocytosis 
plays a major role in the uptake process. The entrapment in endosomal vesicles may in fact 
impose strict limits in terms of modification and degradation of the cargo of interest. 
 
This thesis describes the synthesis of fluorescent peptides and focuses on the problem of 
their delivery into the cytoplasm of living cells. A negatively charged peptide corresponding to 
one of the autophosphorylation sequences of the epithelial grow factor receptor (EGFR), namely 
DADEY992L, was taken as an example to investigate the possibility of creating a cell-permeable 
fluorescent sensor for the EGFR kinase activity in living cells. The use of a conjugate of the cell-
penetrating peptide Penetratin and the probe revealed an endosomal localization in one cell type, 
and surprisingly no uptake in a second cell line tested. Different fluorescent derivatives of 
Penetratin demonstrated variations in cell uptake under different experimental conditions. During 
this study, red fluorescent derivatives of the cell-penetrating TAT peptide were also assessed. 
Although they also showed predominantly accumulation in membrane-bound compartments, 
these appeared to be different from the endosomal vesicles. One TAT variant in particular, 
namely TAT(K-LRh), may be potentially exploited as a novel vector, provided that further 
studies will clarify unambiguously the compartment of its accumulation. 
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To overcome the limits inherent in the use of Penetratin conjugates, a different strategy was 
implemented, which relied on the chemical modification of the probe with bioactivatable 
protecting groups. The rationale behind these modifications was to increase the hydrophobic 
character of the peptide and allow its diffusion into the cells. In particular, acetoxymethyl (AM) 
esters were used to temporarily mask the negative charges of the aspartate and glutamate residues 
present in the peptide sequence. These biodegradable esters are promptly removed by ubiquitous 
non-specific esterases present in cells. The modified fluorescent peptide was able to penetrate 
easily and distribute homogeneously into the cytoplasm and the nucleus of several cell lines, with 
a mechanism resembling passive diffusion. Unfortunately, FRET-based assays did not measure 
any interaction with the EGFR. In vitro analyses showed unmasking of the carboxylate groups, 
albeit with modifications to the peptide backbone, which may have resulted from intramolecular 
condensations and formation of aspartimide residues. In particular, mass spectrometry data 
support this model. A loss of substrate specificity may be expected to result from such 
modifications, which may explain why the fluorescent peptide did not appear to interact with its 
enzyme target despite intracellular delivery having been achieved.  
 
This work highlights the feasibility of a tailored modification of peptides, either by masking 
negatively charged groups as, for example, AM esters, or by conjugating to variant of the TAT 
peptide, for the intracellular delivery of peptidic cargoes. Further refinements may solve the 
problems of poor endosomal escape or backbone modifications, and may yet offer small-
molecule alternatives to genetically encoded probes.  
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Zusammenfassung 
 
Fluoreszente Reporterkonstrukte zum Nachweis von Enzymaktivität in lebenden Zellen, die 
auf Peptiden basieren sind eine ideale Ergänzung und Alternative zu genetisch kodierten 
Konstrukten auf der Grundlage von fluoreszierenden Proteinen, wie das Grün-Fluoreszierende-
Protein oder eine der vielen anderen Farbvarianten. Die etablierten chemischen Verfahren, wie 
vor allem die Festphasensynthese und eine große Außwahl fluoreszenter Farbstoffe, erlauben die 
Herstellung von Verbindungen mit den unterschiedlichsten Eigenschaften. Dies macht sie für den 
Einsatz in einer Vielzahl von Untersuchungen interessant. Das Einbringen dieser Verbindungen 
in lebende Zellen ist sehr schwierig und nur mit langandauernden und invasiven Methoden wie 
der Mikroinjektion möglich, was bisher die Anwendbarkeit stark eingeschränkt hat. 
 
Die Entdeckung von sogenannten zell-penetrierenden Peptiden (CCPs, cell-penetrating 
peptides) vor mehr als zehn Jahren, hat gezeigt, dass einige dieser Verbindungen die 
Zellmembran effizient durchdringen können. Zusätzlich konnten diese, auch angehängte 
hydrophile Moleküle wie DNA, Proteine oder sogar Nanopartikel mitnehmen. Von dem 
anfänglichen Enthusiasmus blieb wenig übrig, als man feststellte, dass Endozytose einen 
Grossteil dieses Effekts ausmachte. Der Einschluss in endosomale Vesikel stellt eine starke 
Einschränkung, vor allem in Bezug auf Modifikation und Zersetzung der einzubringenden 
Verbindung, dar. 
 
Die Synthese fluoreszenter Peptide und vor allem das Problem deren Einbringung in das 
Zytosol lebender Zellen, stehen im Mittelpunkt dieser Arbeit. An dem Beispiel des der 
Autophosphorylierungssequenz des Rezeptors für den epithelialen Wachstumsfaktor (EGFR, 
epithelial growth factor receptor) entsprechenden, negativ geladenen Peptids, DADEY299L, 
sollte die Möglichkeit, eine membrangängigen fluoreszenten Sensor für die Aktivität der EGFR-
Kinase in lebenden Zellen herzustellen, geprüft werden. Die Verwendung eines Konjungats aus 
dem zell-penetrierenden Peptid Penetratin und der Sonde, führte zur Aufnahme in Endosomen in 
einem Zelltyp, während in einem weiteren getesteten Zelltyp überhaupt keine Aufnahme 
nachzuweisen war. Auch konnte mit verschiedenen fluoreszenten Penetratinderivaten gezeigt 
werden, wie die Aufnahme in Zellen unter verschiedenen experimentellen Bedingungen variierte. 
Während dieser Untersuchung, wurden auch rot-fluoreszierende Derivate des zell-penetrierenden 
ix 
TAT-Peptids analysiert. Obwohl diese auch eine Akkumulation in vorwiegend 
membrangebundenen Kompartimenten aufwiesen, erschienen diese jedoch anders als endosomale 
Vesikel. Speziell die TAT-Variante TAT(K-LRh) könnte sich als neuer Vektor erweisen, wenn 
aufgeklärt werden kann in welchen Zellkompartimenten dieses Peptid akkumuliert. 
 
Um die, bei der Verwendung von Penetratin, auftretenden Einschränkungen zu überwinden, 
wurde eine Strategie verfolgt, die auf einer chemischen Modifikation der Sonde mit 
bioaktivierbaren Schutzgruppen basiert. Das Grundprinzip war, den hydrophoben Charakter des 
Peptids zu verstärken, um so die Diffusion durch die Zellmembran zu ermöglichen. Insbesondere 
wurden Azetoxymethylester (AM) verwendet um die negativen Ladungen der in dem Peptid 
vorkommenden Aspartat- und Glutamatreste zu maskieren. Diese bioaktivierbaren Ester werden 
sofort durch unspezifische Esterasen, die in allen Zellen vorkommen, abgespaltet. Die fluoreszent 
markierten Peptide durchdrangen leicht die Plasmamembran, vergleichbar mit passiver Diffusion, 
und verteilten sich homogen im Zytosol und Nukleus in verschiedenen getesteten Zelllinien. 
Leider konnte durch FRET keine Interaktion der Peptide mit dem EGFR nachgewiesen werden. 
In vitro Analysen ergaben, dass die Karbonatgruppen entschützt werden konnten, wenngleich 
dieses zu Modifikationen des Peptidrückgrats durch intramolekulare Kondensation und die 
Bildung von Aspartimidresten geführt haben könnte. Durch diese Modifikationen ließe sich der 
Verlust der Substratspzifität und somit die fehlende Interaktion mit der Kinase erklären, obwohl 
das Peptid in die Zelle eingebracht werden konnte. 
 
Diese Arbeit hebt die Machbarkeit der Einbringung Peptiden in lebende Zellen durch 
massgeschneiderte Modifikationen, entweder indem negativ geladenen Gruppen durch AM oder 
andere hydrolisierbare Ester maskiert werden, oder indem sie mit einem der TAT-Peptide 
konjugiert werden, hervor.  Durch weitere Verfeinerung der Verfahren könnten die auftretenden 
Probleme, wie Einschluß in Vesikel oder das Auftreten von Modifikationen des Peptidrückgrats, 
gelöst werden und so eine Alternative zu den viel größeren genetisch Kodierten Sonden bieten. 
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Abbreviations 
 
Chemicals: 
 
5(6)-TAMRA SE  5(6)-carboxytetramethylrhodamine, succinimidyl ester  
Ac2O  acetic anhydride 
ACN  acetonitrile 
AcOH  acetic acid 
ActPEN  activated Penetratin peptide 
AEEAc  aminoethoxyethoxy acetic acid 
Ahx  aminohexanoic acid 
AM  acetoxymethyl 
Boc  tert-butyloxycarbonyl 
BSA  bovine serum albumine 
Cl-Trt  2-chlorotrityl 
DCI  4,5-dicyanoimidazole 
DCM  dichloromethane 
DIC  diisopropylcarbodiimide 
DIPEA  diisopropylethylamine 
DMF  N,N-dimethylformamide 
DVB  divinylbenzene 
EDTA  ethylenediaminetetraacetic acid 
Fmoc  9-fluorenylmethoxycarbonyl 
H2CO  formaldehyde 
HBTU  2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HOBt  1-hydroxybenzotriazole 
iPrOH  isopropanol 
LRh  Lissamine™-rhodamine B 
LRh-SO2Cl  Lissamine™-rhodamine B sulfonylchloride 
LTG  LysoTracker™ Green 
LTR  LysoTracker™ Red  
Mtt  4-methyltrityl 
NMP  1-methyl-2-pyrrolidinone 
Pbf  2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl 
PEG  polyethylene glycol 
PFA  paraformaldehyde 
PI  propidium iodide 
PLE  porcine liver esterase 
PP  polypropylene 
PS  polystyrene 
tBu  tert-butyl 
tBuOMe  tert-butyl-O-methyl ether 
tBuOOH  tert-butyl hydroperoxide 
xi 
TCEP  tris(2-carboxyethyl)phosphine 
TEA  triethylamine 
TFA  trifluoroacetic acid 
TIS  trisopropylsilane 
TNBS  2,4,6-trinitrobenzenesulfonic acid 
Trt  trityl 
 
Other abbreviations: 
 
(E)GFP  (enhanced) Green Fluorescent Protein 
(E)YFP  (enhanced) Yellow Fluorescent Protein 
a.a.  amino acid(s) 
a.m.u.  atomic mass unit(s) 
DMEM  Dulbecco’s modified Eagle medium 
EGFR  epithelial grow factor receptor 
eq  equivalent(s) 
ER  endoplasmic reticulum 
ESI-MS  Electrospray Ionization – Mass Spectrometry 
FBS  fetal bovine serum 
HPLC  High Performance Liquid Chromatography 
m/z  mass to charge ratio 
NA  numerical aperture 
PMT  photo multiplier tube 
PTP1B  Protein Tyrosine Phosphatase 1B 
RP  reverse phase 
SPE-RP  solid phase extraction-reverse phase 
UV-VIS  ultraviolet-visible 
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1. Introduction 
 
1.1 Peptides and other small molecule-based fluorescent reporters of enzymatic 
activity 
 
Synthetic peptides that mimic natural substrates represent often a good starting point for 
the design of probes aimed at the study of enzyme activities, due to their natural high 
specificity. In particular, when equipped with fluorogenic or fluorescent molecules, they 
enable high-sensitive, fluorescence-based in vitro assays, to be conveniently performed on 
crude cell extracts in vitro, without the need for time-consuming purification procedures. 
Reporters of this kind have been developed, for instance, for the measurement of the in vitro 
activity of the apoptotic caspase-3 enzyme [1] or those of various protein tyrosine 
phosphatases (PTPs) [2] (Fig. 1.1.1). In depth studies, such as those aimed at understanding 
the complex phenomena of signalling networks, require reporting from inside living cells, 
where the contribution of the physiological components of the intact system can be assessed 
and possibly regulated, thus helping to provide a more comprehensive and accurate model 
than the “artificial” environment of a cuvette [3].  
 
x
y w
z
Q f
y w
z
x
Q
 
Fig. 1.1.1 A generic probe for proteases based on a fluorogenic peptide. The design of the substrate includes 
a quencher (Q) for the fluorochrome (f), separated by an hypothetical consensus sequence for the protease 
(xyzw). Upon cleavage, the fluorescent signal can be recorded. This kind of probes are often used in in vitro 
assays [1, 2] (adapted from [3]). 
 
Nevertheless, the in vivo application of fluorescent peptides as non-genetically encoded 
probes for monitoring enzyme activity is usually a demanding task. In fact, the progress in 
this field has notably lagged behind the use of the Green Fluorescent Protein (GFP) and its 
genetically-encoded variants [4]. If extracellular activity can be investigated – as in the case 
of different matrix-degrading enzymes [5-7] – on the other hand one is faced immediately 
with the non trivial task of delivering the reporter molecules inside the cell, in suitable ways 
to preserve both integrity and viability of the system. Ideally, the reporter should freely 
permeate biological membranes, in order to reach the compartment(s) where the specific 
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activity needs to be monitored. Moreover, the fluorophore itself should have negligible 
influence on the localization of the probe. Due to the nature of polar and charged molecules, 
peptide-based reporters – except rare cases [8-10] – are notoriously reluctant to diffuse 
through a lipid bilayer. Indeed, several fluorescent probes for the detection of enzyme activity 
in vivo are not based on peptides, yet they demand a certain grade of chemical modification to 
meet all the requirements for cell permeability. Of this kind, for instance, is the reporter 
PENN/SATE for the detection of phospholipase A2 (PLA2) activity [11], a class of 
phospholipid hydrolases involved in intracellular signalling and inflammation as initiators of 
the arachidonic acid cascade [12, 13]. This probe is built upon a phosphatidylethanolamine 
molecule chemically modified to achieve the highest specificity toward PLA2 enzymes (Fig. 
1.1.2). The charges on the head group are masked by bioactivatable S-acetyl-2-thioethyl 
(SATE) moieties, which are promptly released in the cell upon action of non-specific 
esterases. The fluorescent part of the molecule is composed of two dyes, each sitting at the 
ends of the fatty acid chains and forming a Förster resonance energy transfer (FRET) pair 
[14]: the 7-nitrobenzo-2-oxa-1,3-diazole amine (NBD) and the 2-hydroxy derivative of 9-
diethylamino-5H-benzo[a]phenoxazin-5-one (Nile red). Generally, two fluorophores form a 
FRET pair when the emission spectrum of one (termed donor) overlaps with the excitation 
spectrum of the second (termed acceptor). When certain criteria are met, such as the proximal 
position of the fluorophores (2 – 10 nm) and a favourable dipole-dipole orientation [15], a 
non-radiative transfer of energy occurs to the acceptor upon donor excitation. Under these 
circumstances, light emission from the acceptor is obtained with a concomitant decrease in 
the donor emission. Variations of FRET within a fluorescent reporter provide a direct readout 
of the enzymatic activity since the acceptor/donor intensity ratio can be monitored over time 
and quantified, both in vitro and in vivo [16, 17]. Direct excitation of NBD (435 – 485 nm) in 
the PENN/SATE probe leads to Nile red fluorescence (600 – 660 nm) as long as the molecule 
remains intact, but upon cleavage of the fatty acid chain by PLA2, only emission from NBD is 
obtained (515 – 555 nm), because of the spatial separation of the fluorophores and disruption 
of the FRET pair (Fig. 1.1.2). 
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Fig. 1.1.2. The PENN/SATE FRET reporter for PLA2 activity in vivo. The probe is built upon a modified 
phosphatidylethanolamine backbone featuring the FRET pair NBD/Nile red at the tip of the fatty acid chains. 
The asterisk illustrates the hydrolysable bond by PLA2. To ensure cell permeability, the polar head of the lipid is 
equipped with bioactivatable S-acetyl-2-thioethyl (SATE) groups which are removed upon the action of 
intracellular non-specific esterases. Restoration of charges on the molecule entraps the probe inside the cell. 
Upon hydrolysis of the fatty acid chain, a 20 – 30 fold increase in the emission ratio NBD/Nile red was observed 
in living cells due to disruption of the FRET pair. The probe was able to monitor the onset of PLA2 activity in 
the whole body of a developing Medaka fish embrio (adapted from [11]). 
 
This behaviour was confirmed both in vitro and in various living cell lines, in which the 
probe could easily diffuse in and accumulate at the sites of PLA2 action. Upon hydrolysis of 
the fatty acid chain, 20 – 30-fold changes in emission ratio were recorded. More remarkably, 
the probe could be administered to a developing Medaka fish embryo (age 3 h), where it 
reported the onset of PLA2 activity (between 37 and 48 h of development). The probe 
remained visible until the fish hatched (eight days), indicating also the lack of induced 
toxicity. 
 
A similar concept was applied in an earlier study for the design of the CCF2/AM 
reporter of gene expression, based on a fluorogenic substrate for the bacterial β-lactamase 
[18]. This enzyme catalyzes the hydrolysis of the β-lactam ring in cephalosporins. A FRET 
sensor was designed by incorporating a 6-chloro-7-hydroxycoumarin and a fluorescein dyes 
in the scaffold of a cephalosporin molecule. To ensure cell permeability the construct was 
equipped with bioactivatable acetyl (Ac), butyryl (Bt) and acetoxymethyl (AM) esters (Fig. 
1.1.3). The construct, initially non-fluorescent due to the chemical modifications, penetrated 
into the cells and exhibited FRET (ex. 409 nm, em. 520 nm), indicating successful removal of 
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the masking groups by cellular esterases. The cells, additionally transfected with a β-
lactamase plasmid, produced the enzyme. As a result of the hydrolysis of the β-lactam ring, 
the probe molecule underwent β-elimination to loose the fluorescein moiety. FRET was then 
impossible and the emission of the coumarin fluorophore became prominent. The authors 
could correlate the expression of the β-lactamase with the coumarine/fluorescein emission 
ratios, which were up to 70-fold the initial value. Due to the high sensitivity detection of the 
blue/green fluorescence pattern, the assay demonstrated its utility in the selection, by means 
of flow cytometry, of specific cellular clones co-expressing the β-lactamase enzyme along 
with a gene of interest. 
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Fig. 1.1.3. The CCF/2AM probe for the β-lactamase assay of gene expression in living cells. The fluorogenic 
reporter, modified with acetyl, butyryl and acetoxymethyl esters, enters passively into cells and exhibits FRET 
after the removal of the masking groups by cellular esterases. Expression of a β-lactamase gene in transfected 
cells produces hydrolysis of the β-lactam ring, β-elimination of the fluorescein moiety and disruption of the 
FRET pair. As a consequence, only fluorescence from 6-chloro-7-hydroxycoumarine is detected under excitation 
at 409 nm. The assay reveals useful in the fluorescence automated cell sorting (FACS) of cellular clones co-
expressing the β-lactamase gene in tandem with a protein of interest under the same transcriptional promoter 
(modified from [18]).  
 
The chemical modification of charged functional groups by means of bioactivatable 
moieties, such as the acetoxymethyl esters, has been instrumental for the facile use of several 
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small molecule-based fluorescent sensors, which are nowadays commonly available to the 
cell biologist. The calcium indicators of the Fura or Indo family, or the so-called “viability 
dyes” of the Calcein family are just an example (Fig. 1.1.4). Such kind of modifications 
proved useful when applied also to different classes of molecules, e.g. phosphoinositols (IPs) 
or phosphatidylinositol phosphates (PIPs), enabling their use as permeable probes for cell 
signalling or cell physiology studies [19-21]. In drug design, moreover, they often form the 
basis for prodrugs, compounds in which an active molecule with little bioavailability is 
altered to enhance its pharmacokinetic properties, such as absorption and distribution [22, 23]. 
 
a b
c
 
Fig. 1.1.4. Cell-permeable fluorescent indicators. The Ca++ indicators Fura-2 AM (a) and Indo-2 AM (b) are 
just two examples of the numerous cell-permeable ion indicators now commercially available (e.g. Invitrogen-
Molecular Probes). (c) The Calcein AM fluorogenic molecule: upon hydrolysis of its protecting groups by 
cellular esterases, the molecule fluoresces (ex. 495 nm, em. 515 nm). The protection of the carboxylic groups in 
these molecules with acetyl or acetoxymethyl (AM) esters enables them to freely permeate cell membranes. On 
the contrary, the product of their hydrolysis is retained within the cell. 
 
 
Although studies on peptide prodrugs constituting a significant chapter in the drug 
design literature [24-27], reports on the chemical modification of peptide-based fluorescent 
probes to permit cell entry are hard to find. To achieve cytoplasmic delivery of membrane-
impermeant compounds, microinjection has been routinely used. This technique is normally 
invasive, time consuming, requires good skills and, more importantly, permits to investigate 
only a limited number of cells at a time. Despite these disadvantages, this methodology has 
allowed, for instance, the dynamic study of several kinases, such as protein kinase A (PKA), 
protein kinase C (PKC), cyclin-dependent kinase 2 (CDK2) in Xenopus laevis oocytes [28]. 
Alternative methods which would make the study of a large specimen feasible are actively 
pursued, especially in the view of Systems Biology approaches. A class of molecules named 
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cell-penetrating peptides or protein transduction domains, discovered about fifteen years ago, 
appears to have potential to overcome the limitations inherent in the delivery of hydrophilic 
compounds into cells. An overview of these peptides is given in the next paragraph. 
 
 
1.2 Breaking barriers: the Cell-Penetrating Peptides 
 
In 1988, the investigators Frankel and Pabo, while developing an assay to measure the 
activity of the trans activator protein TAT from the human immunodeficiency virus 1 (HIV-
1), an essential component for the transcription and replication of the viral genome, reported 
“[...] the surprising observation that purified Tat protein can be taken up by cells and 
transactivate [a chloramphenicol acetyltransferase reporter gene under] the HIV-1 promoter” 
[29]. A similar observation was made independently by Green and Loewenstein [30]. Three 
years later Joliot and Prochiantz reported how the Antennapedia homeodomain protein from 
D. Melanogaster, exogenously added to cultured neurons, penetrated diffusely into the cells 
in a receptor-independent manner and increased their morphological differentiation [31]. The 
two discoveries fuelled deeper investigations aimed at finding the determinants of such 
surprising behaviour. In the studies that followed, the TAT arginine-rich domain (TAT49-57, 
[32, 33]) and a 16-residues long peptide from the third helix of the Antennapedia 
homeodomain (Antp43-58, [34]), also characterized by the presence of a short polycationic 
cluster, were found to mimic the features of their parental proteins. TAT49-57 and Antp43-58 
(the latter commonly known nowadays as Penetratin) were hence the lead sequences in the 
new research field of cell-penetrating peptides (CPPs, [35]).1 Also referred to as protein 
transduction domains (PTDs), one can count nowadays not less than thirty different peptides, 
natural or artificial, with sequences ranging from 9 to more than 30 amino acids, which share 
the ability to access the interior of a cell (Tab. 1.2 a. For a review, see [36, 37]). The striking 
feature of these peptides is their capacity to transport across the cell membrane a multitude of 
different cargoes, regardless of their molecular composition or weight. Intracellular delivery 
of peptides [33, 38-46], oligonucleotides including peptide-nucleic acids (PNAs) and short-
interfering RNAs (siRNAs) [47-55], DNA [56-58], antibody fragments or full-length proteins 
                                                 
1
 It is worth to mention the observation, made already in 1965, that homopolymers of cationic amino acids were able to enhance 
the internalization of radiolabelled albumin into cells [36], while in 1978 it was shown that the covalent conjugation of poly-L-
lysine to proteins and small molecules increased their cellular uptake and, in the case of methotrexate, the biological activity of 
the drug [37,38]. 
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[59-69], liposomes, phages and nanoparticles [70-73] have been documented.2 Internalization 
of CPPs occurs in a large number of different cultured cell types [37], while injection of 
various CPP-cargo conjugates in whole animals enables access also to tissues notoriously 
resistant to conventional drug targeting, such as the central nervous system (Fig. 1.2.1) [47, 
57, 63, 74].  
 
name sequence (one-letter code) comments 
TAT49-57 RKKRRQRRR from HIV-1 TAT protein 
penetratin RQIKIWFQNRRMKWKK from Antennapedia homeodomain 
pVEC IAARIKLRSRQHIKLRH from the murine vascular endothelial 
cadherin 
Vpr DTWPGVEALIRILQQLLFIHFRIGCQH from the HIV-1 VPR protein 
CPP from prion protein MANLGYWLLALFVTMWTDVGLCKKRPKP  
buforin TRSSRAGLQWPVGRVHRLLRK antimicrobial peptide 
magainin 
 
GIGKFLHSAKKWGKAFVGQIMNS antimicrobial peptide 
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES antimicrobial peptide 
transportan GWTLNSAGYLLGKINLKALAALAKKIL designed (chimeric) 
MAP KLALKLALKALKAALKLA designed (model amphipathic 
peptide) 
MPG GALFLGFLGAAGSTMGAWSQPKSKRKVC designed 
Pep-1 KETWWETWWTEWSQPKKKRKV designed 
 
Tab 1.2 a. A partial list of natural and synthetic CPPs (adapted from [36]). 
 
 
Fig. 1.2.1 TAT-mediated in vivo delivery of β-galactosidase (120 kD) in several mouse tissues. The presence in 
the brain indicated the successful crossing of the blood-brain barrier (From [63]. Reprinted with permission from 
AAAS). 
                                                 
2
 A more comprehensive list of scientific papers reporting the vectorization properties of TAT, Penetratin and other CPPs can be 
found in [35]. 
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Such impressive vectorization properties soon raised interest on the mechanism of entry: 
one or many? Cell specific or non-specific? Energy-dependent or not? Influenced by the 
cargo? Each reply to any of the questions above would have a high probability to be correct: 
in fact, few topics in cell biology have been so debated in the last ten years as the so-called 
transduction mechanism of the CPPs. The large number of experiments, conditions and 
models used surprisingly did not depict a unified view, but a highly diversified scenario, with 
findings often contrasting one to each other. Much of what is currently known has been 
gathered (mainly via fluorescence microscopy and, more recently, flow cytometry) from 
observations using TAT, Penetratin or poly-arginine analogues, which have been – and 
remain – the most studied peptides of the entire family [75-77]. 
 
The first observations performed on cultured cells pointed toward an energy-
independent mechanism, since cellular accumulation was not impaired when incubations were 
made at low temperature (+4°C) [32, 34] or, for poly-arginine analogues, in the presence of 
sodium azide (an inhibitor of ATP-H+ synthase) [78]. Mutant analyses revealed the 
importance of the overall positive charge for TAT [33] and for Penetratin, along with the role, 
in the latter, of the tryptophan residues [79]. Moreover, no receptor protein appeared 
involved, because retro- (reversed amino acid sequence) or inverso- (all D-amino acids) 
peptides were internalized with the same efficiency [80, 81]. The use of biotinylated versions 
of the peptides probed intracellular localization by means of fluorescently labelled 
streptavidin after cell fixation. The strong nuclear accumulation, with nucleolar staining, 
appeared justified by the presence of a putative nuclear localization sequence (NLS) [32, 82]. 
 
Many of these early observations were recently disputed because of improper 
experimental protocols. For instance, the high overall positive charge of the polycationic 
CPPs promotes a strong adhesion to the negatively charged plasma membrane, which cannot 
be reversed simply by a washing step after incubation. As a result, the quantification of 
cellular fluorescence by flow cytometry is inherently overestimated, as this technique cannot 
discriminate between truly internalized or surface-adherent fluorescent molecules. Indeed, it 
has been shown that more reliable results could be obtained when a trypsinization step or 
chemical quenching of the outer-bound molecules were performed prior to cell counting. 
Notably, it was also demonstrated that intracellular distribution of fluorescent CPPs was a 
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direct artifact of cell fixation procedures [83].3 The abandonment of cell fixation, highly 
encouraged by some investigators [84], in favour of a more rational observation of live 
specimens clearly demonstrated vesicular accumulation of fluorescently labelled CPPs under 
a variety of experimental conditions [83, 85-87]. It is now accepted that endocytosis takes part 
in the uptake of these peptides [36, 83, 88-90]. The term “endocytosis” nevertheless denotes a 
collection of distinctive processes through which exogenous or membrane-bound 
macromolecules can be internalized in the cell and redirected to specific locations [91-95]. In 
accordance with this definition, the examination of endocytic routes conveying CPPs in the 
intracellular environment revealed a multi-faceted scenario. A lipid raft-dependent 
macropinocytosis has been described for the internalization of a TAT49-57-Cre recombinase 
fusion protein in live mouse cells. The rapid uptake, already detectable after 5 min, was 
strongly impaired by the use of the macropinocytosis inhibitors nystatin and β-cyclodextrin 
[96]. A similar observation was made in HeLa cells using an octa-arginine peptide (Arg8) and 
Penetratin, but in the reported study the use of the macropinocytosis inhibitor 
ethylisopropylamiloride (EIPA) and the F-actin polymerization inhibitor cytochalasin D 
particularly suppressed Arg8 entry with little effect on Penetratin, suggesting two distinct 
paths to ingression and the general role of actin filaments in the process [88]. Involvement of 
endocytosis has been shown in several other studies with Penetratin peptides, reporting 
sometimes contrasting conclusions [85, 87, 97]. The uptake of fluorescently-labelled TAT 
peptides has been reported to occur via macropinocytosis [90], while appeared to follow 
mainly a clathrin-dependent pathway in human umbilical vein endothelial cells (HUVEC) 
[98]. On the contrary, the caveolae-dependent endocytosis was shown to be responsible for 
the internalization of TAT-EGFP fusions in several cell lines [65]. Clearly, the panorama of 
the endocytosis-mediated uptake of polycationic CPPs appeares variant, with convincing 
evidences for several types of intervening mechanisms. An apparent free diffusion has been 
detected in some cases also in living cells, under particular conditions [99-102]. There is a 
general agreement now on the fact that a multitude of parameters play their role in the 
internalization process, such as the nature and size of the cargo, the concentration, the cell 
type, its density at the time of the experiment and even the cell cycle stage [36]. It is also 
recognized that CPPs of other classes may have other mechanisms of ingression [35]. 
 
                                                 
3
 Artifactual redistribution of positively charged proteins, like histone H1 or VP22, as a consequence of cell fixation had already 
been described earlier [87]. 
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Other experimental data have suggested the role of membrane-surface, negatively-
charged glucosaminoglycans (GAGs), such as heparan sulfate, as putative “receptors” for the 
polycationic CPPs through the strong affinity to the arginine residues [103, 104]. The TAT 
transduction domain showed binding to heparin with high affinity (an analog of heparan 
sulfate) in vitro [105, 106], while heparin itself modulated the angiogenic and transcriptional 
activity of extracellular TAT [107, 108]. Consisting with these reports, the role of heparan 
sulfate has been demonstrated in living cells. Uptake of a TAT-GFP fusion protein was 
impaired in cells genetically defective in heparan sulfate biosynthesis, or it was competitively 
inhibited by soluble heparin and by treatment with glycosaminoglycan lyases [109]. Similar 
findings were reported for Penetratin conjugates and Penetratin-derivatized liposomes [110], 
and polyarginine peptides [111]. The interaction with heparan sulfate or related GAGs would 
trigger actin organization under the activation of the GTP-binding protein Rac-1 prior to the 
internalization event [111, 112].  
 
If polycationic CPPs enter mainly via an endocytic process, then one must assume the 
existence of an endosomal escape mechanism in support of the wealth of published data 
concerning the biological activity of various and diverse CPPs conjugates [54, 113-119]. 
Endosomal escape of HIV-1 TAT alone was indeed demonstrated [120], while the nuclear 
delivery of a functional Tat-Cre recombinase fusion protein required the use of 
lysosomotropic agents [121]. More elegantly, endosomal escape has been artificially induced 
by incorporation of a fusogenic peptide from the agglutinin protein of influenza virus to a 
CPP-protein conjugate [96, 122], demonstrating that the approach could be eventually 
extended to other kind of constructs. 
 
Despite the persistence of several “dark sides”, the research on CPPs is actively pursued 
world-wide, since many are eager to put into practice the huge pharmacological potential 
inherent in the targeted delivery into cells and tissues of “information-rich” molecules 
(proteins and nucleic acids) for the treatment of human diseases [123-126]. As an example, 
one may cite the numerous applications involving CPPs in disease models such as cancer, 
ischemic stroke or Parkinsonism [127-135], or the advancement offered in diagnosis and 
imaging technology [136]. A much awaited step will be the reliable delivery of siRNAs, 
which is foreseen by many as the “holy grail” of the macromolecular therapeutics of the new 
millennium [137, 138]. 
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2. Scope of the thesis 
 
This thesis describes in detail the synthesis and the evaluation of fluorescent peptides 
designed with the aim of creating cell-permeant sensors for enzyme activity in living cells. In 
particular, our goal was to find the best methodology that could allow the delivery of such 
peptides directly into the cytoplasm of cells and without the aid of invasive techniques, such 
as microinjection or electroporation. Moreover, the methodology had to be of general 
applicability, compatible with a broad range of peptidic substrates, especially those featuring 
a significant number of charged residues. Finally, the delivery had to be effective in different 
cell types.  
We focused our attention on a short sequence reproducing residues 988-993 of one of 
the six autophosphorylation domain of the epithelial grow factor receptor (EGFR), namely 
DADEY992L, and explored the possibility of creating a fluorescent probe for the tyrosine 
kinase activity of the receptor. This peptide contains two aspartate and one glutamate residue 
in its sequence, thus presents a net negative charge at physiological pH. Synthetic peptides 
comprising this and other motifs of the EGFR have already shown to undergo 
phosphorylation at the tyrosine residue in vitro [139, 140]. The EGFR [141] and its role in 
cancer biology [142-147] has been the object of intensive studies, including several based on 
fluorescence microscopy [148-152]. In these, nevertheless, the use of fluorescent, cell-
permeable peptidic probes has hardly been reported. 
To address the problem of cell-permeability of this probe, two strategies were tested: a) 
the conjugation with a vector belonging to the CPPs family (sect. 1.2); b) the chemical 
modification of the negatively charged aspartate and glutamate residues with bioactivatable 
acetoxymethyl (AM) esters to enhance hydrophobicity, thus allowing free diffusion into cells. 
 
The assay we envisioned is based on FRET occurring within the enzyme-substrate 
complex, between our probe and a genetically-encoded Green Fluorescent Protein-labelled 
EGFR (GFP-EGFR) or Yellow Fluorescent Protein-labelled EGFR (YFP-EGFR), stably or 
transiently expressed in cells. The concept of this assay is depicted in Fig. 2.1. This approach 
has already been validated for the study of phosphatase activity [153]. 
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Fig. 2.1. Formation of the enzyme-substrate complex between a generic tyrosine kinase and its substrate 
can be monitored by FRET. The kinase is expressed as a chimera with GFP or YFP, while the peptide probe is 
equipped with a red-emitting fluorophore (rhodamine).  
 
To enable the formation of a FRET pair between GFP-EGFR (or YFP-EGFR) and the 
peptide, we equipped the latter with a red-emitting rhodamine dye, since the emission spectra 
of either GFP or YFP favourably overlap with the excitation spectrum of rhodamine, as can 
be seen from Fig. 2.2. In the FRET pair GFP(YFP)/rhodamine the fluorescent protein serves 
as a donor while the chemical dye as an acceptor. 
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Fig. 2.2. Favourable overlap between emission spectra of Enhanced Green Fluorescent Protein (EGFP, solid 
green line) or Enhanced Yellow Fluorescent Protein (EYFP, solid red line) and excitation spectrum of rhodamine 
(dashed blue line) permit the use of the EGFP/rhodamine or EYFP/rhodamine pairs in FRET-based studies 
(TAMRA = tetramethylrhodamine. Source: Invitrogen-Molecular Probes4). 
 
The synthesis and purification of these peptides, as well as their performance in living 
cells are reported in the following sections. 
 
                                                 
4
 http:\\probes.invitrogen.com. 
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3. Material and methods 
 
3.1 Solid-phase peptide synthesis (SPPS) 
 
All peptides were synthesized on polystyrene based resins (cross-linked with 1% DVB,5 
100 – 200 mesh) using (L)N-α-Fmoc protected amino acids6 and conventional Fmoc 
chemistry protocols (Chan, 2000). Side chain protecting groups for the amino acids were: tBu 
for Asp, Glu, Ser, Thr and Tyr; Boc for Lys; Trt for Gln and Cys; Pbf for Arg. When 
particular orthogonal conditions were required (for side-chain modification on resin) acid-
sensitive Mtt and Cl-Trt groups were used for Lys and Tyr residues, respectively. For the 
synthesis of peptide acids (-COOH terminus) a Wang resin (polymer bound p-alkoxybenzyl 
alcohol) pre-loaded with the required amino acid was used. For the synthesis of peptide 
amides (-CONH2 terminal group) the Rink amide MHBA resin (polymer bound  
4-(2',4'-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucyl-4-methylbenzyl 
hydramine) was employed [154]. A schematic representation of the two solid supports is 
given in Fig. 3.1.1. 
O N
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a                                                                                         b 
Fig. 3.1.1. (a) A generic Fmoc-protected amino acid linked to the Wang resin. (b) The Rink amide MHBA 
support (Nle = norleucine). 
 
Bromomethyl acetate, DIC, DIPEA, DCI, DMF, HBTU, HOBt, NMP, tBuOMe, 
tBuOOH (5 M sol. in nonane), TFA, TIS, TNBS (1% sol. in DMF) were obtained from 
Aldrich-Fluka (Steinheim, Germany), and used without further purification. O-t-butyl-O’-
(4,5-dimethoxy-2-nitrobenzyl)-N,N-diisopropylphosphoramidite was a kind gift from Dr. 
Sirus Zarbakhsh (Schultz group alumnus, EMBL-Heidelberg, Germany). Pre-loaded Wang 
resins and N-α-Fmoc protected amino acids were obtained from Fluka and ORPEGEN 
Pharma GmbH (Heidelberg, Germany). Fmoc-Lys(Mtt)-OH and Fmoc-Tyr(Cl-Trt)-OH were 
                                                 
5
 Please refer to the table of abbreviations for the full name of chemicals and other reagents. 
6
 Residues in a sequence are always numerated from the carboxy terminus to the amino terminus, following the order of 
addition during the synthesis. R1 is the generic amino acid which is directly attached to the solid support (see Fig. 3.1.1 a). 
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purchased from Novabiochem (Merck Biosciences GmbH, Schwalbach/Ts, Germany). Fmoc-
AEEAc-OH linker was obtained from IRIS Biotech GmbH (Marktredwitz, Germany). 
Activated Penetratin (ActPEN) was obtained from MP-QBiogene (Irvine, CA, USA), 
dissolved into 0.5 mL of degassed water, divided into 50 µL single-use aliquots and stored at 
– 80°C. DCM, HPLC-grade water and ACN were obtained from Fisher Scientific Ltd 
(Loughborough, UK). Lissamine™-rhodamine sulfonylchloride (LRh-SO2Cl) was obtained 
from Fluka or Acros Organics (Geel, Belgium). 5(6)-carboxytetramethylrhodamine 
succinimidyl ester (5(6)-TAMRA SE, mixed isomers), Oregon Green® 488 iodoacetamide 
(mixed isomers) and Rhodamine Red™ C2-maleimide (mixed isomers) were purchased from 
Invitrogen-Molecular Probes (Leiden, The Netherlands). The structures of these fluorescent 
dyes are shown in Fig. 3.1.2.  
 
O
SO O
N
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O
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Fig. 3.1.2. The fluorophore reagents used for conjugation to peptides. (a) Lissamine™-rhodamine B 
sulfonylchloride (LRh-SO2Cl, MW 577.1). (b) Oregon Green® 488 iodoacetamide (MW 551.2). (c) Rhodamine 
Red™ C2-maleimide (MW 680.8). (d) 5(6)-carboxytetramethylrhodamine succinimidyl ester (5(6)-TAMRA SE, 
MW 527.5). Commercial preparations containing mixtures of regioisomers were used for fluorophores b, c and 
d. See also Tab. 3.1 b for the spectral properties of these dyes. 
 
Synthesis of peptides was performed manually in fritted polypropylene syringes 
(MultiSynTech GmbH, Witten, Germany) of variable volumes (2.5 – 10 mL) which were 
used for resin quantities of up to 300 mg. For larger amounts, a reactor was used made from a 
50 mL round glass vessel equipped with a sintered glass filter and a 250 mL round-bottom 
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flask connected to the filter outlet for waste solvent collection. While addition of reagents was 
made manually from the top of the vessel through a glass neck (stoppered during the 
synthesis), the removal of solutions was achieved with positive pressure (latex balloon filled 
with argon and connected to the top of the vessel via a glass joint equipped with a teflon 
stopcock). Syringes and the reactor vessel were secured to a flat-bed orbital shaker which 
provided the necessary agitation.  
A typical reaction scheme for peptide synthesis was composed of five steps performed 
at room temperature: 
a. Resin preparation. The resin was poured into a syringe or reaction vessel, washed with 
DCM and allowed to swell in this solvent for 30 min – 1 h. 
b. Fmoc deprotection. The resin was exposed twice to piperidine (20% v/v in DMF),  
for 3 min and 15 min, respectively; after deprotection the resin was washed with DMF (5 x) 
and NMP (1 x). 
c. Coupling. Fmoc-protected amino acids (4 eq) were combined with HBTU (3.95 eq), HOBt 
(4 eq) and dissolved in a minimal volume of NMP. DIPEA (8 eq) was added and the solution 
was stirred for 1 – 2 min before it was transferred to the deprotected resin-bound peptide by 
aspiration (syringes) or via a pipette (reaction vessel). For large scale synthesis starting from 
500 mg of resin, the excess was reduced to 3 eq for each amino acid, HOBt and DIC, 2.95 for 
HBTU, 6 for DIPEA. The coupling reaction was typically conducted for 40 – 60 min on a 
orbital shaker at medium speed of agitation and the efficiency of coupling was routinely 
monitored by the colorimetric TNBS test (see below). When coupling was performed 
overnight, the use of HOBt (4 eq) and DIC (4 eq) was preferred to avoid potential Fmoc 
deprotection due to the prolonged exposure of the resin-bound peptide to DIPEA. After 
successful coupling, the resin was extensively washed with NMP (3 x), iPrOH (3 x) DCM (3 
x) and finally end-capped. Steps b and c are schematically represented in Fig. 3.1.3. 
d. End-capping. Residual unreacted amino groups (even when not revealed by the 
colorimetric test) were capped by swelling the resin in a solution of Ac2O/pyridine 1:9 (v/v), 
2 x 3 min. Afterwards, the resin was extensively washed with DMF (5 x) and a new 
deprotection cycle was started.  
e. Cleavage. Upon completion of the desired sequence the resin-bound peptide was detached 
from its support with concomitant removal of all side-chain protecting groups. After extensive 
washing with NMP (3 x), iPrOH (3 x) DCM (3 x) and drying in vacuo for 30 – 60 min, the 
resin was exposed to a cleavage solution composed of TFA/TIS/water (95:2.5:2.5, v/v/v, 1 ml 
per 10 mg of resin-bound peptide) and left standing for 3 – 4 h with occasional shaking. The 
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resin was filtered and the filtrate containing the cleaved peptide was concentrated in vacuo 
(rotary evaporator). The peptide was precipitated with ice-cold tBuOMe and collected via low 
speed centrifugation in polypropilene (PP) tubes,7 washed with fresh ice-cold tBuOMe, 
centrifuged and dried before being redissolved in AcOH/water (20%, v/v) and ACN (up to 20 
– 25% v/v). The solution was eventually divided in 50 mL PP tubes and lyophilized. 
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Fig. 3.1.3. Schematic representation of Fmoc deprotection (left panel), activation (right panel), and coupling of 
two generic amino acids (R1, R2) during SPPS. 
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 PS tubes showed a markedly reduced resistance to TFA under the mechanical stress of centrifugation, thus their utilization is 
not recommended. 
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TNBS test [154] 
This rapid procedure was routinely performed to check the efficiency of the coupling 
step as well as to confirm Fmoc deprotection. A few grains of washed resin were withdrawn 
and placed in a glass test tube. Three drops of DIPEA (10% v/v in DMF) were added, 
followed by one drop of TNBS/DMF (1%, v/v). The resin was left standing for 5 – 10 
minutes and visually inspected. The presence of free amino groups was revealed by the beads 
changing colour to dark orange-red. This test was normally preferred to the Kaiser test, which 
requires heat and can in some instances lead to false positives, due to the instability of some 
amino protecting groups (for example the Mtt group of Lys). When doubts arose a test 
cleavage was always performed, and the product was checked via ESI-MS. Briefly, a few 
grains of washed and dried resin were transferred to a glass test tube or an Eppendorf vial and 
exposed to 100 – 200 µL of the cleavage cocktail for 1 h. The solution was dried under a 
stream of nitrogen and the cleaved product precipitated by addition of ice-cold tBuOMe. After 
brief centrifugation the ether was discarded, the precipitate redissolved in 50% ACN in water 
+ 1% formic acid (ca. 300 µL) and the solution directly injected into the mass spectrometer. 
 
On-resin orthogonal deprotection of Lys/Tyr residues  
When side-chain modifications on the solid support were necessary, Fmoc-Lys(Mtt)-OH 
or Fmoc-Tyr(Cl-Trt)-OH were incorporated into the synthesis. These orthogonal side-chain 
protecting groups could be removed under milder acidic conditions with 1% TFA in DCM 
(v/v), without cleaving the bond between the peptide and the resin or other protecting groups 
(such as tBu or Boc). TIS was added as a scavenger at 3% (v/v) concentration. The treatment 
was performed three to five times (10 – 15 min each) using enough volume of solution to 
cause the suspension to lose its brilliant yellow colour. Afterwards, the resin was rinsed with 
fresh DCM and NMP. For successful removal of the Mtt or Cl-Trt groups it was important to 
first wash the resin with DCM and dry it in vacuo for 15 – 20 min, as deprotection failed 
when performed after the resin was washed with DMF or NMP. On-resin deprotection of 
Lys(Mtt) residues could easily be monitored by the TNBS test. 
  
High-Performance Liquid Chromatography (HPLC) 
HPLC was routinely used to purify (preparative HPLC) and assess the quality of both 
crude and purified peptides (analytical HPLC). Analytical HPLC was performed with a 
Waters chromatographic system (Waters Corp., Milford, MA, U.S.A.) composed of a binary 
pump (mod. 1525) capable of a maximal flow of 10 mL/min and a dual lambda absorbance 
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UV-VIS detector (mod. 2487). Reverse-phase C18 (RP-18) columns were used: a Merck 
Lichrosorb RP-18 250 x 4 mm x 10 µm (Merck KGoA, Darmstadt, Germany) run with a flow 
rate of 1 mL/min or a Waters Symmetry RP-18 75 x 4.6 mm x 3.5 µm run with a flow rate of 
0.5 – 0.8 mL/min. The mobile phase was composed of water (+ 0.1% TFA) and ACN (+ 0.1% 
TFA). Analytical chromatography was normally performed using a linear gradient of ACN: a 
typical program for the elution of a fluorescently labelled peptide is shown in Tab. 3.1 a. The 
sample was normally dissolved in 30 – 50 µL of 25% ACN immediately prior to injection. 
 
Merck Lichrosorb RP-18  
(250 x 4 mm x 10 µm) 
Waters Symmetry RP-18  
(75 x 4.6 mm x 3.5 µm) 
solvent A: 10% ACN (+ 0.1% TFA) solvent A: 10% ACN (+ 0.1% TFA) 
solvent B: 90% ACN (+ 0.1% TFA) solvent B: 90% ACN (+ 0.1% TFA) 
flow rate: 1 mL/min flow rate: 0.5 – 0.8 mL/min 
injection loop: 20 µL injection loop: 20 µL 
injection volume: 10 µL injection volume: 10 µL 
detection: double lambda 215 + 254(560) nm detection: double lambda 215 + 254(560) nm 
gradient: linear in 20 min (1.5% per min) 
T (min) = 0 % ACN (+ 0.1% TFA) = 25 
T (min) = 20 % ACN (+ 0.1% TFA) = 55 
T (min) = 23 % ACN (+ 0.1% TFA) = 55 
T (min) = 25 % ACN (+ 0.1% TFA) = 25 
T (min) = 30 % ACN (+ 0.1% TFA) = 25 
 
gradient: linear in 10 min (3% per min) 
T (min) = 0 % ACN (+ 0.1% TFA) = 25 
T (min) = 1 % ACN (+ 0.1% TFA) = 25 
T (min) = 11 % ACN (+ 0.1% TFA) = 55 
T (min) = 12 % ACN (+ 0.1% TFA) = 55 
T (min) = 12.5 % ACN (+ 0.1% TFA) = 25 
T (min) = 16 % ACN (+ 0.1% TFA) = 25 
 
Tab. 3.1 a. Standard conditions for analytical HPLC of peptides. 
 
The control of all hardware parameters and the analysis of chromatograms were 
performed with the proprietary Waters software “Empower 2” run on a Intel Pentium® based 
PC (Santa Clara, CA, USA) under the Microsoft Windows 2000® operating system (Mountain 
View, CA, USA). 
This equipment and set-up was also used for semi-preparative purifications. Quantities 
of material up to 0.1 mg (per injection) were purified over the Merck Lichrosorb RP-18 
column mentioned above, with an elution rate of 1 mL/min. Quantities of material up to 0.4 
mg (per injection) were purified over a Supelco Discovery Bio Wide Pore RP-18 column 250 
x 10 mm x 10 µm (Bellefonte, PA, USA) with an elution rate of 5 mL/min. Linear gradients 
of ACN were commonly used, often requiring optimization for a given peptide. 
 
Preparative HPLC was performed using a Knauer chromatographic system (Knauer 
GmbH, Berlin, Germany) composed of a binary pump (mod. K-1800) capable of a maximal 
flow of 100 mL/min, 10 mL injection loop and a single lambda absorbance UV-VIS detector 
(mod. K-2501). Purifications were routinely performed using a Supelco Discovery Bio Wide 
Pore RP-18 column 250 x 21.2 mm x 10 µm charged with 2 – 40 mg of material (per 
3. Material and methods 
 19 
injection). The mobile phase was composed of water (+ 0.1% TFA) and ACN (+ 0.1% TFA). 
A typical run used a linear gradient of ACN from 25 to 55 % over 30 min with a flow rate of 
25 mL/min (1 %/min) and detection at 215, 254 or 560 nm. To improve resolution it was 
sometimes necessary to reduce the gradient rate from 1 to 0.5 %/min. Chromatograms were 
recorded on paper over a Juergens chart recorder (mod. SE 120) coupled to the UV-VIS 
detector, with the gain set to 100 – 200 mV and a chart speed of 30 cm/h. 
Stock solutions of fluorescently labelled peptides were prepared in anhydrous DMSO or 
in dioxane/water 1:1 (v/v) and stored at – 20°C. The concentrations were adjusted according 
to the absorbance values obtained from a diluted solution (1:150 – 1:300) in MeOH or 
buffered water (Tab. 3.1 b). Samples were measured in a 100 µL quartz cuvette (Hellma 
GmbH, Jena, Germany) with an UltroSpec 2100 Pro UV-VIS spectrophotometer (Amersham 
Biosciences, GE Healthcare). Concentration values were calculated on the basis of spectral 
parameters (Absmax, ε) obtained from Invitrogen-Molecular Probes technical resource website 
(Tab. 3.1 b). 
 
LRh-SO2Cl Lissamine™-rhodamine B 
sulfonylchlorhyde 
Absmax 568 nm, ε = 88000 
(MeOH) 
5(6)-TAMRA SE 
(mixed isomers) 
5(6)-carboxytetramethylrhodamine, 
succinimidyl ester 
Absmax 546 nm, ε = 95000 
(MeOH) 
Rhodamine Red™-C2 
maleimide (mixed isomers) 
 Absmax 560 nm, ε = 119000 
(MeOH) 
Oregon Green® 488 
iodacetamide (mixed 
isomers) 
 Absmax 491 nm, ε = 68000  
(H2O, pH 9) 
 
Tab. 3.1 b. Spectral properties (Absmax, ε) of the fluorophores used  
(Invitrogen-Molecular Probes data, http://probes.invitrogen.com). 
 
Mass spectrometry 
Molecular masses were measured using a bench-top ZQ2000 Waters-Micromass ESI 
(Electrospray Ionization) mass spectrometer equipped with a single quadrupole ion trap 
analyzer. Samples were introduced as diluted aqueous solutions, normally 50% ACN and 1% 
formic acid (ca. 100 µL), via an automated capillary syringe (flow rate 10 µL/min). Typical 
values of the hardware parameters of the instrument are summarized in Tab. 3.1 c. 
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desolvation temp.: 150°C gas flow: 380 L/h 
capillary voltage: 3.30 kV cone flow: 80 L/h 
cone voltage: 30 V detection: positive scan mode (ES+) 
200 – 2000 a.m.u., scan time 0.5 sec, 
inter-scan delay 0.3 sec, total scan 
time 1 min. 
 
Tab. 3.1 c. Hardware parameters for a typical ESI-MS analysis of peptides. 
 
The mass spectrometer was also connected directly to the HPLC apparatus for LC/MS 
analysis by joining the capillary probe to the outlet of the UV-VIS detector. A split valve was 
commonly used to halve the flow of mobile phase reaching the capillary probe. The main 
hardware parameters were left unchanged. The instrument, in both the MS and LC/MS 
configurations, was controlled by the “Empower2” software.  
MALDI (Matrix Assisted Laser Desorption Ionization) and ESI-ToF (Electrospray 
Time-of-Flight) mass spectra were performed at the EMBL Proteomic Core Facility by Dr. 
Thomas Franz and co-workers. 
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3.2 Synthesis of LRh-TAT peptide (LRh-Ahx-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-
CONH2) 
 
Rink amide MHBA resin (30 mg, 0.74 µmol/mg, Fig. 3.1.1) was poured into a 2.5 mL 
PP fritted syringe, washed three times with DCM and allowed to swell for 30 min. Synthesis 
was initiated by Fmoc deprotection, followed by washing and then coupling of Fmoc-
Arg(Pbf)-OH (89 µmol, 4 eq) with HOBt/DIC (4 eq each) in NMP for 6 h. The solution was 
discarded, the resin was washed (3 x NMP, 3 x iPrOH, 3 x DCM, 3 x NMP) and the coupling 
was checked via the TNBS test. End-capping of resin was performed next with 1 mL of 
Ac2O/pyridine (1:9, v/v), twice for 3 min. After rinsing with DMF (5 x) and Fmoc 
deprotection, the following amino acid (Fmoc-Arg(Pbf)-OH, 4 eq) was coupled in NMP for 
40 – 60 minutes using HBTU/HOBt/DIPEA (3.95:4:8 eq). This protocol was used for all the 
remaining amino acids and exchanged for the HOBt/DIC protocol (4 eq each) for overnight 
couplings. After addition of the Fmoc-Ahx-OH residue and the Fmoc deprotection cycle, the 
coupling of the dye was performed thus: LRh-SOCl2 (28.2 mg, 46.7 µmol, 2.1 eq) was 
dissolved in 500 µL NMP, DIPEA (11 µL, 66.6 µmol, 3 eq) was added and the dark purple 
solution was drawn into the syringe. The reaction was allowed to proceed overnight in the 
dark. Extensive washing with neat NMP and pyridine/NMP (20% v/v) was required to 
remove excess dye. A final washings was done with iPrOH (3 x), DCM (3 x), then the resin 
was dried in vacuo for 1 h. The peptide was cleaved from the solid support by exposing the 
resin for 3 h to a 5 mL solution of TFA/TIS/water (95:2.5:2.5, v/v/v) in a 10 mL round-
bottom flask, with occasional shaking. The resin was then filtered, washed with neat TFA (2 x 
2 mL) and the filtrate containing the cleaved peptide was concentrated in vacuo. The crude 
peptide was precipitated with ice-cold tBuOMe, collected via centrifugation, washed with 
fresh tBuOMe and redissolved in AcOH/water (20% v/v) plus 0.5 mL portions of ACN (up to 
2 – 3 mL) to get a clear solution. The entire volume (about 20 mL) was divided into two 50 
mL PP tubes and lyophilized. 1.4 mg of the crude lyophilisate were purified by semi-
preparative HPLC using a Supelco Discovery Bio Wide Pore RP-18 column (250 x 10 mm x 
10 µm) with a linear gradient of ACN (+ 0.1% TFA) from 25 to 40% over 20 min (0.75 
%/min), a flow rate of 5 mL/min and detection at 560 nm. Fractions were pooled, lyophilized 
and the resulting material was dissolved in dioxane/water (50% v/v) to give 44 µL of solution 
(2 mM, 0.18 mg, 90 nmol. Yield = 0.4%). Further HPLC analysis was performed using a 
Merck Lichrosorb RP-18 column (250 x 4 mm x 10 µm) with a linear gradient of ACN (+ 
0.1% TFA) from 25 to 40% over 20 min (0.75 %/min), a flow rate of 1 mL/min and detection 
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at 215 and 560 nm. The product eluted as a pair of partially resolved isomers after 9.3 and 9.9 
min (98% overall purity) and its identity was confirmed by ESI-MS (calculated mass for 
C86H147N34O17S2 1992.11, found 665.13 [M+3H+/3], 499.01 [M+4H+/4], 399.46 [M+5H+/5], 
333.06 [M+6H+/6]). The material was kept frozen at – 20°C until use. 
 
3.3 Synthesis of TAT(K-LRh) peptide (CH3O-Arg-Lys-Lys-Arg-Arg-Lys(Ahx-LRh)-Arg-
Arg-Arg-CONH2) 
 
The synthesis of this TAT variant was started from 30 mg of Rink amide MHBA resin 
(0.74 µmol/mg, Fig. 3.1.1) using the general protocol described above (sect. 3.2). Following 
Fmoc deprotection of Arg-3, a Fmoc-Lys(Mtt)-OH residue replaced the wild-type Gln-4 and 
the synthesis proceeded until completion of the sequence. After removal of the terminal Fmoc 
group from Arg-9, the amino terminus was end-capped by swelling the resin in 0.5 mL of 
Ac2O/pyridine (1:9, v/v), twice for 3 min. The resin was washed with NMP (3 x), iPrOH (3 
x), DCM (3 x) and dried in vacuo for 20 min. The removal of the Mtt group was performed 
next, using a solution of TFA/TIS/DCM (1:3:96, v/v/v) as described previously (sect. 3.1) and 
followed by the addition of the Fmoc-Ahx-OH residue. Condensation of LRh dye (28.2 mg, 
46.6 µmol, 2.1 eq), subsequent washings and cleavage from the support were all performed as 
described (sect. 3.2). After lyophilization, 1.9 mg of the crude peptide were purified by semi-
preparative HPLC using a Supelco Discovery Bio Wide Pore RP-18 column (250 x 10 mm x 
10 µm), with a linear gradient of ACN (+ 0.1% TFA) from 25 to 40% over 20 min (0.75 
%/min), a flow rate of 5 mL/min and detection at 560 nm. The pure material was dissolved in 
dioxane/water (50% v/v) to give 53 µL of a 1 mM solution (0.11 mg, 53 nmol. Yield = 0.2%). 
Further HPLC analysis was performed using a Merck Lichrosorb RP-18 column (250 x 4 mm 
x 10 µm) with a linear gradient of ACN (+ 0.1% TFA) from 10 to 50 % over 20 min (2 
%/min), a flow rate of 1 mL/min and detection at 215 and 560 nm. The product eluted as a 
single peak after 13.6 min (97% pure) and its identity was confirmed by ESI-MS (calculated 
mass for C89H155N34O16S2 2020.18, found 679.45 [M+3H+/3], 509.78 [M+4H+/4], 408.04 
[M+5H+/5], 340.23 [M+6H+/6]). The peptide was kept frozen at – 20°C until use. 
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3.4 Synthesis of LRh-DADEYL peptide (LRh-Cys-AEEAc-Asp-Ala-Asp-Glu-Tyr-Leu-
CONH2) 
 
Rink amide MHBA resin (50 mg, 0.74 µmol/mg, Fig. 3.1.1) was poured into a 2.5 mL 
PP fritted syringe, washed three times with DCM and allowed to swell for 30 min. Synthesis 
was initiated by Fmoc deprotection followed by washing and the coupling of Fmoc-Leu-OH 
(4 eq, 148 µmol) with HOBt/DIC (4 eq each) in NMP overnight. The solution was discarded, 
the resin was washed (3 x NMP, 3 x iPrOH, 3 x DCM, 3 x NMP) and the coupling was 
checked via the TNBS test. Residual unreacted amino groups on the resin (which were 
nevertheless not detected by the TNBS test) were end-capped by treatment with 1 mL of 
Ac2O:pyridine (1:9, v/v) twice for 3 min. The resin was then rinsed with DMF (5 x), 
deprotected and the succeeding amino acid (Fmoc-Tyr(tBu)-OH, 4 eq) was coupled in NMP 
for 40 – 60 minutes using HBTU/HOBt/DIPEA (3.95:4:8 eq). This protocol was used for all 
the remaining amino acids and exchanged for the HOBt/DIC protocol (4 eq each) for 
overnight couplings. A TNBS test and a capping step were always performed after each 
coupling. Finally, LRh-SO2Cl (64 mg, 0.11 mmol, 3 eq) was dissolved in 800 µL NMP 
followed by addition of TEA (31 µL, 0.22 mmol, 6 eq). The dark purple solution was drawn 
into the syringe and the resin was allowed to swell for 4 hours in the dark. The whole 
procedure was repeated with fresh materials overnight. Following extensive washings with 
NMP, the resin was rinsed with iPrOH (3 x), DCM (3 x) and dried in vacuo for 1 h. The 
peptide was cleaved from the solid support by exposing the resin for 3 h to a 5 mL solution of 
TFA/TIS/water (95:2.5:2.5, v/v/v) in a 10 mL round-bottom flask, with occasional shaking. 
The resin was then filtered, washed with neat TFA (2 x 2 mL) and the solution containing the 
cleaved peptide was concentrated in vacuo. The dried residue was carefully washed with ice-
cold tBuOMe (3 x) and the crude peptide redissolved in AcOH/water (20% v/v) + ACN (in 
0.5 mL portions up to 2 – 3 mL until the solution was clear). The volume (about 20 mL) was 
divided into two 50 mL PP tubes and lyophilized. 
The crude peptide was redissolved in a small volume of 25% ACN (+ 0.1% TFA) and 
chromatographed in 100 – 200 µL portions using a Supelco Bio Wide Pore RP-18 column 
(250 x 10 mm x 10 µm) with a step gradient of ACN (+ 0.1% TFA): linear 25 to 40% over 10 
minutes; isocratic 40%, 6 minutes; linear 40 to 55% over 4 minutes, flow rate 5 mL/min, 
detection 215 and 560 nm. The desired product eluted after 13.5 minutes. Fractions were 
pooled and lyophilized. The peptide was obtained in high purity, as shown by analytical 
HPLC (Merck Lichrosorb RP-18 column, 250 x 4 mm x 10 µm) and eluted as a single peak 
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with a retention time of ca. 15 minutes. The identity was confirmed by ESI-MS (calculated 
mass for C67H89N11O23S3 1511.53, found 1513.36 [M+H+], 757.32 [M+2H+/2]). The purified 
peptide was dissolved in 30 µL of anhydrous DMSO (3.5 mM, Tab. 3.1 b; 0.16 mg, 105 
nmol. Yield = 0.3%), aliquoted into 0.5 mL vials, sealed under argon and stored at – 20°C.  
 
3.5 Synthesis of LRh-DADEYL-PEN conjugate (LRh-Cys(S-PEN)-AEEAc-Asp-Ala-Asp-
Glu-Tyr-Leu-CONH2) 
 
50 µL (18.4 nmol) of ActPEN peptide in degassed water were mixed with 5.25 µL of a 
3.5 mM solution in DMSO of the LRh-DADEYL peptide (18.4 nmol) in a 0.5 mL Eppendorf 
vial, followed by the addition of 20 µL of degassed ACN to achieve complete solubilization. 
The vial was sealed under argon and the solution was shaken at room temperature overnight. 
Using a modification to this protocol, the ActPEN solution (50 µL) was first lyophilized, 
resuspended in 50 µL of anhydrous ACN saturated with argon, mixed with the LRh-
DADEYL peptide solution in DMSO (5.25 µL) and treated as described above. The conjugate 
was purified over a Merck Lichrosorb RP-18 column (250 x 4 mm x 10 um) as described 
(Tab. 3.1 a). The desired product eluted after 12 minutes and its identity was confirmed by 
ESI-MS (calculated mass: 4072,8 found 1358.51 [M+3H+/3], 1019.10 [M+4H+/4]). Collected 
fractions were pooled and lyophilized. The product from the two conjugation reactions was 
redissolved in anhydrous DMSO to afford 7.5 µL of solution (0.6 mM, Tab. 3.1 b; 17 µg, 4.42 
nmol. Yield = 12%). The material was stored at – 20°C. 
 
3.6 Synthesis of Fmoc-PEN1 Penetratin (Fmoc-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-
Arg-Arg-Met-Lys-Trp-Lys-Lys-COOH) 
 
Fmoc-Lys(Boc)-Wang resin (300 mg, 0.4 – 0.6 µmol/mg) were loaded into a 10 mL PP 
fritted syringe, washed three times with DCM and allowed to swell in this solvent for 60 min. 
Fmoc deprotection, coupling, end-capping and washing steps were performed as previously 
described. Each amino acid was used in an excess of 4 eq. The HBTU/HOBt/DIPEA coupling 
protocol (3.95:4:8 eq) was used (40 – 60 min coupling time) and exchanged with the 
HOBt/DIC protocol (4 eq each) for overnight condensations. A TNBS test was always 
performed to assess efficiency of coupling, followed by an end-capping step. Following the 
attachment of the last residue in the sequence, namely Fmoc-Cys(Trt)-OH-17, the resin was 
                                                 
8
 The exact sequence and composition of the commercial activated Penetratin are not known. Molecular weight of the conjugate 
could only be estimated by the sum of the single molecular weights. 
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extensively washed and dried in vacuo for 1 h. Cleavage was performed at this stage without 
prior removal of the terminal Fmoc group. The dried resin was placed in a round-bottom flask 
and treated with 30 mL of a solution of TFA/TIS/water (95:2.5:2.5, v/v/v) at room 
temperature for 4 h with occasional shaking. The cleavage mixture was filtered and the filtrate 
concentrated in vacuo. The crude peptide was precipitated with the addition of ice-cold 
tBuOMe, triturated and the suspension transferred into 50 mL PP tubes. The crude product 
was collected via low-speed centrifugation (1000 rpm, 4 min), resuspended in fresh ice-cold 
tBuOMe, again centrifuged and dried. Finally, it was redissolved in AcOH/water (20% v/v) 
and lyophilized. The crude material was redissolved in 15 mL of 25% ACN in water (+ 0.1% 
TFA) and purified in three 5 mL injections over a Supelco Discovery Bio Wide Pore RP-18 
column (250 x 21.2 mm x 10 µm) using a linear gradient of ACN (+ 0.1% TFA) as described 
in sect. 3.1. Under these conditions the product eluted after ca. 13 min. Fractions were pooled 
and concentrated in vacuo to eliminate ACN. The remaining solution was divided into 50 mL 
PP tubes and lyophilized to obtain 173.6 mg of product (67.5 µmol. Yield = 45%). The 
purified peptide was assayed by analytical HPLC (Waters Symmetry RP-18 column, 75 x 4.6 
mm x 3.5 µm) using a flow rate of 0.8 mL/min (Tab. 3.1 a): the product eluted as a single 
peak after ca. 7 min. The identity was confirmed by ESI-MS (calculated mass for 
C122H186N35O23S2 2573.38, found 858.66 [M+3H+/3], 644.30 [M+4H+/4], 515.60 [M+5H+/5]). 
 
3.7 Synthesis of Oregon Green® and Rhodamine Red™ Penetratin derivatives OG-
PEN1 and RR-PEN1 
 
Two solutions of Oregon Green® 488 iodoacetamide (mixed isomers) and Rhodamine 
Red™ C2-maleimide (mixed isomers) were prepared by dissolving a small aliquot of each in a 
few microlitres of anhydrous DMF and DMSO, respectively. The concentration of the two 
solutions was measured spectrophotometrically by making a 1:300 dilution in aqueous 
bicarbonate (pH 9) for Oregon Green® 488 iodoacetamide or MeOH for Rhodamine Red™ 
C2-maleimide and adjusted to 10 mM (final volume 23.4 µL) and 5 mM (final volume 23.0 
µL), respectively. Two 0.5 mg aliquots of lyophilized Fmoc-PEN1 peptide (0.2 µmol) were 
redissolved into 25 µL of degassed 25% (v/v) ACN in water and the entire volume was mixed 
with the solutions of the two dyes. Vials were sealed under argon and shaken overnight at 
room temperature in the dark to allow condensation between the free sulfhydryl group of the 
terminal Cys residue in Fmoc-PEN1 peptide and the iodoalkyl moiety of Oregon Green® or 
the maleimide group of Rhodamine Red™. The fluorescent conjugates were purified by semi-
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preparative RP-HPLC using a Merck Lichrosorb RP-18 column (250 x 4 mm x 10 µm), 
detection 215 and 254 nm for OG-PEN1 or 215 and 560 nm for RR-PEN1 peptide (Tab. 3.1 
a). Further analytical HPLC was performed using a Waters Symmetry RP-18 column (75 x 
4.6 mm x 3.5 µm) and a flow rate of 0.8 mL/min (Tab. 3.1 a). Retention times were between 
6.4 – 7.2 min for OG-PEN1 peptide and 7.6 – 8.4 min for RR-PEN1 peptide. The identity of 
products was confirmed by ESI-MS (OG-PEN1: calculated mass for C144H197F2N36O29S2 
2996.45, found 999.31 [M+3H+/3], 749.70 [M+4H+/4]. RR-PEN1: calculated mass for 
C155H222N39O31S4 3253.59, found 1085.33 [M+3H+/3], 814.21 [M+4H+/4]). The two 
fluorescent Penetratin derivatives were stored at – 20°C as 5 mM (OG-PEN1, 13 µL, 65 
nmol. Yield = 33%) and 1 mM (RR-PEN1, 35 µL, 35 nmol. Yield = 18%) solutions in 
anhydrous DMSO. 
 
3.8 Bulk synthesis of resin-bound Fmoc-DADEYL peptide (Fmoc-AEEAc-Asp(tBu)-Ala-
Asp(tBu)-Glu(tBu)-Tyr(Cl-Trt)-Leu-Rink amide resin) 
 
Rink amide MHBA resin (500 mg, 0.72 µmol/mg) was placed in the 50 mL reaction 
vessel, washed three times with DCM and allowed to swell in this solvent for 1 h. Synthetic 
steps, including colorimetric TNBS test, end-capping and washings were made as specified 
earlier (sect. 3.1). Amino acids, coupling reagents and protocols were used as reported in the 
following table (Tab. 3.8 a): 
 
1) Fmoc-Leu-OH 3 eq a.a., HOBt/DIC (3:3 eq), overnight 
2) Fmoc-Tyr(Cl-Trt)-OH 1 eq a.a., HOBt/DIC (1:1 eq), 1 h + 1x overnight + 0.5 eq a.a., 
HBTU/HOBt/DIPEA (0.5:0.5:1 eq), 2 h 
3) Fmoc-Glu(tBu)-OH 3 eq a.a., HBTU/HOBt/DIPEA (2.95:3:6 eq), 1 h + 1 eq a.a., 
HBTU/HOBt/DIPEA (0.95:1:2 eq) 1h 
4) Fmoc-Asp(tBu)-OH 3 eq a.a., HBTU/HOBt/DIPEA (2.95:3:6 eq), 1 h 
5) Fmoc-Ala-OH see entry 4 
6) Fmoc-Asp(tBu)-OH see entry 4 
7) Fmoc-AEEAc-OH 1 eq a.a., HBTU/HOBt/DIPEA (0.5:0.5:1 eq), 1h + 1 eq a.a., 
HOBt/DIC (1:1 eq), overnight 
 
Tab. 3.8 a. Preparation of  the Fmoc-DADEYL peptide (bulk synthesis on Rink amide MHBA resin). 
 
Following the addition of the Fmoc-AEEAc-OH residue, the resin-bound peptide was 
extensively washed and dried in vacuo. A cleavage test was performed on a small quantity of 
resin, without prior removal of the terminal Fmoc group, followed by analytical HPLC using 
a Waters Symmetry RP-18 column (75 x 4.6 mm x 3.5 µm) and a flow rate of 0.8 mL/min 
(Tab. 3.1 a). The product eluted after 8.7 min and its identity was confirmed by ESI-MS 
(calculated mass for C52H66N8O18 1090.45, found 1091.76 [M+H+]). 
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3.9 Synthesis of TAMRA-DADEYL peptide (5(6)-TAMRA-AEEAc-Asp-Ala-Asp-Glu-Tyr-
Leu-CONH2) 
 
Resin-bound Fmoc-DADEYL peptide (13.2 mg, corresponding to 6.9 mg of fully 
protected peptide, 4.5 µmol9, sect. 3.8) was placed in a 1.5 mL Eppendorf vial, deprotected 
twice (10 min each) with 500 µL of 20% (v/v) piperidine in DMF, rinsed with DMF (5 x 500 
µL) and NMP (1 x 1 mL). After brief centrifugation, the excess of solvent was removed by 
careful aspiration with a pipette, allowing the resin to swell in a minimal amount of liquid. 5 
mg of 5(6)-TAMRA SE (9.5 µmol, 2.1 eq) were dissolved into 150 µL of NMP/DCM 1:1 
(v/v) containing 4.8 µL of DIPEA (3 eq) and the solution was transferred to the resin. The 
coupling of the dye was performed in a mixer (900 rpm) at room temperature in the dark. 
Over time, the initial brilliant red solution largely decolourized, while the resin beads 
appeared dark red. After 3 h the solution was discarded and the resin was rinsed with 1 mL 
portions of NMP until the solvent appeared colourless, then it was transferred into a 2.5 mL 
PP syringe, rinsed with DCM (5 x 1 mL) and briefly dried in vacuo. Cleavage from the solid 
support was made by exposing the resin to 2 mL of TFA/TIS/water (95:2.5:2.5, v/v/v) for 3 h 
with gentle shaking. The resin was filtered, washed with neat TFA (2 x 1 mL) and the filtrate 
was concentrated in vacuo. The peptide was triturated in ice-cold tBuOMe, collected by 
centrifugation, rinsed again with fresh tBuOMe, centrifuged, dried, redissolved in 
AcOH/water (20%, v/v) with the addition of ACN (ca. 20% v/v) and lyophilized. The total 
amount of crude labelled peptide was 5.3 mg (4.1 µmol. Yield = 91%). HPLC analysis was 
performed using a Waters Symmetry RP-18 column (75 x 4.6 mm x 3.5 µm) with a flow rate 
of 0.8 mL/min (Tab. 3.1 a). The product eluted in the form of two regioisomers after 4.9 and 
5.4 min. The identity of both was confirmed by ESI-MS (calculated mass for C62H76N10O20 
1280.42, found 1281.83 [M+H+], 641.67 and 641.60 [M+2H+/2]). The lyophilized peptide 
was stored at – 20°C and used directly in the next synthetic step. 
 
3.10 Synthesis of TAMRA-DADEYL-AM3 peptide (5(6)-TAMRA-AEEAc-Asp(AM)-Ala-
Asp(AM)-Glu(AM)-Tyr-Leu-CONH2) 
 
Crude TAMRA-DADEYL peptide (5 mg, 3.9 µmol, 1 eq) was placed in a 2 mL screw-
capped PP vial, sonicated in 250 µL of anhydrous dioxane and freeze-dried. The material was 
                                                 
9
 The amount of bound peptide can be calculated from the following formula: mg peptide = (Qty x MW x s.l.) / (1000 + (MW x 
s.l.)) where Qty = amount of weighed resin, MW = molecular weight of the fully protected peptide, s.l. = substitution level of the 
resin., The value obtained has nevertheless to be considered indicative, as the substitution level is per se approximate and 
tends to decrease during the course of the synthesis. 
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then dissolved in 90 µL of anhydrous DMF, followed by the addition of 1 M DIPEA in 
anhydrous DMF (14 µL, 14 µmol, 3.6 eq) and 3.4 µL of bromomethyl acetate (5.4 mg, 35.1 
µmol, 9 eq). The vial was capped under argon and the reaction was carried out for 1 h at room 
temperature. After this time, the solution was concentrated in vacuo. Analytical HPLC was 
carried out using a Waters Symmetry RP-18 column (75 x 4.6 mm x 3.5 µm) a flow rate of 
0.8 mL/min (Tab. 3.1 a). The crude product was redissolved in 20% ACN in water (+ 0.1% 
TFA) and purified using a Supelco Bio Wide Pore RP-18 column (250 x 21.2 mm x 10 µm) 
with a linear gradient of ACN (+ 0.1% TFA) from 25 to 48% over 30 min (0.75 %/min), a 
flow rate of 25 mL/min and detection at 560 nm. The desired product was isolated as a 
mixture of isomers eluting at 16.5 min. Fractions were pooled, concentrated in vacuo and 
lyophilized. Further HPLC analysis was performed using a Waters Symmetry RP-18 column 
(75 x 4.6 mm x 3.5 µm) with a linear gradient of ACN (+ 0.1% TFA) from 30 to 50% over 15 
min (1.3 %/min), a flow rate of 0.8 mL/min and detection at 215 and 560 nm: the peptide was 
detected as a pair of partially resolved isomers eluting after 6.8 and 7.1 min (overall purity 
91.3%). The identity was confirmed by ESI-MS (calculated mass for C71H88N10O26 1496.59, 
found 1498.13 [M+H+], 749.85 [M+2H+/2]). Finally, the lyophilized peptide was redissolved 
in a few microlitres of dioxane/water 1:1 (v/v) and the concentration was adjusted to 1 mM 
(Tab 3.1 b). The final volume was 165 µL (165 nmol, 0.25 mg. Yield = 4.2%). This solution 
was divided into screw-capped PP vials in 15 µL aliquots, lyophilized and stored at – 20°C 
until use. Immediately before experiments, the product of a single vial was reconstituted in 15 
µL of dioxane/water 1:1 (v/v). 
 
3.11 Synthesis of TAMRA-EYL-AM1 peptide (5(6)-TAMRA-AEEAc-Glu(AM)-Tyr-Leu-
CONH2) 
 
A bulk preparation of the sequence Fmoc-Glu(tBu)-Tyr(tBu)-Leu on Rink amide 
MHBA resin (0.72 µmol/mg) was first performed starting from 500 mg of support and using 
standard protocols (sect. 3.1). 30 mg of this batch (corresponding to 12 µmol of fully 
protected peptide on resin) were first deprotected, rinsed and the Fmoc-AEEAc-OH linker 
(18.5 mg, 48 µmol, 4 eq) was coupled overnight with the HOBt/DIC protocol. Following 
further deprotection and washing cycles, the support was transferred to a 1.5 mL Eppendorf 
vial. 5(6)-TAMRA SE (6.3 mg, 13.2 µmol, 1.1 eq) was dissolved in 150 µL of NMP/DCM 
1:1 (v/v), along with DIPEA (4.4 µL, 24 µmol, 2 eq) and the solution was added to the resin. 
Mode of coupling and rinsing were the same as described in sect. 3.9. The cleavage was 
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performed with 5 mL of TFA/TIS/water (95:2.5:2.5, v/v/v) for 3 h, the crude product was 
precipitated in ice-cold tBuOMe, dried, redissolved in AcOH/water (20%, v/v) and 
lyophilized. The lyophilisate was redissolved in 20% ACN in water (+ 0.1% TFA) and the 
two regioisomers were separated using a Supelco Discovery Bio Wide Pore RP-18 column 
(250 x 21.2 mm x 10 µm) with a linear gradient of ACN (+ 0.1% TFA) from 20 to 33% over 
26 min (0.5 %/min), a flow rate of 25 mL/min and detection at 560 nm. The fractions were 
pooled and lyophilized to get 1.9 and 4.2 mg of each regioisomer, respectively (in total, 6.1 
mg of material, 6.2 µmol. Yield = 52%). 1.1 mg (1.12 µmol, 1 eq) of one regioisomer were 
first resuspended in anhydrous dioxane, lyophilized then dissolved in 30 µL of anhydrous 
DMF, followed by the addition of DIPEA (0.56 µL, 3.4 µmol, 3 eq) and bromomethyl acetate 
(0.33 µL, 3.4 µmol, 3 eq). The reaction was carried out in a screw-capped vial for 30 min 
under argon, then the solution was dried in vacuo. The crude peptide was purified by semi-
preparative HPLC using a Supelco Discovery Bio Wide Pore RP-18 column (250 x 10 mm x 
10 µm) with a linear gradient of ACN (+ 0.1% TFA) from 30 to 42% over 12 min  
(1 %/min), a flow rate of 5 mL/min and detection at 560 nm. Fractions were pooled and 
lyophilized to obtain 0.8 mg (0.76 µmol. Yield = 68%) of a single esterified peptide 
(TAMRA-EYL-AM1) and traces of a double esterified peptide (TAMRA-EYL-AM2). The 
identities of the products were confirmed by ESI-MS (TAMRA-EYL-AM1, calculated mass 
for C54H65N7O15 1051.45, found 1052.69 [M+H+]; TAMRA-EYL-AM2, calculated mass for 
C57H69N7O17 1123.47, found 1124.72 [M+H+]). For cell experiments, 1 – 2 mM stock 
solutions in anhydrous DMSO (Tab 3.1 b) were prepared just before. The material was stored 
at – 20°C. 
 
3.12 Synthesis of TAMRA-EAEEYL-AM3 peptide (5(6)-TAMRA-AEEAc-Glu(AM)-Ala-
Glu(AM)-Glu(AM)-Tyr-Leu-CONH2) 
 
Resin-bound Fmoc-Glu(tBu)-Tyr(tBu)-Leu (52 mg, corresponding to 24.2 µmol of 
fully-protected peptide on resin, sect. 3.11) was deprotected and completion of the sequence 
was performed similarly to what described previously (sect. 3.8). Following addition of the 
linker and a new deprotection cycle, 5(6)-TAMRA SE (14 mg, 26.5 µmol, 1.1 eq) dissolved 
in 250 µL of NMP/DCM 1:1 (v/v) was added to the resin, along with DIPEA (14.7 µL, 79.5 
µmol, 3 eq). Coupling was performed for 4 h in the dark. After the cleavage from the solid 
support, the separation of the two regioisomers was performed over a Supelco Bio Wide Pore 
RP-18 column (250 x 21.2 mm x 10 µm) using a linear gradient of ACN (+ 0.1% TFA) from 
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25 to 35% over 20 min (0.5 %/min), a flow rate of 25 mL/min and detection at 560 nm. The 
two products eluted after 8.2 and 9.4 min, respectively. Fractions were pooled and lyophilized 
to obtain 7.7 mg of the first isomer and 10.7 mg of the second, for a total of 18.4 mg (14 
µmol. Yield = 58%) of labelled peptide. Further HPLC analysis was performed using a 
Waters Symmetry RP-18 column (75 x 4.6 mm x 3.5 µm) with a flow rate of 0.8 mL/min 
(Tab. 3.1 a). The two isomers eluted after 4.7 and 5.3 min, respectively. Their identity was 
confirmed by ESI-MS (calculated mass for C64H80N10O20 1308.56, found 1309.82 [M+H+]). 
For the AM ester synthesis, 3.8 mg of one isomer (2.9 µmol) were first resuspended in 
anhydrous dioxane, lyophilized, then dissolved in 90 µL of anhydrous DMF in a screw-
capped vial. DIPEA (4.5 µL, 26.1 µmol, 9 eq) and bromomethyl acetate (2.6 µL, 26.1 µmol, 9 
eq) were added to the solution and the reaction was carried out for 30 min at room 
temperature under argon. The solution was divided in three vials and dried in vacuo. The 
crude material from one vial was purified by semi-preparative HPLC over a Supelco 
Discovery Bio Wide Pore RP-18 column (250 x 10 mm x 10 µm) using a linear gradient of 
ACN (+ 0.1% TFA) from 30 to 42% over 12 min (1 %/min), a flow rate of 5 mL/min and 
detection at 560 nm. Fractions were pooled and lyophilized to get 0.9 mg of the desired 
product (0.57 µmol. Yield = 59%). A peptide carrying four AM esters was isolated in traces. 
Further HPLC analysis was performed using a Merck Lichrosorb RP-18 column (250 x 4 mm 
x 10 µm) with a flow rate of 1 mL/min (Tab. 3.1 a). The product eluted after 14.8 min and its 
identity was confirmed by ESI-MS (calculated mass for C73H92N10O26 1524.62, found 
1525.91 [M+H+]). For cell experiments, 1 – 2 mM stock solutions in anhydrous DMSO (Tab. 
3.1 b) were prepared just before use. The material was stored at – 20°C. 
 
3.13 Synthesis of TAMRA-DADEY(cgdP)L-AM4 (5(6)-TAMRA-AEEAc-Asp(AM)-Ala-
Asp(AM)-Glu(AM)-Tyr(O2P-O’-AM-O’’-(4,5-dimethoxy-2-nitrobenzyl))-Leu-CONH2) 
 
Resin-bound Fmoc-DADEYL peptide (50 mg, corresponding to 28.7 mg of fully 
protected peptide, 18.7 µmol, sect. 3.8) was rinsed with anhydrous DCM and briefly dried in 
vacuo. Removal of the orthogonal Cl-Trt protecting group was performed with a mixture of 
TFA/TIS/DCM (1:3:96, v/v/v), as described (sect. 3.1). Afterwards, the resin was rinsed with 
DCM (5 x), transferred into a 1.5 mL eppendorf vial and carefully dried in vacuo (the vial 
was closed with a spare cap which was previously punctured by a needle). DCI (22 mg, 0.18 
mmol, 10 eq) was mixed with O-t-butyl-O’-(4,5-dimethoxy-2-nitrobenzyl)-N,N-
diisopropylphosphoramidite (78 mg, 0.18 mmol, 10 eq) and both were dissolved in 300 µL 
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anhydrous DCM. The solution was transferred onto the resin and the vial was shaken 
overnight in the dark. The solution was then discarded and the resin was rinsed with NMP (5 
x 1 mL).  Oxidation was performed by swelling the resin in 500 µL of a 0.5 M solution of 
tBuOOH in NMP (9 volumes NMP + 1 volume 5 M tBuOOH in nonane), twice for 1 h. The 
phosphorylation was confirmed at this stage by performing a test cleavage on a few grains of 
resin after N-terminal Fmoc deprotection. The peptide was assayed by analytical HPLC 
(Waters Symmetry RP-18 column, 75 x 4.6 mm x 3.5 µm) using a linear gradient of ACN (+ 
0.1% TFA) from 10 to 50% over 10 min (4 %/min), a flow rate of 0.8 mL/min and detection 
at 215 and 280 nm. The product eluted after 7.6 min and its identity was confirmed by ESI-
MS (calculated mass for C47H66N9O23P 1143.40, found 1144.83 [M+H+]). Following N-
terminal Fmoc deprotection with 20% (v/v) piperidine in DMF and washing cycles, coupling 
of the dye was performed by swelling the resin 4 h in the dark in 250 µL of a NMP/DCM 1:1 
(v/v) solution containing 5(6)-TAMRA SE (11.8 mg, 37.4 µmol, 1.2 eq) and DIPEA (10.4 
µL, 56.1 µmol, 3 eq) for 4 h in the dark. After extensive washing with NMP, the cleavage was 
performed with 5 mL of TFA/TIS/water (95:2.5:2.5, v/v/v) for 3 h. The crude product was 
precipitated from ice-cold tBuOMe, dried, redissolved in AcOH/water (20% v/v) and 
lyophilized. The lyophilisate was redissolved in 15% ACN in water (+ 0.1% TFA) and 
purified using a Supelco Discovery Bio Wide Pore RP-18 column (250 x 21.2 mm x 10 µm) 
with a linear gradient of ACN (+ 0.1% TFA) from 15 to 45% over 30 min (1 %/min), a flow 
rate of 25 mL/min and detection at 560 nm. The fractions were pooled and lyophilized to 
obtain 13.2 mg of the mixture of the two regioisomers (8.5 µmol. Yield = 45 %). Further 
HPLC analysis was performed using a Waters Symmetry RP-18 column (75 x 4.6 mm x 3.5 
µm), using a linear gradient of ACN (+ 0.1% TFA) from 10 to 50% over 10 min (4 %/min), a 
flow rate of 0.8 mL/min and detection at 215 and 560 nm: the two partially resolved 
regioisomers eluted after 8.5 and 8.7 min. Their identity was confirmed by ESI-MS 
(calculated mass for C71H86N11O27P 1555.54, found 1557.65 [M+H+], 779.58 [M+2H+/2]). 
For the AM ester synthesis, 3.5 mg of product (2.2 µmol) were first resuspended in anhydrous 
dioxane, lyophilized, then dissolved in 90 µL of anhydrous DMF in a screw-capped vial. 
DIPEA (4.6 µL, 26.4 µmol, 12 eq) and bromomethyl acetate (2.6 µL, 26.4 µmol, 12 eq) were 
added to the solution and the reaction was carried out for 30 min at room temperature under 
argon. The crude mixture was concentrated in vacuo. ESI-MS analysis revealed the –AM4 
product (m/z 1845.15) along with the presence of a –AM5 species (m/z 1917.22). Despite 
various attempts at purification, isolation of a clean product failed. 
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Mammalian cell culture, media, transfection protocols 
 
In vivo experiments were performed using HeLa Kyoto, human adeno-carcinoma (MCF-
7) and mouse embryonic fibroblast (MEF) cell lines. In some instances, HeLa Kyoto stably 
transfected with YFP-EGFR10 were also used. HeLa Kyoto and HeLa Kyoto/YFP-EGFR were 
kind gifts from Dr. Vibor Laketa (Pepperkok/Schultz, EMBL, Heidelberg, Germany). MCF-7 
were provided by Prof. Philippe Bastiaens (MPI Molecular Physiology, Dortmund, Germany). 
MEF and plasmids encoding for GFP-PTP1B or GFP-EGFR proteins were kind gifts from 
Prof. Fawaz Haj (UC Davis, CA, USA). Frozen stocks of cells were prepared according to the 
guidelines of the German Collection of Microorganisms and Cell Cultures Centre (DSMZ11 - 
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, 
Germany). 
Cells were routinely cultured in a humidified atmosphere (37°C, 5% CO2) and grown in 
monolayers in 250 mL flasks (Greiner Bio-One GmbH, Frickenhausen, Germany) with 
phenol red-containing DMEM (Invitrogen-Gibco, Paisley, U.K.) at 1.0 g/L (HeLa Kyoto) or 
4.5 g/L (MEF, MCF-7) glucose and supplemented with 10% FBS (PAN Biotech, Aidenbach, 
Germany), 2 mM L-glutamine (Invitrogen-Gibco, Paisley, U.K.), 100 U/mL penicillin 
(Sigma, Steinheim, Germany) and 100 µg/mL streptamycin (Sigma, Steinheim, Germany). 
Cells were regularly passaged twice a week at a sub-confluent state and detached from flasks 
by treatment with 1 mL of a solution of trypsin/EDTA (Sigma, Steinheim, Germany). Upon 
detachment, the cells were resuspended in 9 mL of complete medium and seeded in new 
flasks containing 12 – 14 mL of fresh culture medium. Below is a summary of the dilution 
factors commonly used during cell passages (Tab. 3.14 a). 
 
cell type dilution factor  
(1st passage, 1st day of week) 
dilution factor  
(2nd passage, 4th day of week) 
HeLa Kyoto 1:5 1:10 
MCF-7 1:4 1:8 
MEF 1:10 1:20 
 
Tab. 3.14 a. Dilution factors used for standard cell culture. 
 
The imaging medium used for cell microscopy was based on a HEPES buffer (without 
phenol red, pH 7.4) and its composition is reported in Tab 3.14 b. Peptide solutions were also 
                                                 
10
 The EGFR used in this study represent the isoform Erb1. 
11
 www.dsmz.de. 
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prepared in this medium; it was additionally supplemented with 1% FBS only for MCF-7 
cells. 
 
ingredient final concentration 
NaCl 115 mM 
CaCl2 1.2 mM 
MgCl2 1.2 mM 
K2HPO4 2.4 mM 
glucose 10 mM 
HEPES 20 mM 
NaHCO3 2.2 g/L 
 
Tab. 3.14 b. Composition of the imaging medium. 
 
For microscopic observations, 35 mm-MatTek dishes (MatTek Corp. Ashland, MA, 
USA) or Ibidi µ-VI slides (Integrated Biodiagnostics GmbH, Munich, Germany) were 
routinely used. Each Ibidi µ-VI slide is composed of a high quality plastic material on which 
six parallel chambers are reproduced. Each chamber has a volume of 30 µL and has two small 
reservoirs at either end, through which cells can be seeded and solutions can be dispensed. 
This new product features several advantages: a) the small chamber volume limits the waste 
of test substances; b) the plastic surface allows easy attachment of cells; c) each individual 
chamber guarantees an homogeneous cell growth and the closed space avoids drying of the 
cell monolayer during the experiment; d) up to six experiments can be run simultaneously. 
The small dimensions and the restricted access to the cells may, nevertheless, create some 
discomfort in cases where the experiment requires a frequent exchange of solutions with the 
support fitted onto the microscope stage. The Ibidi µ-VI slide is illustrated in Fig. 3.14.1.  
 
     
 
Fig 3.14.1. The Ibidi µ-6 slide (Integrated Biodiagnostics GmbH, Munich, Germany).  
 
 
Cells were normally seeded following trypsin/EDTA treatment on a sub-confluent 
monolayer (see above), with a specific protocol according to the support used and the 
necessity of transfection: 
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MatTek without transfection: 1.8 – 2.2x105 cells were seeded in 2.0 mL complete 
medium and allowed to adhere overnight. The experiment was normally performed the day 
after, with the cell monolayer at 60 – 80% confluency. 
 
MatTek with transfection: 48 h before the experiment 0.9 – 1.1x105 cells were seeded in 
2.0 mL of complete medium and allowed to adhere overnight. Transfection was performed 
the following day with the reagent Fugene-6 (Roche, Mannheim, Germany) following 
manufacturer’s recommendations and mixing 2 µg of plasmid DNA with 3 µL of reagent in 
150 µL of Optimem (Invitrogen-Gibco, Paisley, U.K.). The solution was left standing 30 min 
at room temperature before being transferred to the cells, which were previously washed and 
incubated in 1.5 mL Optimem. For MCF-7 cells, the standard culture medium was used for 
incubation, while the DNA/transfection reagent complex was prepared in Optimem. 
Experiments and observations were normally performed 16 – 20 h post-transfection, with the 
cell monolayer at 60 – 80% confluency. 
 
Ιbidi µ-VI slide without transfection: 1.0 – 1.2x104 cells (total volume 40 – 50 µL) were 
seeded in each chamber and allowed to adhere overnight. The following day, the cells (60 – 
80% confluent) were washed and incubated with 70 µL of fresh culture medium until the 
experiment began.  
 
Ιbidi µ -VI slide with transfection: 48 h before the experiment 6.8 – 7.2x103 cells (total 
volume 40 – 50 µL) were seeded in each chamber and allowed to adhere overnight. 
Transfection was performed the following day with the reagent Fugene-6, mixing in an 
Eppendorf vial 0.2 µg of plasmid DNA with 0.3 µL of transfection reagent in 10 µL Optimem 
per chamber. The mixture was left standing for 30 min, 60 µL of Optimem per chamber (or 
complete medium for MCF-7 cells) were added and the solution was transferred to the cells 
(about 70 µL per chamber) previously rinsed with Optimem (or complete medium for MCF-7 
cells). Before the addition, the excess of medium was removed, leaving 30 µL on the cells, so 
that the final volume was about 100 µL per chamber. Experiments and observations were 
normally performed 16 – 20 h post-transfection with cells 60 – 80% confluent. 
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3.15 Cell microscopy 
 
Live cell fluorescent microscopy was performed using a Leica SP2 AOBS laser 
scanning confocal microscope (Leica Microsystem, Heidelberg, Germany) equipped with a 
63X / 1.4 NA apochromatic oil objective. Excitation of fluorophores was achieved using the 
488 nm line of an Argon laser (for GFP, YFP and green fluorescent dyes) or the 561 nm line 
of a DPSS (diode pumped solid state) laser (for rhodamine dyes). Fluorescence was detected 
in the spectral window 500 – 530 nm (detector PMT 2) for GFP, YFP, green fluorescent dyes 
and 580 – 650 nm (detector PMT 3) for the rhodamine dyes. Laser scanning was normally 
unidirectional at 400 Mhz speed and the confocal pinhole was set to 1 Airy unit (ca. 114 µm), 
except where indicated. Multi-color images were acquired in sequential mode using the 
“between lines” option (detectors were switched on sequentially after each single line), and 
the signal was averaged every four lines. 
Experiments were performed on cells seeded in MatTek dishes or Ibidi µ-VI slides, as 
described (sect. 3.14). Peptide solutions were typically prepared in 100 µL of serum-free 
imaging medium if MatTek dishes were used, while the volume was reduced to 70 µL in case 
of the Ibidi µ-VI slides, taking into account the residual 30 µL present in each chamber (Fig. 
3.14.1). Only for MCF-7 cells, the level of serum was kept to 1% (v/v) throughout the 
experiment.  
When fluorescent Penetratins or their conjugates were used, the cells were incubated in 
serum-free culture medium (or at 1% FBS v/v for MCF-7 cells) containing 3% BSA (w/v) 
and 30 µg/mL DNAse I, for one hour prior the experiment (37°C). Afterwards, the cells were 
rinsed and incubated at room temperature or 37°C with solutions of the fluorescent peptides in 
concentrations and for the time periods indicated. Cells were then washed at least five times 
with imaging medium containing 3% BSA and imaged. To assess co-localization of dyes in 
endosomal compartments, some hardware parameters of the microscope were changed: the 
scanning speed was increased to 800 – 1000 Mhz, while the average of the signal was reduced 
to two lines. These changes resulted in a faster microscopic acquisition which was necessary 
to cope with the rapid movements of the endosomes. The drop of the intensity of the signal 
due to the faster scanning velocity had to be compensated with an increase of the pinhole 
aperture which, in turn, increased the thickness of the confocal plane. 
Acquired images were analyzed with the open-source software ImageJ (NIH, USA). 
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3.16 Time lapse recording of TAMRA-DADEYL-AM3 uptake in living HeLa Kyoto and 
MCF-7 cells 
 
HeLa Kyoto and MCF-7 cells were seeded in MatTek dishes or Ibidi µ-VI slides as 
described (sect. 3.14) and cultured overnight to allow adhesion. Before the experiment was 
started, cells were washed three times with imaging medium and incubated in this for 15 min 
at room temperature. Having secured the support to the microscope stage, the medium was 
carefully removed and a 10 µΜ solution of the peptide in imaging medium was dispensed in 
the centre of the MatTek dish (or in one reservoir of a single chamber in the Ibidi µ-VI slide). 
The microscope turret was placed back in position for acquisition, the focal plane and 
exposition were rapidly checked and time lapse recording was started. All these operations 
were normally completed within 20 – 30 sec of the addition of the peptide. While laser power 
and detector gain were previously adjusted using an equally concentrated solution of the 
peptide, care was taken to verify that the detector gain was set to a low-medium value to 
avoid pixel saturation at the end of the experiment, due to the strong increase of the 
fluorescence signal. Images were acquired every 6.5 sec for a total of 15 min (HeLa Kyoto 
cells) or every 15 sec for a total of 20 min (MCF-7 cells). Finally, the cells were rinsed five 
times with fresh imaging medium and a new single acquisition was recorded. 
For quantification of peptide uptake in a single cell, three regions of interest (ROIs) 
were selected: one in the cytoplasm, one in the nucleus and one in an unoccupied portion of 
the support which served as a background reference. First, the background intensity was 
calculated through the entire stack of pictures, averaged and normalized. Subsequently, the 
ratio between the average fluorescence values within the cellular ROIs and the normalized 
background was calculated for each time point. The resulting values were plotted using the 
analysis software “Origin” (OriginLab Corp., Northampton, MA, USA). 
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3.17 FLIM of YFP-EGFR in HeLa Kyoto cells incubated with the TAMRA-DADEYL-AM3 
peptide 
 
HeLa Kyoto stably transfected with YFP-EGFR were seeded in MatTek dishes as 
described (sect. 3.14) and cultured overnight to allow adhesion. Cells were rinsed, incubated 
with a 10 µM solution of the peptide in imaging medium for 20 minutes at room temperature, 
rinsed again and incubated with freshly prepared EGF in imaging medium at a final 
concentration of 100 ng/mL. Microscopic observation was performed with an Olympus 
Fluoview 1000 laser scanning microscope equipped with a 60X / 1.35 NA apochromatic oil 
objective. Excitation of YFP was achieved using the 488 nm line of an Argon laser and its 
fluorescence emission was detected in the spectral window 500 – 550 nm. Excitation of 
TAMRA was achieved using the 561 nm line of a DPSS (diode pumped solid state) laser and 
its fluorescence emission was detected in the spectral window 580 – 650 nm. For FLIM 
measurements, the YFP was excited with a 25 ns pulsed diode laser radiation at 470 nm. 
Emitted light was collected in a photon counter through a 525/50 nm passband filter. 
Normally, the signal was collected with a continuous exposure to the pulsed laser for 1 – 2 
minutes, according to the level of expression of the protein. Analysis of the YFP lifetime was 
done via the software “SymphoTime” vers. 4.3 (PicoQuant GmbH, Berlin, Germany). 
 
 
3.18 Acceptor photobleaching experiment in HeLa Kyoto cells incubated with the 
TAMRA-DADEYL-AM3 peptide 
 
HeLa Kyoto cells were seeded in MatTek dishes or Ibidi µ-VI slides and transfected 
with GFP-EGFR plasmid as described (sect. 3.14). 24 h post-transfection, the cells were 
washed and incubated with a 5 µM solution of TAMRA-DADEYL-AM3 peptide in imaging 
medium, for 45 min at room temperature. After rinsing, the cells were incubated with freshly 
prepared EGF in imaging medium (100 ng/mL) for 15 min at room temperature. The cells 
were then rinsed and fixed with a 3.7 % (v/v) PFA solution in imaging medium for 20 min at 
room temperature. After rinsing, excess of PFA was quenched with a 50 mM glycine solution 
in imaging medium for 20 min at room temperature. Finally, cells were rinsed and imaged 
under the Leica SP2 AOBS microscope (sect. 3.15). For the photobleaching procedure, 
selected cells were exposed to 30 cycles of irradiation with the 561 nm laser set at the highest 
power. FRET efficiencies were calculated using the Leica software routines, according to the 
formula FRETeff = (Dpost – Dpre)/ Dpost, where Dpost is the fluorescence intensity of the donor 
after bleaching, Dpre is the fluorescence intensity of the donor before the bleaching. During the 
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experiment, care was taken to keep a constant value for the area of any ROIs, so to have an 
equal value of the irradiation intensity : area ratio during the photobleaching. 
 
 
3.19 Preparation of cell lysates 
 
HeLa Kyoto, MCF-7 and MEF cells were each cultivated in monolayers in five 600 mL 
flasks (Nunc A/S, Kamstrupvej, Denmark). The cells were harvested at 95% confluency by 
treatment with trypsin/EDTA, resuspended in 50 mL of complete medium, centrifuged (800g, 
3 min) washed twice with 50 mL of HEPES 20 mM (pH 7.4) containing 10% FBS and twice 
with the same buffer without FBS, and centrifuging at 800g for 4 min after each wash. 
Finally, the cells were resuspended in 10 mL of ice-cold HEPES 20 mM (pH 7.4) and lysed 
on ice by sonication. The lysates were divided into 1.5 mL tubes and the cell debris was 
pelleted by centrifugation (15000g, 20 min, + 4°C). The supernatants were pooled and mixed 
with glycerol up to a final concentration of 20% (v/v). The solutions were clarified through 
0.45 µm filters (Millex-HV Durapore membrane, Millipore, Carrigtwohill, Co. Cork, Ireland). 
3 mL of these preparations were further concentrated by centrifugation (14000g, 3 h, + 4°C 
over Amicon Microcon concentrators, cut-off 3000 daltons, Millipore). The protein content 
was quantified with the Bradford assay in a 96-well plate reader (λ = 595 nm) using BSA as a 
standard and adjusted to 2 µg/µL for each cell lysate. The preparations were kept frozen  
(– 20°C) in 50 µL aliquotes. 
 
 
3.20 Esterase assay of cell lysates, PLE, mouse and fetal bovine sera using α-naphthyl 
acetate 
 
95 µL of HEPES (20 mM, pH 7.4) was added to a 96-well plate, followed by 3 µL of 
HeLa Kyoto, MEF or MCF-7 cell lysates, or 3 µL of mouse or fetal bovine serum,12 or 3 µL 
(3 mU) of a diluted solution of PLE (Sigma, Steinheim, Germany) in HEPES (20 mM, pH 
7.4). 2 µL of a 10 mM stock solution in ethanol of α-naphthyl acetate was subsequently added 
(0.2 mM final concentration). The reactions were stopped after 30 min (for cell lysates) or 10 
min (for PLE, mouse serum, fetal bovine serum) by adding 25 µL of a solution of Fast Blue B 
salt (tetra-azotized o-dianisidine/ZnCl2 0.3% w/v) in aqueous 3.5% (w/v) SDS, freshly 
prepared and kept in the dark. After 15 min of incubation (at room temperature and at dark), 
the plate was inserted in a Tecan 96-well plate spectrophotometer and the absorbance reading 
                                                 
12
 Heparin-containing mouse serum was provided by the EMBL Mouse facility and kept at – 20°C until use. 
3. Material and methods 
 39 
was performed at 620 nm. Each sample was assayed in triplicate. Blank solutions were 
prepared as described but without addition of α-naphthyl acetate, while a 0.2 mM solution of 
α-naphthol (from a 10 mM ethanolic stock solution) in HEPES (20 mM, pH 7.4) served as a 
positive control. To assess esterase activity after heat treatment, small aliquotes of cell lysates, 
mouse and fetal bovine sera were incubated at 56°C for 45 min and then used as described 
above. The protease inhibitor cocktail (EDTA-free, in tablets, Roche, Mannheim, Germany) 
was prepared as a 7x stock solution by dissolving one tablet in 1.5 mL of water and it was 
used at 1x final concentration as recommended by the manufacturer. 
 
 
3.21 Mass analysis of products of esterase activity over AM-esterified peptides 
 
To a 5 µM solution of TAMRA-DADEYL-AM3, TAMRA-EYL-AM1, TAMRA-
EAEEYL-AM3 peptides in HEPES 20 mM (pH 7.4) were added cell lysates or mouse serum 
up to a final concentration of 3% (v/v) (100 µL total volume), or 3 mU of PLE. The samples 
were incubated at room temperature for 30 min (cell lysates, mouse serum) or at 37°C 
overnight (PLE). Proteins were precipitated by adding 400 µL of ice-cold ethanol and 
solutions were kept on ice for 30 min. Afterwards, the samples were centrifuged at + 4°C 
(15000g, 30 min) and the supernatants were concentrated in vacuo. The concentrated material 
was resuspended in 1 mL of a 10% (v/v) ACN solution in water containing 0.1% TFA (v/v). 
The solution was desalted through a SPE-RP C-18 cartridge (50 mg resin/1 mL capacity, 
Supelco, Bellefonte, PA, USA), previously rinsed with 1 mL MeOH and equilibrated with 1 
ml of a 10% (v/v) ACN solution in water (+ 0.1% TFA, v/v), by washing with 1 mL of the 
equilibration solution and eluting the products with 1 mL of a 50% (v/v) ACN solution in 
water (+ 0.1% TFA, v/v). The eluate was concentrated in vacuo up to ca. 150 µL and directly 
used for MALDI or ESI-MS analysis. 
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4. Results 
 
4.1 The rhodamine-labelled LRh-TAT49-57 and TAT(K-LRh) peptides and their uptake in 
living cells 
 
The arginine-rich TAT49-57 domain (Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg) is among 
the most studied cell-penetrating peptides, as documented by the extensive literature available 
[76, 125, 137]. While green fluorescent derivatives have been described in several 
investigations [32, 83, 101, 156, 157], the use of a red fluorescent conjugate has been reported 
less often [157]. Moreover, a previous study indicated that the substitution Gln54Ala in the 
wild-type sequence was not detrimental to the translocation of the peptide in living cells, 
while any single Arg/Ala or Lys/Ala substitution had a remarkable negative influence [81]. 
Following these indications, two peptides were synthesized and equipped with the red 
fluorophore Lissamine™-rhodamine (LRh). The peptides, named LRh-TAT49-57 and TAT(K-
LRh), differed for the site of conjugation: while in LRh-TAT49-57 the fluorophore was linked 
to the N-terminus via an aminohexanoic acid spacer, in the branched derivative TAT(K-LRh) 
the fluorophore occupied a lateral position. In order to obtain this novel TAT conjugate, a Lys 
residue was incorporated (as Fmoc-Lys(Mtt)-OH) in the sequence in place of the wild-type 
Gln (Gln54Lys). Upon completion of the linear sequence and acylation of the free N-
terminus, the orthogonal Mtt protecting group was removed, allowing the sequential coupling 
of the aminohexanoic acid linker and the LRh dye on the resin. The structures of the two 
peptides are represented in Fig. 4.1.1. 
 
It is important to underline the fact that, at the time the TAT peptides were synthesized, 
our research group lacked pieces of equipment (mass spectrometer, double-pump preparative 
HPLC, semi-preparative RP columns) which later allowed accurate purification and 
characterization of these and the peptides synthesized thereafter. Thus, silica-gel plates were 
initially used for purification of the TAT peptides, with eluent mixtures composed of 
ammonia, alcohols (methanol, isopropanol or n-butanol) and chloroform in different ratios. 
This procedure was overall unsatisfying. In particular, desorption of the compounds from the 
chromatographic plate was always troublesome, with significant loss of material and 
contamination with silica particles. Despite the removal of the bulk of by-products (visible as 
discrete fluorescent bands on the silica plate) and the identification of the fractions containing 
the desired peptides via MALDI mass spectrometry, the quality of these purifications 
remained poor and could not be improved until HPLC and LC/MS analyses became a regular 
routine in our laboratory, and the necessary instrumental skills were acquired. 
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Fig. 4.1.1. Lissamine™-rhodamine derivatives of the TAT49-57 peptide. (top) LRh-TAT49-57. (bottom) 
TAT(K-LRh), with the Lys residue substituting the wild-type Gln coloured in red (Materials and methods, sect. 
3.2, 3.3). 
 
 
In preliminary experiments, HeLa Kyoto cells were incubated with a solution of 
partially-purified TAT peptides. As a result, both peptides showed uptake into vesicles, which 
were scattered throughout the cytoplasm and the perinuclear area (Fig. 4.1.2 a, b). No staining 
of the cell nuclei was detected, despite a putative nuclear localization sequence (NLS) being 
previously argued in this region of the TAT peptide [32, 82]. Moreover, the distribution was 
in contrast from that documented in fixed cells [32, 157]. Interestingly, the TAT(K-LRh) 
peptide was internalized with the same efficiency, indicating that the location of the dye in the 
molecule did not impair the uptake (Fig. 4.1.2 b). 
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                                                                            a                                                                        b 
Fig. 4.1.2. Partially-purified LRh-TAT and TAT(K-LRh) peptides showed uptake in vesicles in living 
HeLa Kyoto cells. Cells were incubated with a 10 µM solution of either LRh-TAT (a) or TAT(K-LRh) (b) 
peptides in imaging medium for 15 min at room temperature. After rinsing, cells were imaged unfixed. Both 
peptides, which had a low grade of purity, were internalized in vesicles distributed throughout the cytoplasm and 
the perinuclear area. No nuclear fluorescence was visible (Material and methods, sect. 3.15). 
 
 
Nevertheless, more recent literature data warned about an artifactual redistribution of 
TAT (and other polycationic peptides) as a result of fixation procedures [83]. Indeed, those 
observations could be verified when HeLa Kyoto cells were fixed after exposure to the LRh-
TAT49-57 and TAT(K-LRh) peptides: the fluorescent signal redistributed evenly in the 
cytoplasm of the cells, with additional staining of the nucleoli (Fig. 4.1.3). 
 
     
                                                                            a                                                                        b 
Fig. 4.1.3. LRh-TAT and TAT(K-LRh) peptides redistributed evenly into cytoplasm and nucleoli of HeLa 
Kyoto cells following fixation. Cells were incubated with a 10 µM solution of either LRh-TAT (a) or TAT(K-
LRh) (b) peptides in imaging medium for 15 min at room temperature, washed, fixed with a solution of 
MeOH:acetone (1:1, v/v) at room temperature for 3 min, washed and imaged. As a result of fixation, both 
peptides redistributed evenly in the cytoplasm, showing at the same time a high affinity for nucleolar structures. 
Scale bar = 10 µm (Material and methods, sect. 3.15). 
 
 
More recently (during the completion of this experimental work), a careful purification 
and characterization of the LRh-TAT49-57 and TAT(K-LRh) peptides could be achieved. 
Surprisingly, analytical HPLC showed the LRh-TAT49-57 peptide as a mixture of 
regioisomers, obtained in 98% overall purity after semi-preparative purification (Fig. 4.1.4). 
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On the contrary, the TAT(K-LRh) peptide was obtained as a single product of 97% purity 
(Fig. 4.1.5). This finding may reflect the fact that, routinely, different batches of the 
rhodamine dye were used. Nevertheless, none of these preparations clearly stated the presence 
of isomers in the composition of the product. Final purification afforded these peptides in low 
yield (0.4 and 0.2%, respectively), nevertheless enough material was obtained to perform new 
experiments in HeLa Kyoto cells. 
 
 
                                             a                                                                                                                  b 
Fig. 4.1.4. The LRh-TAT49-57 peptide. (a) Analytical HPLC performed after semi-preparative purification 
showed two regioisomers eluting after 9.3 and 9.9 min, with a 98% overall purity. (b) ESI-MS confirmed both 
regioisomers as [M+3H+/3] (m/z 665.13), [M+4H+/] (m/z 499.01), [M+5H+/5] (m/z 399.46) and [M+6H+/6] (m/z 
333.06) species (Material and methods, sect 3.2). 
 
 
                                             a                                                                                                                   b 
Fig. 4.1.5. The TAT(K-LRh) peptide. Analytical HPLC performed after semi-preparative purification showed 
a single product eluting after 13.6 min (purity = 97%). (b) ESI-MS confirmed the identity of the peptide as 
[M+3H+/3] (m/z 679.45), [M+4H+/4] (m/z 509.78), [M+5H+/5] (m/z 408.04) and [M+6H+/6] (m/z 340.23) 
species (Material and methods, sect 3.3). 
 
 
Surprisingly, after incubation with a 5 µM solution of either LRh-TAT49-57 or TAT(K-
LRh), the fluorescence localized differently from what observed earlier (Fig. 4.1.2): the 
peptides appeared to concentrate in compartments resembling the endoplasmic reticulum or 
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mitochondria (Fig. 4.1.6). Vesicles were virtually absent, while some bright spots were 
noticed in the periphery of the plasma membrane, indicating possible sites of peptide 
aggregation [101].  
 
     
                                                                            a                                                                        b 
     
                                                                            c                                                                        d 
Fig. 4.1.6. Distribution of purified LRh-TAT49-57 and TAT(K-LRh) peptides in living HeLa Kyoto cells. 
Cells were incubated with a 5 µM solution of either LRh-TAT49-57 (a, b) or TAT(K-LRh) (c, d) peptides in 
imaging medium for 10 min at room temperature. Fluorescence distribution suggested localization of peptides in 
compartments such as endoplasmic reticulum or mitochondria. Bright fluorescent spots were also detected on the 
plasma membrane. Pictures a and c represent transmitted light (phase contrast) images. Scale bar = 10 µm 
(Material and methods, sect. 3.15). 
 
 
Notably, LRh-TAT49-57 appeared to exert toxic effects when HeLa Kyoto cells were 
incubated with a 10 µM solution for 5 min, a circumstance which induced abnormal changes 
in the cell shape and cytoplasmic vacuolization (Fig. 4.1.7). TAT(K-LRh) was not tested 
under these conditions, nevertheless both peptides appeared to be well tolerated by this cell 
type when used at 5 µM concentration and up to 10 min of incubation time (room 
temperature). 
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                                                                            a                                                                        b 
Fig. 4.1.7. LRh-TAT49-57 exerted toxic effects on HeLa Kyoto cells at a higher concentration. Cells were 
incubated with a 10 µM solution of LRh-TAT peptide in imaging medium (a, b) for 5 min at room temperature. 
Abnormal changes in cell shape were evident, with a concomitant cytoplasmic vacuolization. Picture a represent 
a transmitted light (phase contrast) image. Scale bar = 20 µm (Material and methods, sect. 3.15). 
 
The behaviour of the LRh-TAT49-57 peptide was also tested in other cell types. In MEF 
cells, uptake was evident after an incubation of 10 min and a peptide concentration of 5 µM 
(results not shown), but a higher number of cells appeared stained after 30 min with a peptide 
concentration of 10 µM. No clear sign of toxicity was visible under these conditions (Fig. 
4.1.8). MCF-7 cells were stained after exposure to a 2.5 µM solution for 30 min (Fig. 4.1.9), 
while the peptide was toxic when cells were incubated 10 min with a concentration of 10 µM 
(results not shown). 
 
     
                                                                            a                                                                        b 
Fig. 4.1.8. Uptake of the LRh-TAT49-57 peptide by MEF cells. Cells were incubated with a 10 µM solution of 
LRh-TAT49-57 peptide in imaging medium for 30 min at room temperature (a, b). Uptake was visible in a large 
number of cells. Picture a represent a transmitted light (phase contrast) image. Scale bar = 20 µm (Material and 
methods, sect. 3.15). 
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                                                                            a                                                                        b 
Fig. 4.1.9. Uptake of the LRh-TAT49-57 peptide by MCF-7 cells. Cells were incubated with a 2.5 µM solution 
of LRh-TAT peptide in imaging medium for 30 min at room temperature (a, b). Uptake was visible in 
membrane-bound compartments in the perinuclear area. Picture a represent a transmitted light (phase contrast) 
image. Scale bar = 20 µm (Material and methods, sect. 3.15). 
 
 
The uptake of the TAT(K-LRh) peptide in MEF and MCF-7 cell types is currently under 
investigation. The use of known fluorescent markers will be instrumental in order to possibly 
clarify the nature of the compartments where these rhodamine-labelled TAT peptides appear 
to accumulate. In particular, it will be of interest to verify whether the two peptides distribute 
in the same organelles in living cells and to test the possible effect on the distribution due to 
the use of different fluorophores. 
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4.2 The rhodamine labelled LRh-DADEYL probe and its Penetratin conjugate LRh-
DADEYL-PEN peptide 
 
The condensation of the Lissamine™-rhodamine dye (Fig. 3.1.2) was the most 
troublesome step toward the synthesis of the LRh-DADEYL probe (Fig. 4.2.1). While it is 
common practice in the synthesis of fluorescently labelled peptides to insert a spacer between 
a bulky fluorophore and the peptide sequence, previous studies in our laboratory had shown 
the benefits afforded by the insertion of a polar, hydrophilic linker to enhance water solubility 
of this probe [158]. Thus, the linker AEEAc was inserted following the residue Asp-6. 
Moreover, earlier observations revealed how the conjugation of the dye itself to this linker 
was enhanced by the presence of a cysteine residue as a “junction node”. With the additional 
aim of linking the probe to the Penetratin sequence via a disulfide bond, this residue could 
indeed accomplish two functions simultaneously.  
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Fig. 4.2.1. The LRh-DADEYL probe. Upon completion of the amino acid sequence the hydrophilic linker 
AEEAc was introduced, while a Cys residue served as “junction node” to facilitate conjugation of the 
Lissamine™-rhodamine dye as a sulfonamide. The free sulfhydryl group served for the subsequent fusion to the 
ActPEN peptide. The carboxy terminal group was in the form of amide (CONH2) due to the use of the Rink 
amide resin (Materials and methods, sect. 3.4). 
 
Notably, differences were observed in the coupling of the dye according to its 
commercial source and the protocol used for conjugation: LRh-SO2Cl obtained from Acros 
(certified “pure” by the manufacturer) failed to couple in the presence of DIPEA; on the other 
hand, LRh-SO2Cl from Fluka successfully coupled only in the presence of TEA. Repeating 
the protocol twice did not guarantee saturation of all free amino groups on resin, as revealed 
by HPLC of the crude reaction mixture (Fig. 4.2.2, a). Furthermore, the utilization of the dye 
from this commercial source – for which no specification of purity was given – was always 
characterized by the appearance of several by-products, the most prominent being a [M + 34] 
a.m.u. species eluting 1.5 min later than the desired product (Fig. 4.2.2, a). Despite the 
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presence of various contaminants the desired product was successfully purified by semi-prep 
HPLC (Fig. 4.2.2, b), although the final yield was low (0.3%, sect. 3.4) 
 
 
                                                             a                                                                                                                         b 
 
 
          c 
Fig. 4.2.2. Analytical HPLC and MS over LRh-DADEYL peptide (Merck Lichrosorb RP-18 250 x 4 mm x 
10 um). (a) Chromatogram of the crude product after LRh conjugation to the resin-bound peptide: the peak 
eluting at 12.5 min represented unlabelled peptide, the peak eluting at 14.6 min corresponded to the desired 
product and the peak eluting at 16 min was an uncharacterized by-product with a mass difference of + 34 a.m.u. 
(b) LRh-DADEYL peptide after semi-preparative purification. (c) ESI-MS of the product identified as a [M + 
H+] (m/z 1513.36) and [M + 2H+/2] (m/z 757.32) species (Material and methods, sect. 3.4). 
 
The conjugation of the LRh-DADEYL probe to the commercially available vector 
“activated Penetratin” (ActPEN) was possible due to the presence of a N-terminal pyridyl 
disulfide function.13 Such a group enables the fusion via a disulfide bond to a free thiol group. 
Thus, the branched peptide LRh-DADEYL-PEN was synthesized by mixing equimolar 
amounts of the two species in a water/ACN solution (Fig.4.2.3, a). 
 
 
                                                 
13
 The exact sequence and composition of the commercial “activated Penetratin” are not known. The activating function is likely 
to be the 3-nitro-2-pyridylthio group of a N-terminal cysteine. Indeed, this kind of amino acid is available as a building block for 
SPPS (see Fig. 4.2.3 b). 
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                                                                  a                                                                                             b 
Fig. 4.2.3. LRh-DADEYL-PEN conjugate. (a) Conjugation to the sulfhydryl group of the cysteine residue in 
LRh-DADEYL peptide via the N-terminal pyridyl disulfide function in the “activated Penetratin” (Materials and 
methods, sect. 3.5). (b) Boc-Cys(Npys)-OH, a commercially available, activated cysteine residue for SPPS, 
suitable for the formation of disulfides (see also footnote 1). 
 
 
In practice, the conjugation proceeded poorly (Fig. 4.2.4, a). Notably, most of the probe 
simply did not fuse to ActPEN. In addition to that, and despite the utilization of degassed 
solvents in an argon atmosphere, a significant portion of LRh-DADEYL homodimerized (Fig. 
4.2.4 a; 4.2.5 bottom panel) indicating that the steric hindrance due to the adjacent rhodamine 
may not be the explanation for the low conjugation levels to ActPEN. A similar protocol 
using neat ACN reduced significantly the formation of the dimer without any increase of the 
desired product (Fig. 4.2.4, b). Poor solubility of the ActPEN peptide in these conditions 
could be reasoned. Nevertheless, an organic co-solvent appeared necessary in the reaction 
mixture in order to keep the LRh-DADEYL peptide freely soluble. Despite the low efficiency 
of the conjugation, all the species eluted with distinct retention times, making purification 
straightforward. The desired product could be isolated in 12% yield (sect. 3.5). The 
homodimer [LRh-DADEYL]2 could also be isolated and treated with the disulfide reducing 
agent TCEP, although this step was not routinely performed. However, this product was 
employed as a negative control in the uptake experiments in living cells (sect. 4.3). 
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                                               a                                                                                          b  
Fig 4.2.4. HPLC analysis of the conjugation products between ActPEN and LRh-DADEYL peptides 
(Merck Lichrosorb RP-18 250 x 4 mm x 10 µm). (a) Reaction performed in water/ACN between equimolar 
amounts of LRh-DADEYL and ActPEN peptides: the product eluting at ca. 12 min corresponded to the 
conjugate, the product eluting at ca. 15.5 min was unreacted LRh-DADEYL and the product eluting at ca. 18 
min appeared to be the [LRh-DADEYL]2 homodimer (b) The same reaction performed in ACN. (Materials and 
methods, sect. 3.5). 
 
 
 
 
Fig 4.2.5. ESI-MS analysis of the conjugation products between ActPEN and LRh-DADEYL peptides. Top 
panel: conjugated product LRh-DADEYL-PEN peptide as [M+3H+/3] (m/z 1358.51) and [M+4H+/4] (m/z 
1019.10) species. Centre panel: monomer LRh-DADEYL as [M+H+] (m/z 1513.06) and [M+2H+/2] (m/z 757.09) 
species. Bottom panel: dimer [LRh-DADEYL]2 as [M+2H+/2] (m/z 1512.43) and [M+3H+/3] (m/z 1008.65) 
species (Materials and methods, sect. 3.5). 
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4.3 Uptake of LRh-DADEYL-PEN conjugate by living MEF and MCF-7 cells  
 
The conjugate product LRh-DADEYL-PEN was designed with the rationale of creating 
a system where the vector Penetratin could, once inside the cells, release its cargo moiety 
thanks to the susceptibility of disulfide bridges toward reduction in the cytoplasmic 
environment. Differently from the “tandem” constructs where vector and cargo are 
permanently fused [116, 117], here the cargo molecule would not suffer from an 
unpredictable behaviour of the vector inside the cell. Moreover, the use of a purified 
conjugated product enables us to perform observations and draw conclusions free from 
artefacts that fluorescent contaminant species (i.e. unconjugated peptide, dye, by-products, 
etc.) may create.  
 
When living MEF cells were incubated with purified LRh-DADEYL-PEN conjugate (1 
µM) at room temperature, the cells specifically accumulated the construct, as shown by the 
lack of staining by the fluorescent unconjugated monomer LRh-DADEYL or the faint 
staining by the homodimer [LRh-DADEYL]2 under the same experimental conditions (Fig. 
4.3.1 b, e, g). A magnified inspection of the cells’ interior revealed however a distinct focal 
distribution in cytoplasm and the perinuclear area, suggesting an endosomal accumulation of 
the probe (Fig. 4.3.1 c). These findings would support recent literature data on uptake of the 
Penetratin vector in living cells [85]. 
Surprisingly, there was no internalization by MCF-7 cells (Fig. 4.3.2). The microscopic 
observations revealed how the conjugate remained excluded from the cell cytoplasm, or 
strongly adhered in patches along the plasma membrane even after repeated washing. This led 
to the speculation that MEF and MCF-7 cells may have a different behaviour toward the 
internalization of the Penetratin vector, or its conjugates. 
 
         
                                     a                                                                    b                                                                      c                             
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                                                                 d                                                       e                    
     
                                                                 f                                                       g                     
Fig. 4.3.1. LRh-DADEYL-PEN conjugate showed focal cytoplasmic distribution in MEF cells. Cells were 
incubated for 45 min at room temperature with a 1 µM solution of the probe conjugate in imaging medium. The 
Penetratin conjugate was taken up by the cells in endosomal compartments (b, c. Note: the diffused level of 
fluorescence visible is due to out-of-focus fluorescence and not to a real diffused distribution of the probe). The 
monomer LRh-DADEYL (d-e) or the dimer [LRh-DADEYL]2 (f-g) showed no or neglegible uptake in the same 
experimental conditions. Pictures a, d, f represent transmitted light images. Fluorescent images b, c, e, g were 
acquired using constant microscope settings (laser power and detector gain). Picture c represent an enlarged view 
of the area marked in picture b. Scale bar = 10 µm. 
 
 
     
                                                                 a                                                       b                      
Fig. 4.3.2. LRh-DADEYL-PEN conjugate did not penetrate into MCF-7 cells. (a) Cells were incubated with 
a 1 µM solution of the probe conjugate in imaging medium (+ 1% FBS) for 45 min at room temperature. No 
significant uptake was visible in the cytoplasm while aggregates appeared on the plasma membrane. (b) The 
same area imaged after extensive rinsing of the dish. Scale bar = 20 µm. 
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4.4 The fluorescent Penetratin derivatives OG-PEN1 and RR-PEN1 
 
In order to understand further the different uptake behaviour of the LRh-DADEYL-PEN 
conjugate by MEF and MCF-7 cells a synthesis of novel fluorescent derivatives of Penetratin 
was undertaken. This was necessary, since fluorescent Penetratins are not available 
commercially at present. The aim here was to elucidate how differences in the cargo 
(simulated now by two different fluorophores) could affect the internalization in one or more 
cell type. 
 
These new fluorescent probes were based on the original sequence of Penetratin, termed 
PEN-1, which has been described in detail in the literature [34, 75]. The fluorophores Oregon 
Green® 488 iodoacetamide and Rhodamine Red™ C2-maleimide were chosen (Fig. 3.1.2) and 
conjugated post synthesis to the free thiol group of an N-terminal cysteine residue. Differently 
to the LRh-DADEYL-PEN conjugate (Fig. 4.2.3 a) the covalent bond between the 
fluorophore and the peptide was in this case not susceptible of reduction in the cell. 
The synthesis started with the assembly of the Fmoc-PEN1 peptide (Fig. 4.4.1). The 
Fmoc group of the N-terminal cysteine residue was deliberately left in place before the final 
cleavage from the resin, because it was observed that its presence was beneficial in retarding 
the elution of the peptide, allowing better conditions for purification by HPLC (Fig. 4.4.2). 
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Fig. 4.4.1. The Fmoc-PEN1 peptide. A Cys residue was introduced N-terminally to the Arg-16 to allow 
conjugation with fluorescent dyes. The Fmoc group was left in place to facilitate the purification of the peptide 
(Materials and methods, sect. 3.6). 
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                                                          b                                                                                                               c 
Fig. 4.4.2. LC/MS analysis over the Fmoc-PEN1 peptide. Analytical HPLC (a) and ESI-MS (b) of the pure 
product, characterized as [M+3H+/3] (m/z 858.66), [M+4H+/4] (m/z 644.40) and [M+5H+/5] (m/z 515.60) 
species (Materials and methods, sect. 3.6). 
 
 
The products of the conjugation between Fmoc-PEN1 and the fluorophores, depicted in 
Fig. 4.4.3, were in both cases composed of two species, due to the use of commercial 
mixtures of isomers for both Rhodamine Red™ C2-maleimide and Oregon Green® 488 
iodoacetamide (Fig. 3.1.2). These isomers could be resolved – at least partially – by analytical 
HPLC and characterized by ESI-MS (Fig. 4.4.4). 
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                                                   a                                                                                             b 
Fig. 4.4.4. The RR-PEN1 and OG-PEN1 peptides. The two dyes were linked to the Penetratin sequence via 
the sulfhydryl group of the terminal Cys residue. (a) RR-PEN1. (b) OG-PEN1 (Material and methods, sect. 3.7). 
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                                                         a                                                                                                                     b 
 
                                                         c                                                                                                                     d 
Fig. 4.4.4. LC/MS analysis over the RR-PEN1 and OG-PEN1 peptides. (a) HPLC of purified RR-PEN1. (b) 
ESI-MS of RR-PEN1: the peptide was identified as [M+3H+/3] (m/z 1085.33) and [M+4H+/4] (m/z 814.31) 
species. (c) HPLC of purified OG-PEN1. (d) ESI-MS of OG-PEN1: the peptide was identified as [M+3H+/3] 
(m/z 999.31) and [M+4H+/4] (m/z 749.70) species (Materials and methods, sect. 3.7). 
 
 
4.5 Uptake of OG-PEN1 and RR-PEN1 in living MEF cells 
 
In addition to the previous experiments, a comparative study of the new Penetratin 
derivatives was made using MEF and MCF-7 cells as model.  
An initial observation was made when MEF cells were incubated at room temperature 
with the two conjugates: while RR-PEN1 appeared to be internalized into the cell body in a 
focal, perinuclear fashion (Fig. 4.5.1 a, b), the uptake of OG-PEN1 was not detected (Fig. 
4.5.1 c, d). Notably, the latter conjugate was only internalized when the experiment was 
performed at 37°C (Fig. 4.5.1 e, f). These observations suggested how the different cargo may 
have contributed to the adoption of a different mechanism of internalization by MEF cells, 
which in the case of OG-PEN1 proved effective only at physiological temperature (37°C). 
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Fig. 4.5.1. RR-PEN1 and OG-PEN1 Penetratin derivatives showed different uptake behaviour in MEF 
cells. Cells were incubated with 5 µM RR-PEN1 or OG-PEN1 in imaging medium for 3h at room temperature. 
Only RR-PEN1 showed focal, perinuclear accumulation in cells (a, b) while OG-PEN1 was not internalized 
under these conditions (c, d). Nevertheless, the latter was taken up by cells at 37°C showing a distribution 
similar to that of RR-PEN1 (e, f). Pictures a, c, e represent transmitted light images. Scale bar = 20 µm (Material 
and methods, sect. 3.15). 
 
Further analyses were performed with the goal of understanding the nature of the 
endosomal vesicles which appeared to trap the two fluorescent Penetratins. Since the shape 
and distribution of these structures closely resembled those typical of lysosomes, co-
localization experiments with lysosomal markers were attempted. 
 
MEF cells were incubated with a mixture of RR-PEN1 and LysoTracker® Green (LTG). 
The two dyes visibly co-localized (Fig. 4.5.2), indicating that many of the vesicles which 
entrapped RR-PEN1 were of lysosomal origin. This conclusion was nevertheless harder to 
4. Results 
 57 
make when the converse experiment was performed, namely the incubation in the same 
conditions with a mixture of OG-PEN1 and LysoTracker® Red (LTR). Overall, the uptake 
was reduced with a concomitant reduction in co-localization (Fig.4.5.3). Although further 
experiments should be performed to reinforce these findings, one explanation could be that 
RR-PEN1 and OG-PEN1 distribute in MEF in endosomal compartments of a different nature. 
This could also explain why OG-PEN1 gained entry to the cell interior only at 37°C (Fig. 
4.5.1 e, f). Ultimately, co-incubation with a mixture of OG-PEN1 and RR-PEN1 could have 
solved this riddle: surprisingly, the combination of the two caused (in this cell line) toxic 
effects which complicated the experiment and made the interpretation of the fluorescence 
distribution cumbersome (results not shown). 
                                    LTG                                                            RR-PEN1                                                             merge 
         
                                       a                                                         b                                                          c 
Fig. 4.5.2. RR-PEN1 and the lysosomal marker LysoTracker® Green (LTG) co-localize in living MEF 
cells. Cells were incubated (1h 45min, 37°C) with a mixture of LTG (a) and RR-PEN1 (b) in imaging medium at 
0.75 µM and 2.5 µM, respectively. The dye and the peptide appeared to co-localize, as shown in the overlay 
picture (c). Scale bar = 20 µm (Material and methods, sect. 3.15). 
 
                                    LTR                                                              OG-PEN1                                                          merge 
         
a                                                         b                                                         c 
Fig. 4.5.3. OG-PEN1 and the lysosomal marker LysoTracker® Red (LTR) showed reduced uptake and co-
localization in living MEF cells. Cells were incubated (3h, 37°C) with a mixture of LTR (a) and OG-PEN1 (b) 
in imaging medium at 0.75 µM and 2.5 µM, respectively. Images showed both a reduced number of fluorescent 
vesicles and a less evident co-localization between the OG-PEN1 peptide and the LTR lysosomal marker (c). 
Scale bar = 20 µm (Material and methods, sect. 3.15). 
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Literature data on Penetratin indicated that this vector exerted toxic effects from 
concentration doses of 30 µM, above which permeabilization of cell membranes occurred 
[85]. Despite these findings, intracellular distribution of Penetratin following incubation at 
high doses was not specified in the published study. Hence, an experiment was performed in 
which MEF cells were exposed to a short pulse of a high concentration (100 µM) of OG-
PEN1 peptide. Propidium iodide, a nuclear dye which is normally excluded by cells that 
preserve membrane integrity, was also added. Microscopic observation revealed that, during 
the pulse, propidium iodide gained access to the nucleus of all cells, indicating a 
permeabilization effect exerted by the high dose of Penetratin (Fig. 4.5.4 b, e). OG-PEN1 
distributed richly in vesicles and, in addition, to the plasma membrane, nuclear envelope and 
some fine cytoplasmic structures. In some cases, portions of the nuclear compartment were 
also weakly stained (Fig. 4.5.4 a, d). Whether membrane permeabilization can be considered 
a threat for cell viability may be a matter of discussion. Nevertheless, in all subsequent 
experiments the use of a low concentration of Penetratins (1 – 5 µM) was preferred. 
 
                                    OG-PEN1                                                            PI                                                                  merge 
         
a                                                          b                                                          c 
         
d                                                          e                                                          f 
Fig. 4.5.4. Exposure to high dose of Penetratin caused membrane permeabilization in living MEF cells. 
Cells were pulsed (10 min, room temp.) with 100 µM OG-PEN1 and 1 µg of propidium iodide (PI, from 1 
mg/mL stock solution in water) in imaging medium. OG-PEN1 distributed in large vesicles, plasma membrane, 
nuclear membrane and possibly nucleus and other cytoplasmic structures (a, d). All cells presented noticeable 
nuclear staining by PI (b, e) indicating that the high dose of Penetratin induced membrane permeabilization, 
hence the access to the nuclear compartment to PI. Scale bar = 20 µm (a – c), 10 µm (d – e) (Material and 
methods, sect. 3.15). 
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4.6 Uptake of OG-PEN1 and RR-PEN1 by living MCF-7 cells 
 
As illustrated previously (sect. 4.3), human adeno-carcinoma cells showed no evident 
uptake of the LRh-DADEYL-PEN probe at room temperature. On the contrary, this cell line 
showed uptake of both RR-PEN1 and OG-PEN1 peptides when the experiment was 
performed at 37°C. Similarly to MEF cells (sect. 4.5), the distribution appeared mainly in 
vesicles in the cytoplasm and in the perinuclear area (Fig. 4.6.1). 
 
     
a                                                       b 
Fig. 4.6.1. RR-PEN1 and OG-PEN1 were internalized by MCF-7 cells at 37°C. Cells were incubated with 5 
µM of either RR-PEN1 (a) or OG-PEN1 peptide (b) in imaging medium (+ 1% FBS) for 3 h at 37°C. Under 
these conditions the cells internalized both the fluorescent peptides into vesicles. OG-PEN1 could also be 
observed locally concentrated in the perinuclear space (b). Scale bar = 10 µm (Material and methods, sect. 3.15). 
 
Moreover, the two fluorescent peptides appeared to co-localize in the same 
compartments (Fig. 4.6.2 a – c). Interestingly, and in contrast to what was observed for MEF 
cells (sect. 4.5), RR-PEN1 alone showed a less evident co-localization with the lysosomal 
marker LTG (Fig. 4.6.2 d – i). This could indicate that in MCF-7 cells the membrane-bound 
compartments that trapped RR-PEN1 (and for homology, OG-PEN1) may differ from the 
acidic late endosomes (lysosomes). 
 
                                    OG-PEN1                                                       RR-PEN1                                                          merge 
         
a                                                           b                                                          c 
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                                      LTG                                                             RR-PEN1                                                          merge 
         
d                                                           e                                                          f 
         
g                                                           h                                                          i 
Fig. 4.6.2. RR-PEN1 and OG-PEN1 co-localized, while weak co-localization appared between RR-PEN1 
and LysoTracker® Green (LTG) in living MCF-7 cells. Cells were incubated with a mixture of OG-PEN1 
and RR-PEN1 (2.5 µM + 2.5 µM, picts. a, b) in imaging medium (+ 1% FBS) for 3.5 h at 37°C or with a 
mixture of LTG and RR-PEN1 peptide (1 µM+2.5 µM, picts. d, e) for 3.5 h at 37°C in the same medium. While 
the two fluorescent Penetratins appeared to share the same compartments (c), a less clear co-localization was 
observed between LTG and RR-PEN1 peptide (f, i), indicating that the latter could distribute into endosomal 
compartments of a different nature from the acidic late endosomes stained by LTG. Pictures g – i represent an 
enlarged area of pictures d – f. Scale bar = 10 µm (a – f); 2 µm (g – i) (Material and methods, sect. 3.15). 
 
 
The photo-induced release of fluorescent substances from endosomal compartments has 
been already documented in the literature as a possible means for the redistribution of probes 
within the cell body [159]. This phenomenon was also observed when MCF-7 cells incubated 
with RR-PEN1 were pulse-exposed to the irradiation of the mercury lamp of the microscope. 
A redistribution of fluorescence was evident, but a more accurate observation revealed that 
the peptide did not appear homogeneously distributed in the cytoplasm, while it was dispersed 
in a higher number of membrane-bound compartments from the initial endosomes. 
Background intensity became also appreciable, suggesting membrane damage and leakage 
from cells (Fig. 4.6.3 a – c). Despite some investigator speculating that this procedure may be 
usefully exploited [159], possible photo-toxicity may be a practical limitation of this approach 
(Fig. 4.6.3 d, e). 
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a                                                           b                                                          c 
     
d                                                       e 
Fig. 4.6.3. Redistribution of RR-PEN1 peptide in MCF-7 cells upon wide-field arc-lamp illumination. Cells 
were incubated with 5 µM RR-PEN1 in imaging medium (+ 1% FBS) for 3 h at 37°C. After a first image 
acquisition (a), the specimen was illuminated with three pulses (10 sec + 5 sec pause) of white light. A new 
picture of the same area was then recorded (b), showing evident redistribution of the peptide. The localization 
appeared mainly in globular structures scattered in the cytoplasm, as well as in the nuclear membrane and, to a 
lesser extent, in the nucleus (c). Another area of the specimen (d) revealed noticeable induction of “blebbing” 
and apoptosis in the cells after a similar exposure (e). Picture c represents an enlarged view of the area marked in 
picture b. Pictures d, e are transmitted light images. Scale bar = 20 µm (a, b, d, e); 10 µm (c) (Material and 
methods, sect. 3.15). 
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4.7 The AM ester strategy for cell penetration and cytoplasmic distribution: the 
TAMRA-DADEYL-AM3 peptide 
 
The focal, endosomal distribution of the Penetratin-conjugated DADEYL peptide (LRh-
DADEYL-PEN, sect. 4.2) appeared to be the limiting characteristic of the approach based on 
a polycationic vector for the cytoplasmic delivery of the designed probe when used in lower, 
cell-amenable concentrations. To circumvent the problem of sequestration in membrane-
bound compartments and to allow an effective cytoplasmic distribution of the probe, a 
different strategy was investigated, based on the modification of the negatively-charged 
residues of the peptide (Asp, Glu) as alkyl esters. The intention was to create an uncharged 
molecule and to assess its capability of diffusing across the plasma membrane. The advantage 
of this protection would rely upon the activity of non-specific esterases present in cells: the 
hydrolysis of the ester moieties would allow, in the biological milieu, the restoration of the 
charge and the entrapment in the cell, facilitating the interaction of the peptidic probe with the 
target enzyme.  
For this reason, it was decided to equip the DADEYL peptide with acetoxymethyl (AM) 
groups. While this strategy has been applied to various compounds (sect. 1.1), to the best of 
our knoledge it has not been documented so far on fluorescently-labelled peptides. Upon 
esterification, the envisioned peptide structure looked as represented in Fig. 4.7.1 a. 
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Fig. 4.7.1. The acetoxymethyl ester (AM) modification of Asp and Glu residues of the DADEYL peptide. 
(a) The alkylation product by the action of bromomethyl acetate and DIPEA (note the C-terminal amidation; the 
linker and the fluorophore molecules are omitted). (b) The hydrolysis of the AM esters by non-specific cellular 
esterases, with concomitant loss of acetic acid and formaldehyde, would restore the peptide in its native 
condition (Material and methods, sect. 3.10). 
 
To rely upon the ready availability of the probe without the need of costant re-syntheses, 
a bulk preparation of resin-bound DADEYL peptide was started from 500 mg of Rink amide 
support. The synthesis proceeded according to the standard Fmoc-SPPS protocols, with some 
minor modifications (sect. 3.8, Tab. 3.8 a):  
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– the Fmoc-Tyr(Cl-Trt)-OH residue was incorporated into the sequence instead of the 
standard Fmoc-Tyr(tBu)-OH. The lability of the Cl-Trt protecting group to mild acidic 
treatment afforded the possibility to perform side-chain modifications directly on the 
solid support, namely phosphorylation (see sect. 4.13 below). Nevertheless, this building 
block failed to couple with the HBTU/HOBt/DIPEA protocol when used in a single step 
with an excess of 3 eq. The condensation was on the contrary successful when 
performed in three successive steps, using twice 1 eq of a.a. with the HOBt/DIC 
protocol, followed by 0.5 eq of fresh reagents using the HBTU/HOBt/DIPEA protocol; 
– the Fmoc-Glu(tBu)-OH residue required a total of 4 eq (3 + 1) in order for the TNBS 
test to appear negative; 
– the Fmoc-AEEAc-OH linker was successfully coupled using a total of 2 eq in two 
successive steps, limiting the waste of this costly building block. 
 
HPLC analysis performed after a test cleavage confirmed that the product was obtained 
in high purity, although a smaller excess of reagents was used in the synthesis (Fig. 4.7.2).  
 
 
                                             a                                                                                          b 
Fig. 4.7.2. Bulk synthesis of resin-bound DADEYL peptide. The product was obtained in high purity, as 
showed by HPLC (a) and confirmed by ESI-MS (b) as a [M+H+] (m/z 1091.76) species (Material and methods, 
sect. 3.8). 
 
The utilization of the Lissamine™-rhodamine presented several drawbacks and 
limitations, as previously mentioned. While the material obtained from one commercial 
supplier (Fluka) coupled efficiently, its low grade of purity required a careful purification of 
the labelled peptide (Fig. 4.2.2 a). Moreover, whereas the condensation to the TAT peptides 
via the aminohexanoic linker was straightforward (sect. 4.1), an additional cysteine residue 
needed to be added as a “junction node” after the AEEAc linker in the DADEYL peptide. 
Finally, the dye itself proved to adversely affect the solubility of the latter (sect. 4.2). With the 
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aim of reducing these limitations, a different fluorophore of the rhodamine family was chosen 
for labelling, namely carboxytetramethylrhodamine, commercially obtained as a mixture of 
isomers and pre-activated by means of a succinimidyl ester (5(6)-TAMRA SE, Fig. 3.1.2 d). 
Conjugation of 5(6)-TAMRA SE to the Fmoc-deprotected peptide was straightforward 
and complete using an excess of about 2 eq of reagent.14 The crude product was obtained in 
high yields (ca. 91%) and good purity (94%). The two regioisomers were also clearly resolved 
by HPLC (Fig. 4.7.3).  
 
 
                                            a                                                                                              b 
Fig. 4.7.3. The TAMRA-DADEYL peptide. (a) Regioisomers due to commercial preparation of the dye could 
be resolved analytically by HPLC (retention times of 4.9 and 5.4 min) and confirmed by ESI-MS analysis (b) as 
[M+H+] and [M+2H+/2] species. Due to its purity (94%), the product was used directly in the next synthetic step 
(Material and methods, sect. 3.9). 
 
 
AM ester formation was performed on the labelled peptide in anhydrous DMF with an 
excess of bromomethyl acetate and DIPEA – 9 and 3.6 eq, respectively – and without any 
prior purification (sect. 3.10). LC/MS analysis on the crude product revealed numerous 
species, mainly due to the presence of isomer mixtures: in addition to the desired product (m/z 
1497.70) and some starting material (m/z 1281.59), peptides carrying one (m/z 1353.65) or 
two (m/z 1425.75) AM esters were clearly recognized. Other m/z values belonged to a peptide 
with an intact t-butyl group (m/z 1338.69, + 57 a.m.u.) which underwent one (m/z 1410.69), 
two (m/z 1482.79), three (m/z 1554.85) and finally four (m/z 1627.86) alkylations with 
bromomethyl acetate (Fig. 4.7.4). These results proved an additional alkylation on the 
molecule.15  
 
                                                 
14
 It was observed that a slight excess of 1.2 eq was generally sufficient to obtain a complete conjugation reaction. 
15
 From a repeated alkylation reaction, the peptide TAMRA-DADEYL-4AM (four AM esters) could indeed be isolated in traces. 
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                                            a                                                                                              b 
Fig. 4.7.4. TAMRA-DADEYL-AM peptides. (a) The crude mixture showed a high number of peaks, mainly 
due to the presence of regioisomers. The various products could be nevertheless recognized by the ESI-MS 
analysis (b) (Material and methods, sect. 3.10). 
 
Careful purification allowed the isolation of the product bearing three AM esters in 
4.2% yield (Fig. 4.7.5). With a satisfactory overall purity (> 91%), the little amount obtained 
was nevertheless sufficient to carry out the in vitro and in vivo experiments described here. 
The lyophilized peptide was normally reconstituted in 15 µL of dioxane/water 1:1 (v/v) to get 
a 1 mM stock solution and was routinely used in vivo at a final concentration of 10 µM (1:100 
dilution). In total, eleven vials of TAMRA-DADEYL-AM3 peptide were prepared. The 
product proved to be stable for several months when stored lyophilized at – 20°C.16 
 
 
                                            a                                                                                              b 
Fig. 4.7.5. The TAMRA-DADEYL-AM3 peptide. The purification afforded the product alkylated with three 
AM esters as a pair of partially resolved regioisomers (a). Despite the low yield (ca. 4%), the product was 
obtained with more than 90% overall purity. By ESI-MS analysis (b), both isomers could be identified as 
[M+H+] and [M+2H+/2] species (Material and methods, sect. 3.10). 
 
                                                 
16
 Solutions in water/dioxane were also stable up to one month when stored under the same conditions. 
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4.8 Uptake of TAMRA-DADEYL-AM3 in living HeLa Kyoto, MCF-7 and MEF cells 
 
The use of the TAMRA-DADEYL-AM3 peptide in in vivo experiments immediately 
revealed significant differences compared to the LRh-DADEYL-PEN probe (sect. 4.2) in two 
out of three cell lines tested. HeLa Kyoto and MCF-7 cells revealed a strong intracellular 
accumulation already detectable after 20 min of incubation at room temperature (Fig. 4.8.1). 
Remarkably, both the cytoplasm and the nucleus were homogeneously stained; fluorescent 
vesicles were also detectable at higher magnification (Figs. 4.8.3, 4.8.4). The evident 
accumulation in the nuclear compartment was probably due to a possible affinity of the 
TAMRA dye to chromatin. While Kyoto cells showed an equal uptake in virtually all cells 
(Fig. 4.8.1 a), the intracellular concentration of the peptide appeared to vary in different 
MCF-7 cells (Fig. 4.8.1 b). In both cases, however, the goal of cytoplasmic delivery of the 
TAMRA-DADEYL-AM3 peptide was successfully achieved, even in MCF-7 cells, which 
previously showed no uptake of the LRh-DADEYL-PEN peptide (sect. 4.2). 
 
     
a                                                       b 
Fig. 4.8.1. TAMRA-DADEYL-AM3 peptide distributed homogeneously in living HeLa Kyoto or MCF-7 
cells. HeLa Kyoto (a) and MCF-7 cells (b) were incubated with a 10 µM solution of TAMRA-DADEYL-AM3 in 
imaging medium for 20 min at room temperature. Under these conditions the fluorescent peptide distributed in 
both cytoplasm and nucleus. Scale bar = 20 µm (Material and methods, sect. 3.15).  
 
While the probe was routinely used on these cells at a final concentration of 10 µM, a 
good level of staining was also achieved at 5 µM. Serum was normally omitted throughout the 
incubation time, or kept at 1% for MCF-7 cells. Nevertheless, presence of serum even at 10% 
concentration did not appreciably disturb the intracellular accumulation of the peptide (Fig. 
4.8.2). 
 
4. Results 
 67 
     
                                                                             a                                                          b 
Fig. 4.8.2. Serum did not impair accumulation of TAMRA-DADEYL-AM3 peptide in living MCF-7 cells. 
Cells were incubated for 20 min at room temperature with a 10 µM solution of TAMRA-DADEYL-AM3 in 
imaging medium containing either 1% (a) or 10% FBS (b). The presence of serum at 10% concentration did not 
adversely affect uptake of the peptide. Scale bar = 20 µm (Material and methods, sect. 3.15). 
 
Over-expression of a given protein did also not interfere with the uptake of the probe. 
HeLa Kyoto stably transfected with YFP-EGFR (Fig. 4.8.3) or MCF-7 cells transiently 
transfected with GFP-PTP1B (Fig. 4.8.4) gave equally strong levels of fluorescent signal from 
the internalized peptide. Moreover, the distribution matched that which was observed in non 
transfected cells. 
 
                             YFP-EGFR                                            TAMRA-DADEYL-AM3                                               merge 
         
a                                                           b                                                          c 
Fig. 4.8.3. Expression of YFP-EGFR did not interfere with TAMRA-DADEYL-AM3 uptake in HeLa Kyoto 
cells. HeLa Kyoto stably transfected with YFP-EGFR (a) were incubated with a 10 µM solution of TAMRA-
DADEYL-AM3 in imaging medium for 20 min at room temperature. Over-expression of the membrane protein 
did not adversely affect uptake of the probe (b, c). Scale bar = 10 µm (Material and methods, sect. 3.15). 
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                             GFP-PTP1B                                          TAMRA-DADEYL-AM3                                             merge 
         
a                                                          b                                                          c 
Fig. 4.8.4. Expression of GFP-PTP1B did not interfere with uptake of TAMRA-DADEYL-AM3 in MCF-7 cells. 
Cells transiently transfected with the ER localized GFP-PTP1B chimera (a) were incubated with a 10 µM 
solution of TAMRA-DADEYL-AM3 in imaging medium (+ 1% FBS) for 20 min at room temperature. Over-
expression of the protein did not adversely affect uptake of the probe (b, c). Scale bar = 10 µm (Material and 
methods, sect. 3.15). 
 
Surprisingly, the probe behaved differently in MEF cells: a diffuse staining was 
observed only at high concentration (45 µM), along with accumulation in vesicles (Fig. 4.8.5 
b, c). Nevertheless, the cells appeared to suffer this condition, featuring a more round shape 
and a tendency to detach from the surface of the support. At a lower concentration (30 µM), 
only vesicles were detected (Fig. 4.8.5 e, f), reminiscent of the situation experienced with the 
LRh-DADEYL-PEN probe and the fluorescent Penetratins (sect. 4.2 and sect. 4.5). Moreover, 
TAMRA-DADEYL-AM3 appeared to co-localized with the lysosomal marker LTG in late 
endosomes (Fig. 4.8.6 a – c). Taking into consideration these findings, along with the 
notorious resistance of MEF cells to standard protocols for cell transfection, this cell line was 
not investigated further. 
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a                                                          b                                                          c 
         
d                                                          e                                                          f 
Fig. 4.8.5. Distribution of TAMRA-DADEYL-AM3 in living MEF cells. Cells were incubated with a 45 µM 
(b) or 30 µM (e) solution of TAMRA-DADEYL-AM3 in imaging medium for 30 min at room temperature. The 
peptide showed a diffused distribution only at the higher concentration (c). Pictures a, d represent transmitted 
light images. Pictures c and f represent an enlarged view of the marked area in pictures b and e. Scale bar = 20 
µm (a, b, d, e); 10 µm (c, f) (Material and methods, sect. 3.15). 
 
                  TAMRA-DADEYL-AM3                                                 LTG                                                               merge 
         
                                      a                                                           b                                                          c 
Fig. 4.8.6. TAMRA-DADEYL-AM3 co-localized with LysoTracker® Green (LTG) in living MEF cells. 
Cells were incubated with a mixture of TAMRA-DADEYL-AM3 and LTG (30 µM + 5 µM, pict. a, b) in 
imaging medium for 45 min at 37°C. The overlay picture shows co-localization in late endosomes (c). Scale bar 
= 10 µm (Material and methods, sect. 3.15). 
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To study the modality of uptake of the TAMRA-DADEYL-AM3 peptide, time lapse 
recordings were made in HeLa Kyoto and MCF-7 cells (sect. 3.16). A plane of observation 
was selected where the cell body appeared dark with respect to the fluorescent surroundings: 
by doing so, the accumulation of the peptide over time could be easily followed and 
differences between a cytoplasmic or nuclear distribution could be assessed. 
HeLa Kyoto and MCF-7 cells were incubated with a 10 µM solution of the peptide, as 
previously described (Material and methods, sect. 3.15). The acquisition revealed cytoplasmic 
and nuclear staining in both cell types already after 5 min (Fig. 4.8.7 b and 4.8.8 b). At the 
end of the incubation time (15 min for Kyoto, 20 min for MCF-7) the fluorescence signals 
from cytoplasm and nucleus of the cells were clearly distinguishable from the background 
(Fig. 4.8.7 c and 4.8.8 c). The scenario was particularly striking when the excess of peptide 
was rinsed from the support. The fluorescence appeared evenly distributed in the cytoplasm, 
but at the same time small dark vesicles were detectable: these regions of exclusion added 
further evidence of a real cytoplasmic distribution of the peptide (Fig. 4.8.7 d and 4.8.8 d).  
 
           
a                                                          b                                                          c 
     
d                                                       e 
Fig. 4.8.7. Accumulation of TAMRA-DADEYL-AM3 in living HeLa Kyoto cells as revealed by time-lapse 
microscopy. Cells were incubated with a 10 µM solution of TAMRA-DADEYL-AM3 in imaging medium for 15 
min at room temperature. Acquisitions were recorded at 6.5 sec intervals. The pictures represent the uptake at t = 
0 (a), t = 5 (b) and t = 15 min (c) from the addition of the peptide. The areas marked in picture c were used to 
quantify the level of fluorescence over time, as reported in the graph below (Fig. 4.8.9). (d) Fluorescent image of 
the specimen after rinsing. (e) The specimen imaged under transmitted light (phase contrast). Scale bar = 10 µm 
(Material and methods, sect. 3.16). 
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More importantly, this analysis clearly showed that distribution of the TAMRA-
DADEYL-AM3 peptide in the cytoplasm (and nucleus) did not result from a “vesicle uptake 
and release” mechanism, but more likely from free diffusion through membranes. The 
presence of bright vesicles appeared to be a result of staining by diffusion of the free peptide 
from within the cytoplasm. 
 
           
a                                                          b                                                          c 
     
d                                                       e 
Fig. 4.8.8. Accumulation of TAMRA-DADEYL-AM3 in living MCF-7 cells as revealed by time-lapse 
microscopy. Cells were incubated with a 10 µM solution of TAMRA-DADEYL-AM3 in imaging medium (+ 
1% FBS) for 20 min at room temperature. Acquisitions were recorded at 15 sec intervals. The pictures represent 
the uptake at t = 0 (a), t = 5 (b) and t = 15 min (c) from the addition of the peptide. The areas marked in picture c 
were used to quantify the level of fluorescence over time, as reported in the graph below (Fig. 4.8.9). (d) 
Fluorescent image of the specimen after rinsing. (e) The specimen imaged under transmitted light (phase 
contrast). Scale bar = 10 µm (Material and methods, sect. 3.16). 
 
In order to shred light on the dynamics of the uptake process in these two cell types, a 
single cell was chosen and three different regions of interest (ROIs) were picked: nucleus, 
cytoplasm and background (Fig. 4.8.7 c and 4.8.8 c). Care was taken to choose those cellular 
regions where the peptide distribution was the most uniform. Calculations were made as 
previously described (Material and methods, sect. 3.16) and the resulting graphs are plotted in 
Fig. 4.8.9 and Fig. 4.8.10. 
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                                                                   a                                                                                          b 
Fig. 4.8.9. Trend of accumulation of the TAMRA-DADEYL-AM3 peptide in living HeLa Kyoto and  
MCF-7 cells. HeLa Kyoto and MCF-7 cells were incubated with a 10 µM solution of TAMRA-DADEYL-AM3 
in imaging medium, as described (Material and methods, sect. 3.16). Variation of fluorescence over time was 
measured in ROIs within a single cell (Fig. 4.8.7 and 4.8.8) where the intensity distribution appeared 
homogeneous. The curves represent the fluorescence intensity values normalized against the background (black 
line) in the nucleus (blue line) and the cytoplasm (red line) of a single HeLa Kyoto (graph a) and MCF-7 cell 
(graph b). Note the different ratio of peptide accumulation in the two cell lines (nuc.= nucleus, cyt. = cytoplasm, 
bkg. = background). 
 
These data suggested differences in the behavior of Kyoto cells compared to MCF-7 
cells, although the peptide accumulated in the nucleus at a faster rate compared to the 
cytoplasm in both cell types (Fig. 4.8.9, blue curves in graphs a, b). In the Kyoto cells the 
fluorescence intensity in the nucleus reached the background level (here used as a reference 
value) shortly after 4 min and doubled after 15 min; the intensity in the cytoplasm reached the 
background level after about 7 min ending in a final value of about 1.3-fold the reference after 
15 min. In MCF-7 cells the intensity in the nucleus equalled the background after more than 
10 minutes, while the one in the cytoplasm took about 16 min. After 20 min the overall 
intensity in the nucleus and cytoplasm was about 1.6- and 1.1-fold the reference value, 
respectively. 
Analysis of the plots suggested an exponential trend for uptake in Kyoto cells, reminiscent 
of a “saturation-like” mechanism. Nevertheless, a similar experiment performed in this cell 
line using a 5 µM peptide concentration and extending the incubation time to 1 h (room 
temp.) showed a more linear behaviour (Fig. 4.8.10), comparable to MCF-7 uptake where the 
correlation appeared mostly linear both in nucleus and cytoplasm (Fig. 4.8.9 b). Whether 
these conclusions could be extended to all MCF-7 cells is not clear, because different cells of 
the same specimen internalized the peptide to a different level, as showed (Fig. 4.8.1). 
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Nevertheless, these findings would support a free diffusion mechanism of cellular import of 
the AM-esterified peptide. 
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Fig. 4.8.10. Accumulation of the TAMRA-DADEYL-AM3 peptide in living HeLa Kyoto cells appeared 
linear at a reduced concentration. Cells were incubated with a 5 µM solution of TAMRA-DADEYL-AM3 in 
imaging medium, as described (Material and methods, sect. 3.16). The acquisition was made every minute for a 
total of 60 min of incubation. Variation of fluorescence over time was measured in ROIs within a single cell as 
done previously (Fig. 4.8.9). The curves represent the fluorescence intensity values normalized against the 
background (black line) in the nucleus (blue line) and the cytoplasm (red line) of a single cell. In these 
conditions the uptake appeared to be more linear in both cytoplasm and nucleus and matched that observed in 
MCF-7 cells (Fig. 4.8.9 b) at higher peptide concentration (nuc.= nucleus, cyt. = cytoplasm, bkg. = background) 
(Material and methods, sect. 3.16). 
 
 
4.9 Influence of the number of AM esters on the cellular uptake  
 
The synthesis of a short tri-peptide equipped with the TAMRA fluorophore and a single 
AM ester (TAMRA-EYL-AM1, Fig. 4.9.1) was performed on a small scale using synthetic 
conditions described earlier (sect. 3.11). The use of this small fragment revealed interesting 
observations: 
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Fig 4.9.1. The TAMRA-EYL-AM1 peptide. The proposed structure with the AM ester on the Glu residue 
coloured in red (MW 1051.16). 
 
a) the separation of the TAMRA conjugates by HPLC, not performed on the longer 
peptide, afforded the two products with an overall yield of about 52% (Fig. 4.9.2). The use of 
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only one isomer in the AM esterification reaction allowed a straightforward identification of 
the products by LC/MS analysis: the presence of an additional AM ester on the molecule was 
confirmed and the TAMRA-EYL-AM1 and TAMRA-EYL-AM2 peptides could be isolated by 
semi-preparative HPLC (Fig. 4.9.3). 
 
 
                                              a                                                                                           b 
Fig. 4.9.2. The TAMRA-EYL peptide. (a) HPLC analysis performed on the crude mixture following 
conjugation with 5(6)-TAMRA SE showed the expected two regioisomers, which in this case where separated 
by preparative chromatography before performing the AM esterification reaction. (b) ESI-MS confirmed both 
regioisomers as [M+H+] (m/z 980.7) species (Material and methods, sect. 3.11). 
 
 
1
2
3
2
3
 
                                              a                                                                                          b 
Fig. 4.9.3. The TAMRA-EYL-AM1 and TAMRA-EYL-AM2 peptides. (a) In the alkylation reaction only one 
isomer was used, facilitating the analysis and separation of the products. The peak appearing at 4.7 min (n.1, 
11%) corresponded to unreacted starting material, the one at 5.3 min (n. 2) was the peptide carrying one AM 
ester (69%), while the last one at 6.7 min (n. 3) was a peptide carrying two AM esters (17%). (b) The two 
peptides were characterized by ESI-MS as [M+H+] species (TAMRA-EYL-AM1, m/z 1052.69, spectrum n.2; 
TAMRA-EYL-AM2, m/z 1124.82, spectrum n.3. Material and methods, sect. 3.11). 
 
4. Results 
 75 
b) ESI-MS/MS analysis on the fragments obtained from the TAMRA-EYL-AM2 peptide 
inferred the presence of the second AM ester functionality on the carboxylic group of the 
TAMRA. Nevertheless, the presence of an esterified tyrosine could not be excluded (Tab. 4.9 
a).17 
 
AM at C-terminus AM at N-terminus (TAMRA) 
  
expected observed 563.74 expected observed 563.74 
558.6 558.3 (background) 631.7 - 
N-terminal 
759.8 759.3 832.8 831.3 
365.4 - 292.4 292.95 
C-terminal 
566.6 - 493.5 493.3 
 
Tab. 4.9 a. ESI-MS/MS analysis of the TAMRA-EYL-AM2 peptide. Fragmentation products obtained 
from the species with m/z 563.74 (corresponding to the double-charged peptide). The signals observed would be 
compatible with peptides carrying one AM ester either on the TAMRA (m/z 831.3, 292.9. 493.3) or at the C-
terminus, likely on the Tyr residue (m/z 759.3). Only the signal at m/z 831.3 was nevertheless intense enough to 
be recorded unambiguously. 
 
c) Incubation of HeLa Kyoto cells with TAMRA-EYL-AM1 and TAMRA-EYL-AM2 
peptides in the same experimental conditions used for the TAMRA-DADEYL-AM3 
surprisingly revealed no or negligible cellular uptake (Fig. 4.9.4). This finding may suggest 
the need of a minimal number of three AM esters on this peptidic substrate in order to get an 
efficient translocation in cells. Of course, this speculation requires a more careful verification 
(the presence of different fluorophores on the peptide may also play a role). 
 
       
                                                                        a                                                            b 
 
                                                 
17
 It must be stressed the fact that the instrumentation used for ESI-MS/MS at the EMBL Proteomic Core Facility is not designed 
for the analysis of low molecular weight species. Hence, the results here reported have a certain grade of uncertainty and 
cannot be considered conclusive. 
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                                                                        c                                                            d 
Fig. 4.9.4. Incubation of living HeLa Kyoto cells with TAMRA-EYL-AM1 or TAMRA-EYL-AM2 revealed 
a lack of or poor peptide uptake. Cells were incubated with a 10 µM solution of TAMRA-EYL-AM1 or 
TAMRA-EYL-AM2 in imaging medium for 20 min at room temperature. In these conditions there was either a 
lack of staining with the TAMRA-EYL-AM1 peptide (a, b) or a very faint one with the TAMRA-EYL-AM2 
peptide (c, d). Pictures a and c represent transmitted light (phase contrast) images. Scale bar = 10 µm (Material 
and methods, sect. 3.15). 
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4.10 Analysis of interaction between TAMRA-DADEYL-AM3 peptide and EGFR assayed 
by FLIM/FRET microscopy 
 
The translocation properties of the TAMRA-DADEYL-AM3 peptide (sect. 4.8) formed 
the basis for its use as a probe to monitor the activity of the receptor tyrosine-kinase EGFR. 
To verify the possibility of monitoring this interaction in living cells, a series of experiments 
based on Förster Resonance Energy Transfer (FRET) were performed.  
 
In the system proposed here the FRET event would only occur upon the specific 
interaction between the enzyme (equipped with a donor fluorophore) and its substrate 
(equipped with an acceptor fluorophore. See Fig. 2.1.2). This approach has already been 
validated as a tool for the study of an enzyme-substrate interaction in vivo [153]. A Green 
Fluorescent Protein (GFP) or a Yellow Fluorescent Protein (YFP) are well suited to act as 
donors toward the acceptor rhodamine, because of the favourable overlap between the 
emission spectra of GFP or YFP and the excitation spectrum of rhodamine (Fig. 2.1.1)  
 
In a fluorescence lifetime imaging (FLIM) experiment, the FRET event is recorded as a 
decrease of the fluorescence donor’s lifetime. Via the so-called global analysis of the FLIM 
image, the fractions of molecules undergoing FRET can be evaluated, affording temporal and 
spatial resolution for the observed phenomena [17, 160]. Despite the fact that only one 
fluorophore is observed, this kind of assay requires more specialized instrumentation with 
respect to a conventional FRET setup: the donor is repeatedly excited with a pulsed laser of a 
suitable wavelength, and the exponential decay of its fluorescence is recorded and analyzed. 
The experiments reported here have been made possible thanks to the availability of a 
confocal FLIM microscope at the laboratories of Prof. Philippe Bastiaens (Max Plank 
Institute of Molecular Physiology, Dortmund, Germany). 
 
HeLa Kyoto cells stably transfected with a construct YFP-EGFR were incubated with a 
10 µM solution of TAMRA-DADEYL-AM3 for 20 min and stimulated with EGF (100 
ng/mL). Lifetime images were recorded starting from 5 min after EGF addition and every 10 
min (Fig. 4.10.2). Despite the presence of peptide in the cells, FLIM analysis did not show a 
variation of the YFP lifetime value, which remained constant around its average value of ca. 
3.0 ns throughout the observation period (1 h). A rise in the background signal in the 
rhodamine channel indicated leakage of fluorescent product from the cells, which 
nevertheless continued to appear brightly stained (Fig. 4.10.2 c). An apparent delay of 
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internalization of the EGFR was noticed and considered as a possible effect of the probe. 
Nevertheless, further experiments revealed that the peptide did not impair EGFR 
internalization when used in the same experimental conditions, and the previous findings 
were attributed to physiological variations between different cell batches (observations by Dr. 
Vibor Laketa, EMBL, results not shown). 
 
In order to reinforce the FLIM observations, an “acceptor photobleaching” experiment 
was performed next. In this assay the acceptor is bleached by high power laser illumination 
and the fluorescence intensity of the donor is recorded and compared to the original value 
before the bleaching. If the two fluorophores are part of an effective FRET pair, an increase of 
the donor fluorescence (unquenching) is normally observed as a direct result of a decrease in 
FRET.  
 
         
                                 a                                                          b                                                          c 
          
2.4 ns
3.8 ns
 
              LT = 3.04 ns (5 min)                                        LT = 3.04 ns (15 min)                                       LT = 3.06 ns (45 min) 
                                 d                                                         e                                                          f 
Fig. 4.10.2. Lifetime of YFP did not show reduction in HeLa Kyoto cells stably transfected with YFP-
EGFR upon incubation with the TAMRA-DADEYL-AM3 peptide. Cells were incubated with TAMRA-
DADEYL-AM3 peptide at 10 µM in imaging medium (20 min, room temp.), washed and incubated with EGF 
(100 ng/mL). (a) Trasmitted light image (phase contrast) of the cells. (b) YFP-EGFR. (c) TAMRA-DADEYL-
AM3 peptide. (d, e, f) Lifetime of YFP was recorded starting 5 min after EGF addition and every 10 min up to 1 
h. Pictures represent a colour-coded average value for the YFP lifetime measured after 5, 15 and 45 min, 
respectively (the analysis was restricted only to the two cells present in the centre of the field). Fluorescence 
signal from the peptide was clearly detectable in the cells throughout the experiment, although a rise of the 
background signal indicated possible leakage (c). LT = lifetime. Scale bar = 20 µm. (Material and methods, sect. 
3.17). 
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HeLa Kyoto cells were transiently transfected with a GFP-EGFR construct and 
incubated with the TAMRA-DADEYL-AM3 peptide at 5 µM for 45 min. The extended 
incubation time was to verify whether hydrolysis of AM ester groups in vivo would have 
required a longer period of time. Cells were then stimulated with EGF (100 ng/mL) for 15 
min, fixed and the acceptor photobleaching experiment was performed. Nevertheless, GFP 
fluorescence did not significantly vary after bleaching of the rhodamine, indicating a lack of 
FRET between the peptide and GFP-EGFR (Fig. 4.10.3). 
 
 
     
                                 a                                                                       b                          
           
                                 c                                                                        d                                                                        e 
Fig. 4.10.3. Acceptor photobleaching of the TAMRA-DADEYL-AM3 peptide did not reveal unquenching 
of GFP-EGFR in HeLa Kyoto cells. Cells transiently transfected with GFP-EGFR were incubated with a 5 µM 
solution of TAMRA-DADEYL-AM3 peptide in imaging medium (45 min, room temp.), washed, incubated with 
EGF (100 ng/mL) for 15 min and finally fixed (3.7% PFA). The upper panel shows the cells imaged in the red 
channel before (a) and after the bleaching of one single cell. The lower panel shows the cells imaged in the green 
channel before (c) and after the bleaching (d). (e) Colour-coded picture expressing values of FRET efficiency. 
As illustrated, the cell which underwent bleaching (circled with the red line) showed intensity values identical to 
the unbleached neighbouring cells, indicating lack of FRET. Scale bar = 10 µm (Material and methods 3.18). 
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4.11 In vitro assessment of esterase activity over the TAMRA-DADEYL-AM3 peptide 
 
The outcome of the FRET-based experiments reported above suggested a lack of 
interaction between the peptide and the receptor, perhaps due to inefficient hydrolysis of the 
AM ester groups in vivo. To verify this hypothesis, the stability of the TAMRA-DADEYL-
AM3 peptide toward esterase activity was assessed in vitro. 
Cell lysates were produced from HeLa Kyoto, MEF and MCF-7 cells (sect. 3.19). Their 
esterase activity was confirmed by means of a colorimetric test which used α-naphthyl acetate 
as a model substrate (Fig. 4.11.1). Commercial Porcine Liver Esterase (PLE, a known 
member of cellular carboxylesterases) mouse and fetal bovine serum were also tested for 
comparison. In this assay, the α-naphthol produced by enzymatic hydrolysis of α-naphthyl 
acetate reacts with an o-dianisidine derivative (named Fast Blue B) to produce a highly 
absorbing substance at 620 nm [161]. The amount of the latter correlates directly with the 
amount of α-naphthol produced, providing a qualitative readout of esterase activity contained 
in the sample. 
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Fig. 4.11.1. The colorimetric esterase assay based on α-naphthyl acetate and Fast Blue B. 
 
HeLa Kyoto, MEF and MCF-7 cell lysates showed high levels of esterase activity (85 to 
95% of the substrate was converted to α-naphthol), which was not affected by protease 
inhibitors but was sensitive to heat: following incubation at 56°C for 45 min, a 71% reduction 
in activity was observed for the Kyoto lysate, 48% for the MEF lysate and 65% for the MCF-
7 lysate (Fig. 4.11.2).  
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Fig. 4.11.2. Esterase assay of cell lysates using α-naphthyl acetate. A 0.2 mM solution of α-naphthyl acetate 
in HEPES (20 mM, pH 7.4) was incubated for 30 min at room temperature with 3% lysate (2 µg/µL protein 
content) obtained from HeLa Kyoto, MEF and MCF-7 cells. After addition of Fast Blue B, absorbance was 
measured at 620 nm. Each value represents the average of three independent measurements, normalized against 
the absorbance of a 0.2 mM solution of α-naphthol used as a control. All cell lysates showed high esterase 
activity against α-naphthyl acetate, which was reduced after heat treatment (56°C, 45 min) but remained 
insensitive to the presence of protease inhibitors. H.i. = heat inactivation; p.i. = protease inhibitors cocktail 
(Material and methods, sect. 3.20). 
 
Mouse serum also showed potent esterase activity, but its value was reduced both by 
heat treatment (ca. 55% reduction) and protease inhibitors (ca. 35% reduction) (Fig. 4.11.3 a). 
Lower levels of activity were found for PLE and FBS, with the latter showing a 26% 
reduction following heat treatment (Fig. 4.11.3 b). 
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                                                         a                                                                                                                 b 
Fig. 4.11.3. Esterase assay of mouse serum, porcine liver esterase (PLE) and fetal bovine serum (FBS) 
using α-naphthyl acetate. A 0.2 mM solution of α-naphthyl acetate in Hepes 20 mM (pH 7.4) was incubated 
with 3% mouse serum (a) or with 3 mU PLE, 3% FBS and 3% heat-inactivated FBS (b) for 10 min at room 
temperature. After addition of Fast Blue B, absorbance was recorded at 620 nm. Each value represents the 
average of three independent measurements, normalized against the absorbance of a 0.2 mM solution of α-
naphthol used as a control. Mouse serum showed high esterase activity which was reduced both by heat and 
protease inhibitors (55% and 35% reduction, respectively). Lower levels of activity were shown by PLE and 
FBS. H.i. = heat inactivation; p.i. = protease inhibitors cocktail (Material and methods, sect. 3.20). 
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The stability of the TAMRA-DADEYL-AM3 peptide to the various esterase sources was 
then tested: first, a solution of the probe was incubated with mouse serum, PLE or HeLa 
Kyoto cell lysate, then the mixture was transferred to living cells and the translocating 
capability of the peptide was assessed by direct observation. A 10 min exposure to mouse 
serum was sufficient to dramatically affect the peptide, which proved no longer able to 
penetrate the cells (Fig. 4.11.4 a). Pre-incubation with cell lysate produced a similar situation, 
with fluorescence detectable in cells only at a very low level (Fig. 4.11.4 b). Surprisingly, the 
peptide resisted PLE action: a 10 min exposure to this enzyme did not affect translocation, 
which was not impaired even after a prolonged incubation of 1 h (Fig. 4.11.4 c). From these 
indirect observations it was concluded that both cell lysate and mouse serum were able to 
process the peptide in a relatively short time, thereby abolishing its penetrating capability, 
presumably via the hydrolysis of its AM groups. Conversely, PLE was found to have a less 
dramatic effect, if any. 
 
         
                                        a                                                                         b                                                                       c 
Fig. 4.11.4. Pre-exposure to mouse serum or to cell lysate, but not to PLE, impaired cell translocation of 
the TAMRA-DADEYL-AM3 peptide. A 5 µM solution of TAMRA-DADEYL-AM3 peptide in imaging 
medium was incubated with 3% mouse serum (10 min, room temp.), 3% HeLa Kyoto cell lysate (30 min, 37°C) 
or 3 mU PLE (1 h, 37°C). HeLa Kyoto cells were afterwards incubated with the three mixtures for 30 min at 
37°C. While pre-incubation with mouse serum (a) and cell lysate (b) markedly abolished the penetration of the 
peptide into cells, PLE on the contrary did not affect this capability (c). Scale bar = 20 µm. 
 
 
In order to further probe these observations, mass spectrometric analyses on the 
products of the esterase activity were performed (sect. 3.21). Incubation of the TAMRA-
DADEYL-AM3 peptide with both mouse serum and cell lysates afforded unexpected results: 
the major signals – m/z 1245.4, 1317.4, 1335.6, 1407.5 – appeared to correspond to peptides 
which retained up to two AM esters while featuring a concomitant dehydration. In both 
experiments equal species were observed, but the peptide corresponding to the complete 
hydrolysis of the AM groups could not be detected (Fig. 4.11.5, top & centre panels). 
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Proteolytic activity could also be excluded, because samples treated with heat-inactivated cell 
lysates or mouse serum, or with protease inhibitors, gave spectra identical to those here 
reported (see Appendix, Fig. A2). Moreover, the TAMRA-DADEYL peptide (without AM 
esters), tested as a control with cell lysates or mouse serum, proved to be stable (Fig. 4.11.5, 
bottom panel). 
 
The mass spectrum of the products obtained from an overnight incubation of the 
TAMRA-DADEYL-AM3 peptide with PLE gave additional pieces of information (Fig. 
4.11.6): in this case a peptide which underwent a complete hydrolysis of all the AM ester 
groups could be detected (m/z 1281.44). Notably, a product retaining one AM ester was also 
visible (m/z 1353.46), despite the long period of incubation with the enzyme. 
 
Following MALDI-MS, the same sample was subjected to ESI-MS/MS analysis: the 
fragmentation products originating from the peptide with m/z 1353.46 (Fig. 4.11.6) proved to 
be compatible with the presence of a single AM ester on Glu-3, Asp-4 or Asp-6 (Fig. 4.11.7). 
Interestingly, the single AM ester present in the TAMRA-EYL-AM1 peptide (MW 1051.45) 
largely resisted hydrolysis when incubated with cell lysates, while was fully hydrolyzed after 
incubation with mouse serum (Fig. 4.11.8). This would provide some evidence for a 
differential esterase activity of cell lysate and mouse serum toward a Glu(AM)-Tyr-Leu 
tripeptide in vitro. 
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Fig. 4.11.5. TAMRA-DADEYL-AM3 and TAMRA-DADEYL peptides incubated with cell lysate or mouse 
serum. MALDI mass spectra relative to the products of the incubation of the TAMRA-DADEYL-AM3 peptide 
(5 µM) with 3% cell lysate (top panel) or 3% mouse serum (centre panel) for 30 min at room temperature. In 
both experiments equal species were produced. Under similar conditions the TAMRA-DADEYL peptide did not 
yield any relevant product (bottom panel, mouse serum incubation). The products that may have originated the 
masses recorded in these spectra are represented in Fig. 4.11.9 (Material and methods, sect. 3.21). 
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Fig. 4.11.6. The TAMRA-DADEYL-AM3 peptide incubated with PLE. MALDI mass spectrum relative to 
the products of the incubation of the TAMRA-DADEYL-AM3 peptide (5 µM) with 3 mU PLE at 37°C 
overnight. A product without residual AM esters (m/z 1281.44) is marked in red, while species matching those 
recorded after incubation of the peptide with cell lysates or mouse serum are marked in blue (see Fig. 4.11.5) 
(Material and methods, sect. 3.21). 
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Fig. 4.11.7. ESI-MS/MS analysis on the product with m/z 1353.46 originating from incubation of the 
TAMRA-DADEYL-AM3 peptide with PLE (see Fig. 4.11.6). The table reports the calculated m/z values 
relative to the fragments originating at the level of the peptide backbone, with the observed species written in 
bold. The fragments compatible with the presence of one residual AM group on Glu-3, Asp-4 or Asp-6 are 
marked with a red asterisk.  
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Fig. 4.11.8. The AM ester on Glu-3 in the TAMRA-EYL-AM1 peptide largely resisted hydrolysis when 
incubated with cell lysate, while was fully hydrolyzed after incubation with mouse serum. Mass spectra 
relative to the products of the incubation of the TAMRA-EYL-AM1 peptide (5 µM, MW 1051.45) with 3% cell 
lysate (top panel, MALDI mass spectrum) or 3% mouse serum (bottom panel, ESI-MS mass spectrum) for 30 
min in HEPES 20 mM (pH 7.4) and at room temperature. While incubation with cell lysate produced little 
hydrolysis of the single AM ester (m/z 980.44, [M+H+]), complete hydrolysis was observed after incubation with 
mouse serum (the two species with m/z 659.50 and 822.64 visible in the ESI-MS spectrum derived from those 
with m/z 687.50 and 850.61, respectively, which were fragmentation products of the peptide backbone) 
(Material and methods, sect. 3.21). 
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Various models may be proposed to explain the species observed in the mass analyses 
given in Fig. 4.11.5 and Fig. 4.11.6. One may envisage a process triggered by the presence of 
the AM esters: for instance, the different peptides may have originated via cyclization of the 
aspartate residues to the aspartimide, followed by their spontaneous hydrolysis (Figs. 4.11.9, 
4.11.10). The latter event would justify the additional products observed in the mass spectrum 
given in Fig. 4.11.6, which may have formed during the extended incubation time. The 
spontaneous loss of water from peptides at higher mass appears less likely, since as shown in 
Fig. 4.11.5, the peptide without AM esters did not undergo any modification under the same 
experimental conditions. 
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Fig. 4.11.9. Possible products originating from the TAMRA-DADEYL-AM3 peptide after incubation with 
cell lysate, mouse serum or PLE. Cyclization of aspartate residues remains speculative and would require 
additional experimental evidence to be proved.  
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Fig. 4.11.10. A possible route to the products derived from the incubation of the TAMRA-DADEYL-AM3 
peptide with cell lysate or mouse serum. The hydrolysis of a single aspartimide residue would lead to a total of 
four products having the same observed mass (m/z 1335.50, [M+H+], Fig. 4.11.5).   
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4.12 Effects of the Glu/Asp substitution in the DADEYL probe: in vitro and in vivo evaluation of 
the TAMRA-EAEEYL-AM3 peptide 
 
To verify possible differences in the pattern of AM ester hydrolysis, the synthesis of the 
TAMRA-EAEEYL-AM3 peptide was performed, in which all the Asp residues were 
exchanged to Glu (Fig. 4.12.1). 
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Fig 4.12.1. The TAMRA-EAEEYL-AM3 peptide. The proposed structure with the AM esters on the Glu 
residues coloured in red (MW 1524.62). 
 
Similarly to what was described earlier (sect. 4.9), care was taken to separate the 
products of the condensation of the 5(6)-TAMRA SE dye. By using only one of the two 
regioisomers, alkylation and subsequent purification could be accomplished easily. Along 
with the desired product, the reaction afforded in low yield also a peptide bearing four AM 
esters (Fig. 4.12.2). 
 
1
2
3
3
2
 
Fig. 4.12.2. LC/MS analysis of the crude from the AM-esterification reaction. The product eluting at 12.7 
min (peak n.1, 11.5%) carried two AM esters, the one eluting at 14.8 min (peak n.2, 59%) three (TAMRA-
EAEEYL-AM3, m/z 1525.91 [M+H+], mass n. 2, top right), the one eluting at 16.8 min (18%) four (TAMRA-
EAEEYL-AM4, m/z 1597.82 [M+H+], mass n. 3, bottom right). See Material and methods, sect. 3.12. 
 
In order to verify the location of the four AM moieties on the molecule, the latter 
peptide was subjected to ESI-MS/MS analysis. Unfortunally, low intensity signals were 
obtained from this sample, with an overall lack of accuracy and since the result could not be 
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confidently interpreted, it will not be reported here. Nevertheless, the penetrating capability of 
both peptides was tested in living HeLa Kyoto cells. The TAMRA-EAEEYL-AM3 peptide 
distributed intracellularly in cytoplasm, nucleus and cytoplasmic structures resembling 
vacuoles (Fig. 4.12.3 a, b). Surprisingly, the TAMRA-EAEEYL-AM4 peptide stained the 
cells only to a very limited extent (Fig. 4.12.3 c, d).  
 
     
a                                                       b 
     
c                                                       d 
Fig. 4.12.3. The TAMRA-EAEEYL-AM3 peptide distributed intracellularly, while the TAMRA-EAEEYL-
AM4 peptide did not translocate efficiently in living HeLa Kyoto cells. Cells were incubated with a 10 µM 
solution of TAMRA-EAEEYL-AM3 (a, b) and TAMRA-EAEEYL-AM4 (c, d) in imaging medium for 20 min at 
room temperature. Under these conditions the -AM3 peptide distributed in the cell body, nucleus and other 
cytoplasmic structures resembling vacuoles. The -AM4 peptide was detected in cells only to a very limited 
extent. Images were acquired without prior removal of peptide solutions. Pictures a and c represent transmitted 
light (phase contrast) images. Scale bar = 20 µm (Material and methods, sect. 3.15).  
 
The reasons underlying this difference are still unclear. The possibility that alkylation of 
the carboxylic group of the TAMRA molecule (already speculated in sect. 4.9) negatively 
affects cell penetration requires additional analytical evidence, in order to be clarified 
unambiguously. 
 
Similarly to previous in vitro experiments (sect. 4.11), the TAMRA-EAEEYL-AM3 
peptide was incubated with cell lysate and mouse serum to verify AM ester hydrolysis. The 
mass analysis revealed that, when incubated with cell lysate (Fig. 4.12.4), this alkylated 
peptide possessed a higher resistance compared to the corresponding TAMRA-DADEYL-
4. Results 
 91 
AM3 peptide (Fig. 4.11.5). Nevertheless, the loss of one or two AM ester moieties was 
detectable, along with species which may have originated through cyclization (loss of 90 
a.m.u.). This speculation would imply a phenomenon which, under the conditions tested, 
would extend also to glutamate residues. The product corresponding to a complete hydrolysis 
of the AM esters was on the contrary not detectable. In addition, species with lower mass 
indicated possible degradation not observed in the case of the TAMRA-DADEYL-AM3 
peptide (Fig. 4.11.5).  
 
 
Fig. 4.12.4. The TAMRA-EAEEYL-AM3 incubated with cell lysate. MALDI mass spectrum relative to the 
products of the incubation of the TAMRA-EAEEYL-AM3 peptide (5 µM) with 3% cell lysate for 30 min in 
HEPES (20 mM, pH 7.4) and at room temperature. Along with the starting material carrying three AM esters 
(m/z 1525.59, [M+H+]) peptides with two AM esters (m/z 1453.56, [M+H+]) were detected. From these two 
species may have originated, via a speculative cyclization and elimination of the AM moiety (– 90 a.m.u.), the 
products with m/z 1435.55 and 1363.52, respectively. Peptides displaying one AM ester (m/z 1381.53, [M+H+]) 
were also visible, but no product deriving from a complete AM esters hydrolysis. The presence of signals at m/z 
value < 1300 may prove additional degradation. Compare with Fig. 4.11.5 (Material and methods, sect. 3.21).  
 
 
Following incubation with mouse serum, products corresponding to the hydrolysis of 
one (m/z 1453.61, [M+H+]), two (m/z 1381.58, [M+H+]) and three AM esters (m/z 1309.55, 
[M+H+]) could be found. Interestingly, additional products observed in the previous 
experiment were not detected, while the starting material (m/z 1526.63, [M+H+]) was present 
only in traces (Fig. 4.12.5). 
 
4. Results 
 92 
 
Fig. 4.12.5. The TAMRA-EAEEYL-AM3 incubated with mouse serum. MALDI mass spectrum relative to 
the products of the incubation of the TAMRA-EAEEYL-AM3 peptide (5 µM) with 3% mouse serum for 30 min 
in HEPES (20 mM, pH 7.4) and at room temperature. In these conditions traces of the starting material were 
detected (m/z 1526.63, [M+H+]), along with products of hydrolysis of one AM ester (m/z 1453.61, [M+H+]), two 
AM esters (m/z 1381.58, [M+H+]) and three AM esters (m/z 1309.55, [M+H+]). No secondary by-products were 
detectable. Compare with Figs. 4.11.5 and 4.12.4 (Material and methods, sect. 3.21).  
 
Altogether, these findings provide evidence for a differential susceptibility of γ-
glutamyl-AM esters toward hydrolysis compared to β-aspartyl-AM esters, when exposed to 
the esterase activity of cell lysate or mouse serum in vitro. Whether this situation is also 
reflected in vivo awaits confirmations. The TAMRA-EAEEYL-AM3 peptide is currently 
under investigation in the laboratories of Prof. Bastiaens (MPI Molecular Physiology, 
Dortmund, Germany). 
 
4.13 AM ester derivative of a phosphorylated DADEYL probe: a brief summary 
 
During the course of this experimental work the synthesis of an AM ester derivative of a 
phosphorylated, rhodamine-labelled DADEYL probe was attempted. A peptide with a caged 
phosphate group was designed, i.e. a phosphate bearing a particular masking group removable 
via photolysis. Generally, caged compounds are inactive until irradiated (decaged) with light 
of a suitable wavelength (near-UV for the o-nitrobenzyl caging groups). The activation can be 
conveniently performed using standard microscope equipment. From a caged precursor 
introduced in the cell (for instance, by means of microinjection), the active molecule can be 
produced in an effective concentration to elicit a specific biological response, affording great 
temporal and spatial resolution. Clearly, cell-permeable derivatives expand remarkably the 
versatility of caged compounds, which have already been used in a large number of 
investigations and have proved to be essential components of the toolbox available to modern 
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cell biology [162, 163]. In particular, a caged phosphorylated, rhodamine-labelled DADEYL 
peptide has been recently used to monitor activity of Protein Tyrosine Phosphatase 1B 
(PTP1B) in living cells in a FLIM-based study [153]. The intention was to produce a cell-
permeable derivative similar to the described TAMRA-DADEYL-AM3 peptide (sect. 4.8). 
 
As mentioned previously (sect. 4.7), the incorporation of a Tyr(Cl-Trt) into the sequence 
allowed phosphorylation of the Tyr residue on the resin, following selective removal of the 
Cl-Trt group. This was achieved by swelling the resin-bound peptide with a 1% (v/v) solution 
of TFA in DCM (sect. 3.1). Phosphorylation was accomplished in two steps, in analogy to 
published procedures [164]: 1) phosphitylation of the phenolic  
-OH group of the tyrosine with O-t-butyl-O’-(4,5-dimethoxy-2-nitrobenzyl)-N,N-
diisopropylphosphoramidite;18 2) PIII to PV oxidation using t-butyl hydroperoxide. These two 
steps are summarized in Fig. 4.13.1. The caged phosphorylated peptide was obtained with a 
purity of 89% as assessed by HPLC and its identity was confirmed by ESI-MS (Fig. 4.13.2). 
Following Fmoc deprotection from the N-terminus, the peptide was conjugated to the 5(6)-
TAMRA SE fluorophore, then cleaved from the support and purified by preparative HPLC, 
affording 13.2 mg (yield = 45%) of the rhodamine-labelled, caged phosphorylated peptide, 
obtained with an overall purity of 98% (mixed isomers). Next, an alkylation reaction was 
performed to produce the AM ester derivative (sect. 3.13). Although MS analysis revealed the 
presence of the desired compound in the crude mixture (m/z 1845.15, [M+H+], Fig. 4.13.3), 
its isolation via HPLC was not successful. TFA was omitted throughout the chromatographic 
process to avoid premature hydrolysis of the ester on the phosphate moiety. By doing so, 
nevertheless, the detection of peaks became difficult, due to the overall poor resolution of the 
spectrum. Collection of various fractions was attempted, but the highest m/z value obtained 
by MS analysis was eventually 1738.2, thus differing by 107 a.m.u. from that expected. Other 
strategies were attempted to achieve the isolation of the desired product, including ion 
exchange and reverse-phase chromatography on SPE mini-columns, or solvent extraction (by 
using anhydrous ethyl acetate or toluene) but all these procedures were unsuccessful. Given 
these difficulties, further efforts in this direction were not pursued. 
 
                                                 
18
 The compound was a synthesized by Dr. Sirus Zarbakhsh (Schultz group alumnus, EMBL-Heidelberg, Germany) according to 
published protocols [169]. 
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Conditions:
i.   1% TFA (v/v) in DCM
ii.  1. O-t-butyl-O'-(4,5-dimethoxy-2-nitrobenzyl)-N,N-diisopropyl phosphoramidite (10 eq), 
         DCI (10 eq) / anh. DCM, overnight
     2. tbuOOH (ca. 0.5M) in NMP, 2 x 1h
iii.  5(6)-TAMRA SE (1.1 eq) / NMP : DCM (1:1, v/v), 4h (dark)
iv.  TFA/TIS/water (95:2.5:2.5, v/v/v), 3 h
v.   Bromomethyl acetate (12 eq), DIPEA (12 eq)/ anh. DMF, 30 min
 
Fig. 4.13.1. Synthetic route to the caged phosphorylated, rhodamine-labelled, AM-esterified DADEYL 
peptide. The resin-bound peptide (a) was treated with a 1% TFA solution in DCM to remove the orthogonal 
group Cl-Trt from the Tyr residue (b). Treatment with O-t-butyl-O’-(4,5-dimethoxy-2-nitrobenzyl)-N,N-
diisopropyl phosphoramidite followed by oxidation with t-butyl hydroperoxide afforded the caged phosphate 
group on Tyr (c). Following labelling with 5(6)-TAMRA SE, cleavage and purification, the peptide was 
alkylated with the intention of synthesising the AM ester derivative (d). Although MS analysis confirmed the 
product, every attempt to isolate the compound failed (note: the AEEAc spacer and the TAMRA fluorophore are 
omitted from the drawing). (Material and methods, sect. 3.13.) 
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                                                              a                                                                                                                       b 
Fig. 4.13.2. The caged phosphate on the Tyr side chain in the DADEYL peptide. (a) HPLC analysis showing 
the caged phosphorylated peptide eluting after 7.6 min in 89% purity. (b) ESI-MS identified the product as a 
[M+H+] (m/z 1144.83) species (Material and methods, sect. 3.13). 
 
 
 
                                                              a                                                                                                                       b 
Fig. 4.13.3. The rhodamine labelled, caged phosphorylated DADEYL peptide. (a) HPLC analysis showing 
the peptide as a mixture of partially resolved regioisomer eluting after 8.5 and 8.7 min in 98% overall purity. (b) 
ESI-MS identified the product as a [M+H+] (m/z 1557.65) and [M+2H+/2] (m/z 779.58) species (Material and 
methods, sect. 3.13). 
 
 
 
Fig. 4.13.4. ESI-MS analysis on the crude mixture from the AM esterification reaction. The –AM4 ester 
product is visible with m/z 1845.15 ([M+H+]), along with the –AM5 ester species, m/z 1917.22 ([M+H+]). Every 
attempt performed to purify the desired peptide was unfortunally unsuccessful (Material and methods, sect. 
3.13). 
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5. Discussion 
 
The goal of this thesis was the evaluation of the most suitable strategy aimed at the 
delivery to the cytoplasm of different cell types of synthetic peptide-based probes for the 
detection of enzyme activity in fluorescence-based (FRET) assays. In particular, we explored 
the possibility to confer cell-permeant properties to highly charged peptides like, for instance, 
the sequence DADEYL which comprises the residues 988-993 of the epithelial grow factor 
receptor (EGFR), and mimics one of the autophosphorylation domains. This sequence is 
known to be phosphorylated on the tyrosine residue in vitro [139, 140]. Based on this peptide, 
we intended to design a fluorescent probe to monitor the kinase activity of the EGFR in living 
cells. This probe was synthesized via the SPPS technique (sect. 3.1, 4.2) and equipped with a 
red fluorescent dye (rhodamine) in order to establish an ideal FRET pair with a GFP- or YFP-
tagged EGFR construct (sect. 2.1). Moreover, a previous study indicated how this same 
sequence, when displaying a phosphorylated tyrosine, served as a probe of the protein 
tyrosine phosphatase 1B (PTP1B) [153]. Ideally, this substrate would serve interchangeably 
as a sensor for a GFP(YFP)-EGFR construct, or for a GFP(YFP)-PTP1B construct in EGFR-
expressing cells.  
 
This sequence, presenting a net negative charge at physiological pH, is poorly 
permeable to cell membranes. To achieve the task of a non-invasive intracellular delivery of 
this reporter, two possibilities have been considered: 1) the conjugation to a vector belonging 
to the family of the cell-penetrating peptides (CPPs) (sect. 1.2); 2) the modification of its Asp 
and Glu residues in order to enhance hydrophobicity and to allow its diffusion through the 
plasma membrane. 
 
Two rhodamine derivatives of the cell-penetrating TAT peptide [137], termed LRh-
TAT49-57 and TAT(K-LRh) have been synthesized (LRh = Lissamine™-rhodamine, fig 3.1.2 
a) and analyzed regarding their translocating properties in living cells (sect. 4.1). TAT(K-
LRh) is a novel fluorescent variant which, to the best of our knowledge, has remained so far 
undocumented. Initial observations on living HeLa Kyoto cells were performed using these 
compounds with a low grade of purity. Uptake into vesicles was observed, enough to initially 
judge the limitation of these peptides as potential vectors for the probe (Fig. 4.1.2). A diffused 
distribution in the cytoplasm was unfortunately the result of fixation procedures, and as such 
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could not be hailed as a valuable property of the TAT vectors (Fig. 4.1.3). This observation 
underlined the importance of performing experiments in living, unfixed cells only. 
Nevertheless, a new set of experiments using a highly purified preparation of the TAT 
peptides revealed a different scenario and reinforced the significance of a proper purification 
procedure. The vectors were still internalized in membrane-bound compartments, and 
although the nature of these has not been clarified, they appeared to be different from the 
endosomal vesicles initially observed (Fig. 4.1.6). The final localization may have been the 
result of the affinity of the Lissamine™-rhodamine dye for a specific cell compartment, but 
the lack of endosomal vesicles may have been denoted a different mode of cell entry. Time-
lapse microscopy experiments will help to address this point. Moreover, the use of known 
fluorescent markers will be instrumental in revealing a possible co-localization in a specific 
organelle. A fluorescein-labelled 16-mer peptide containing the fragment TAT47-57 
(YGRKKRRGRRR) has been found to penetrate and accumulate in different proportions in 
cytoplasm and nucleus of living fibroblasts, in about 50% of the cells within the sample [101]. 
In another study, a similar fluorescein-TAT47-57 derivative appeared to access also the nuclei 
of HeLa cells [99]. Here it has been shown how a large number of living mouse embryonic 
fibroblasts picked up the LRh-TAT49-57 peptide, but clearly without nuclear or endosomal 
accumulation (Fig. 4.1.8). This observation put emphasis on how different fluorophores may 
contribute to the final localization of a cell-penetrating peptide in live cells. Of particular 
interest in this study was the finding that the derivative TAT(K-LRh) (Fig. 4.1.1) retained the 
capability to permeate cells and accumulate, apparently, in compartments similar to those 
stained by the linear LRh-TAT49-57 peptide (Fig. 4.1.6). This confirmed the results of an 
earlier study, in which the authors described how a fluorescent Gln54Ala variant of the 
TAT49-57 domain was still capable of penetrating into cells, as measured by flow cytometry. 
Indeed, the Gln54Ala substitution appeared to be the only one permissive within the 
polycationic sequence [81]. It is surprising, nevertheless, to note how this old observation has 
fuelled little further research: in this respect, the new Tat(K-LRh) variant may serve as a 
novel, branched polycationic vector (see sect. 6). A concern regarding the TAT peptides may 
be their potential cytotoxicity. Nevertheless, this issue appeared to be cell specific – some cell 
types were more tolerant than others (MEF vs. HeLa Kyoto and MCF-7, sect. 4.1) and must 
determined in each case. 
 
While the TAT peptides were analyzed only with respect to their translocation 
properties, a commercial activated Penetratin preparation was conjugated via a disulfide 
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bridge to the DADEYL probe and the uptake was evaluated in living MEF and MCF-7 cells 
(sect. 4.2, 4.3). The results appeared disappointing: the construct was internalized in 
endosomal vesicles in MEF cells (Fig. 4.3.1), while no uptake was recorded in MCF-7 cells 
under the same experimental conditions (Fig. 4.3.2). The use of two red and green fluorescent 
derivatives of Penetratin (RR-PEN1 and OG-PEN1), synthesized ad hoc (sect. 4.4), displayed 
a different uptake and distribution behaviour. In particular, MEF cells internalized the red 
Penetratin at room temperature, while uptake of the green Penetratin occurred only at 37°C, 
suggesting a possible role of additional components in the uptake process (Fig. 4.5.3). Despite 
both Penetratins appearing to concentrate in vesicles, co-localization with endosomal markers 
was evident only for the red Penetratin, indicating the possibility that the vesicles which 
entrapped the two Penetratins were not of the same nature. On the contrary, MCF-7 cells 
showed accumulation of the red and green Penetratins in the same compartments at 37°C, 
which nevertheless may have differed from the late acidic endosomes (Fig. 4.6.2). These 
results demonstrated how the response of a single cell toward variants of the same vector can 
vary, here simulated by the presence of two different fluorophores. Such comparative studies, 
surprisingly, has been rarely conducted in the area of fluorescent CPPs [165].  
 
When used in large excess, (100 µM) Penetratin did not substantially change its 
distribution, while it compromised the membrane integrity of MEF cells as probed by the 
nuclear stain propidium iodide (PI), a dye membrane-impermeable to intact cells (Fig. 4.5.4). 
Cell morphology appeared visibly altered under transmitted light (refer to picture A1 in 
Appendix and compare nucleus and cell shape with Figs. 4.5.1 a – e). Moreover, the 
concentrated pattern of the PI staining could have reflected compaction of chromatin, thus 
indicating an on-going apoptotic process (Andrew Riddel, Flow Cytometry Core Facility, 
EMBL-Heidelberg, Germany, personal communication). Previous studies in K562 cells 
indicated a toxic level for Penetratin of about 30 µM, above which cell membrane 
permeabilization was assessed by flow cytometry with a calcein leakage test [85]. Membrane 
permeabilization is usually considered a sign of altered cell physiology and compromised 
viability: for example, cells that display PI fluorescence are normally excluded from 
quantification analyses during flow cytometry [166]. Finally, it was shown that the light-
induced endosomal release of a fluorescent Penetratin in MCF-7 cells was characterized by 
evident photo-toxicity damage (Fig. 4.6.3) and clearly illustrated the limits of this kind of 
approach [159].  
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The sequestration in membrane-bound compartments of the TAT and Penetratin vectors, 
either alone or in conjugation with the probe of interest, appeared the major limitation for the 
scopes of this work. To overcome this fact, a different approach was devised. The negatively-
charged Asp and Glu residues of the DADEYL fluorescent reporter were equipped with 
bioactivatable protecting groups in the form of acetoxymethyl (AM) esters (sect. 4.7). The 
rationale for this was to enhance the hydrophobic character of the molecule, thus allowing a 
direct diffusion through cell membranes. Once inside the cells, the probe would have been 
restored to its original condition by the action of non-specific ubiquitous esterases. Although 
successfully applied in the case of other molecules (sect. 1.1), the use of AM esters on 
flurescently-labelled peptides has not been extensively documented. The modification was 
performed after the complete synthesis, including the fluorophore 5(6)-TAMRA SE 
conjugation (sect. 4.7). This work demonstrated that the side-chain esterification of aspartate 
or glutamate residues with acetoxymethyl groups is a feasible process. Yields of the desired 
products increased and purifications were easily accomplished when the peptides bearing the 
two regioisomers of the TAMRA dye were separated by chromatography prior to the 
alkylation reaction (sect. 4.9, 4.12).  
 
Remarkably the peptide with three AM esters (TAMRA-DADEYL-AM3) distributed 
uniformly in the cytoplasm and nucleus of living HeLa Kyoto, and virtually in any cell 
present in the sample (Fig. 4.8.1 a). MCF-7 cells were also stained in a high number, although 
the intracellular concentration appeared to vary (Fig. 4.8.1 b). Accumulation in the cell nuclei 
may be attributed to the affinity of the TAMRA dye for chromatin. The modified peptide was 
well tolerated up to 25 µM, but a concentration as low as 5 µM was sufficient to give a 
noticeable signal (the peptide was routinely used at 10 µM concentration). The distribution 
was also effective in the presence of serum (Fig. 4.8.2) and in cells either transiently or stably 
transfected (Figs. 4.8.3, 4.8.4): this was an important achievement, because the Penetratin 
conjugate was often found to be less prone to distribute in transfected cells. 
 
Time lapse microscopy enabled the internalization process of the TAMRA-DADEYL-
AM3 peptide to be followed, showing differences in the uptake ratio between HeLa Kyoto and 
MCF-7 cells (Figs. 4.8.9, 4.8.10). Nevertheless, the kinetics would be consistent with free 
diffusion through membranes. The difference observed may be due, for instance, to a different 
membrane composition between the two cell lines. This hypothesis could be eventually 
extended to MEF cells, which conversely showed uptake in vesicles and some diffuse 
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fluorescence only at a high peptide concentration (50 µM) (Fig. 4.8.5). Unexpectedly, a 
tripeptide displaying only one or two AM esters (TAMRA-EYL-AM1 and -AM2, sect. 4.9), 
could not translocate efficiently (Fig. 4.9.4). There are no good explanations for such 
behaviour, and the hypothesis of a minimal number of modified residues to produce an 
effective translocation needs more experimental support. Mass spectrometry analyses on the 
TAMRA-EYL-AM2 peptide suggested the carboxylic group of the TAMRA dye as the 
additional alkylation site, although the involvement of the phenolic side chain of tyrosine 
could not be excluded (Tab. 4.9 a). 
 
Despite the important goal of a cytoplasmic distribution of the chemically-modified 
DADEYL probe being achieved, fluorescence-based studies to probe the peptide-enzyme 
interaction failed (sect 4.10). To investigate the possible reasons, a series of in vitro 
experiments were designed. First, esterase sources were chosen (cell lysate, mouse serum, 
FBS, PLE) and their activity tested using the model compound α-naphthyl acetate. A high 
esterase activity was confirmed for cell lysates and mouse serum, a medium grade for PLE 
and a low grade for FBS (Figs. 4.11.2, 4.11.3). Next, the TAMRA-DADEYL-AM3 peptide 
was incubated with the various esterase sources and the products analyzed via mass 
spectrometry (sect. 4.11). The results revealed how, along with incomplete AM ester 
hydrolysis, the peptide likely underwent secondary modifications which may have included 
cyclization of aspartate residues to form aspartimide moieties (Figs. 4.11.5, 4.11.6, 4.11.9); 
these, in turn, may have undergone spontaneous hydrolysis, with the consequence of the 
formation of β-amino acid residues (Fig. 4.11.10). At this stage it is not possible to claim 
whether the supposed modifications also occurred in the cell environment, but if so, they 
would contribute significantly to the loss of affinity of the substrate and the lack of a specific 
response. Clearly, the hypotheses formulated from these in vitro data need further 
investigations to be tested, with the help of additional analytical techniques. To assess 
possible differences in the hydrolysis of the AM esters, a mimic of the DADEYL peptide 
containing only glutamate residues in place of the aspartate (TAMRA-EAEEYL-AM3), was 
synthesized (sect. 4.12). Its penetration into cells appeared equally efficient (Fig. 4.12.3). 
Mass spectrometry analysis following incubation with cell lysate showed also in this case an 
incomplete hydrolysis of AM esters, probably accompanied by the formation of additional 
degradation products (Fig. 4.12.4). Interestingly, the same peptide underwent a “clean” 
5. Discussion 
 101 
hydrolysis of the AM groups when incubated with mouse serum (Fig. 4.12.5). This may 
reflect a differential esterase activity present in cell lysates and mouse serum.  
Finally, the chemical synthesis of a caged phosphorylated, AM-esterified peptide 
(TAMRA-DADEY(cgdP)L-AM4, sect. 4.13) was successful as indicated by mass 
spectrometry, while its isolation failed, probably due to a higher propensity to hydrolyse than 
the TAMRA-DADEYL-AM3 peptide. 
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6. Conclusions 
 
This work reported the following observations: 
 
a) despite its use in numerous applications (sect.1.2), the vector Penetratin 
appeared unsuitable for the delivery of the designed DADEYL probe. Both the 
conjugate LRh-DADEYL-PEN and two different fluorescence derivatives of 
the vector showed a constant entrapment in vesicles, some of which are of 
lysosomal origin.  
b) TAT(K-LRh), a novel branched derivative of the TAT49-57 domain appeared to 
distribute in different membrane bound compartments from the endosomal 
vesicles, and as such it may be used as a novel vector for delivery of probes in 
specific cell locations (see sect. 7).  
c) Direct modification of the negatively-charged residues of the DADEYL 
peptide in the form of acetoxymethyl esters allowed a straightforward, highly 
efficient penetration in the cytoplasm and nucleus of two different cell types 
(HeLa Kyoto and MCF-7 cells). Unfortunally, no activity of the probe could be 
detected in fluorescent-based assays, likely because of secondary modifications 
which could have reduced its affinity for the target enzyme (EGFR). 
Understanding the exact nature of these modifications (so far only postulated 
on the basis of in vitro data) will help eventually to modify the strategy 
regarding the esterification step. Different kind of esters could in fact reveal 
themselves more suited for this temporary protection and less prone to 
deleterious side reactions. This may be usefully extended to the synthesis of 
alkyl-protected, phosphorylated peptides in order to achieve a better stability of 
these compounds.  
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7. Outlook 
 
The family of the polycationic cell-penetrating peptides largely catalyzes nowadays the 
attention of the investigators [75, 125, 137, 167]. In this work a novel TAT variant – TAT(K-
LRh) – has been presented. Equipped with a Lissamine™-rhodamine dye, this peptide gained 
access to the intracellular environment without apparent distribution in endosomal vesicles. 
Further studies will need to be performed in order to assess the influence of different 
fluorophores to the intracellular localization. Moreover, the co-incubation with known 
fluorescent markers will help to identify the cellular organelle(s) involved in its accumulation. 
Particularly interesting will be to verify whether the peptide localizes in mitochondria, since 
this possibility has so far been disputed for the TAT peptide or its protein conjugates [168-
171]. The accumulation in a different compartment from the endosome, if confirmed, will 
provide the interesting perspective of redirecting conjugates with cargoes of interest 
specifically to that compartment. Alternatively, for a more general use of the vector, an 
activated thiol group could be inserted into the sequence to enable conjugation via disulfides 
[172]. Hence, the construct would have the advantage to undergo spontaneous hydrolysis in 
the reducing environment of the cell. The branched TAT(Q54K) peptide would look as 
represented in Fig. 7.1. 
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Fig. 7.1. A branched TAT(Q54K) peptide as a novel TAT-based cargo. The Lys residue (red) would be 
introduced with an orthogonal protecting group such the Mtt group (sect. 4.1). Insertion of 3,3’-dithiodipropionic 
acid followed by reduction (e.g. mercaptoethanol) would further elongate the chain (green). Last, activation of 
the free thiol group with dithio-bis(5-nitropyridine) (DTNP, blue) would permit conjugation to a cargo via 
disulfide bridge formation. 
 
 
Poly-arginine peptides having a minimal number of six to nine residues (Arg6 – Arg9) 
are synthetic TAT analogues known to translocate into cells [118, 167, 173]. In previous 
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studies tryptophan residues were shown to be important for the internalization process of 
Penetratin [79]. These residues may be eventually combined in novel peptides comprised of 
modules such as [Trp-Arg-Trp-Arg]n or [Gly-Arg-Trp-Arg]n (n = 3 or 4). These peptides may 
display interesting characteristics in terms of cell translocation. Eventually, an activated 
terminal thiol group would enable conjugation to a cargo via a disulfide bridge (Fig. 7.2). 
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Fig. 7.1. Novel poly-arginine analogues. Would peptides comprised of modules such as [Trp-Arg-Trp-Arg]n or 
[Gly-Arg-Trp-Arg]n (n = 3 or 4) mimic and improve upon the features of both TAT and Penetratin vectors?  
 
 
 
The AM-esterified DADEYL peptide has shown excellent translocating properties, with 
the capability of diffusing evenly through the cytoplasm and nucleus of cells. Unfortunately, 
the peptide seemed to favour secondary modifications which altered the structure and 
properties of the probes. Nevertheless, short oligopeptides bearing acetoxymethyl (or other) 
esters may yet serve as good candidates for the role of vector. The experience obtained with 
the TAMRA-DADEYL-AM3 peptide may pave the way to the use of a vector built upon the 
sequence [Asp(O-AM)-X]n (n = 3) where X would be, for instance, Ala or another small 
hydrophobic/ uncharged amino acid. In this case, the conjugation via disulphide to a cargo 
would be performed preferably prior the alkylation step, since the free sulfhydryl group would 
likely compete for the alkylating reagent or be the cause of cross-reactions. The possibility of 
using different alkyl moieties should also be evaluated, having in mind that bulky or longer 
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chain esters may be detrimental to the solubility. A vector such as the one depicted in Fig. 7.3 
may be usefully exploited, for instance, for the internalization of small, cell-impermeable 
compounds. 
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Fig. 7.3. Proposed vector based on AM ester-protected oligopeptide. A sequence based on the module 
[Asp(O-AM)-X]n ( X = Ala; n = 3) linked to a cargo via disulphide bridge may be potentially useful for 
cytoplasmic delivery. 
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Appendix 
 
 
      
 
Fig. A1. (left) A transmitted light image showing MEF cells after the pulse with 100 µM OG-PEN1 peptide. 
Severe changes in the morphology of the cells are evident. (right) The fluorescent image as reported in fig. 4.5.4 
c. Scale bar = 20 µm. 
 
 
 
Fig. A2. Products of the incubation of the peptide TAMRA-DADEYL-AM3 with heat-inactivated (56°C, 45 
min) cell lysate (top panel), or with cell lysate in the presence of proteases inhibitors (bottom panel). 
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